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ABSTRACT OF DISSERTATION 
 
DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF THREE 
SERIES OF LOBELANE ANALOGS AS INHIBITORS OF THE VESICULAR 
MONOAMINE TRANSPORTER (VMAT2) 
 
Methamphetamine (METH) abuse is a serious problem in the United States and 
worldwide.  The reward experienced by METH users is due to the increase in 
extracellular dopamine (DA) concentrations caused by an interaction between METH and 
the DA transporter (DAT) as well as the Vesicular Monoamine Transporter-2 
(VMAT2).  The reward felt by users of METH leads to further use of the drug and 
subsequent abuse.  The current project examined the ability of three novel series of 
lobelane analogs to interact with a binding site on the Vesicular Monoamine Transporter-
2 (VMAT2) in an attempt to inhibit the effects of METH.  Lobelane is a defunctionalized 
analog of Lobeline, a natural product found in Lobelia inflata which has been shown to 
bind to VMAT2 and inhibit its function.  Rational drug design methodology and organic 
synthesis was used to generate a library of three series of lobelane analogs.  In total, 107 
compounds were synthesized and examined.  Compounds were assayed for affinity in a 
high-throughput [3H] dihydrotetrabenazine (DTBZ) radioligand binding screen as well as 
for function in a [3H] DA uptake assay.  Several compounds were identified which 
possess affinity as well as selectivity for the DTBZ binding site on VMAT2 [JPC-077 
(Ki=0.19 µM), JPC-094 (Ki=0.15 µM), JPC-096 (Ki=0.19 µM), and JPC-106 (Ki=0.19 
µM)]. The same four compounds exhibited inhibition of [3H]DA uptake [JPC-077 
(Ki=9.3 nM), JPC-094 (Ki=13 nM), JPC-096 (Ki=20 nM), and JPC-106 (Ki=83 nM)]. 
With the assay data generated from the library of compounds, several structure activity 
relationship (SAR) based ligand based pharmacophore models were developed to guide 
future ligand design. 
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Chapter 1 
Goals of the study and literature review 
1.1 Hypotheses 
 This study involved three central hypotheses.  One hypothesis of this work was 
that structural analogs of lobelane that maintain the 2,6-diphenethylpiperidine scaffold 
but introduce preferred moieties into the phenyl rings present in lobelane can be designed 
and synthesized that increase binding affinity for the vesicular monoamine transporter-2 
(VMAT2), and that these analogs will increase the functional inhibition of VMAT2 and 
modify the effects of Methamphetamine (METH) on VMAT2.  A second hypothesis of 
this work is that structural analogs of lobelane in which the 2,6-phenethyl moieties 
lobelane are changed to 1,4-phenethyl moieties will lead to a  further increase in affinity 
for VMAT2, and also increase potency to functionally inhibit VMAT2 to better modify 
the effect of METH on VMAT2. A third hypothesis of this work was that introduction of 
heteroatoms into the piperidine ring of the lobelane scaffold will result in compounds 
with increased water solubility, while maintaining improved affinity for VMAT2 when 
compared to lobelane. 
1.2 Overall Aims 
 Psychostimulant abuse has become a severe worldwide problem that has shown 
no sign of lessening the hold that it has on much of mainstream society.  There exists an 
ongoing need for new therapies and medications that can provide efficacy in the 
treatment of psychostimulant abuse.  METH especially is identified as an addictive and 
increasingly popular psychostimulant drug, and there are no effective Food and Drug 
Administration (FDA) approved pharmacological treatments available for the addicts 
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who wish to quit.  This project has been designed to address those people who currently 
abuse psychostimulants such as METH and need an effective therapy that will help them 
to break away from their addiction.  Within the following dissertation, the design and 
synthesis of a library of analogs similar to lobelane is described, with alterations designed 
into the molecules in an attempt to make them more potent at the target protein: VMAT2, 
and to ultimately provide one or multiple candidates that could ultimately become a 
treatment for psychostimulant abuse for the part of the population that currently abuses 
psychostimulants but wishes to quit. 
1.3 Methodology to be utilized in this study 
• To utilize the established drug discovery process to afford likely candidates for 
treatment of METH abuse 
• To design molecules that can be synthesized that have characteristics that would 
increase the likelihood of their affinity and functional inhibition of VMAT2 
• To use organic chemistry methods to synthesize and purify the previously 
designed molecules in sufficient quantities as to afford their testing via high 
throughput affinity assays as well as functional assays 
• Once pharmacological assay data has been obtained, to use modern methods of 
ligand based pharmacophore modeling of the VMAT2 binding/uptake sites that 
may allow further generations of molecules to be developed that show even 
further enhanced potency and selectivity at VMAT2 
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1.4 Overview of Drug Discovery 
 Drug discovery consists of the combined processes in which new drugs are 
invented, evaluated for their pharmacological activity and thereby selected for lead 
molecule identification and subsequent optimization.  A flow chart describing the drug 
design process is shown in figure 1.1.  Rational drug design is the inventive process by 
which new medications are found based on a discovered target of biological origin.  
Drugs are commonly small organic molecules that either activate or inhibit the normal 
function of a protein or biomolecule target, and that interaction leads to a therapeutic 
benefit or advantage in the patient to which the designed drug is given (Drews, J., 2000). 
Prior scientific investigation reveals the key biological workings and mechanisms of both 
the normal physiological function of the protein or biomolecule target and also the altered 
state of function that is caused by a disease or other outside influence, such as drug abuse.  
The identified mechanisms by which the proteins in question work provide drug 
discovery scientists areas to manipulate, probe, and take overall advantage of in hopes of 
developing novel pharmacotherapeutics that can provide a controlled curative medical 
intervention.  As these discovered physiological mechanisms are elucidated, their 
processes and inner workings are seen as prime potential novel drug targets to the drug 
discovery scientist.  When considered in the most basic way, drug design involves the 
design and synthesis of small molecules that are complementary to and correspond with 
the shape and local net charge of the biomolecular target with which they are designed to 
target and which therefore bind to the biomolecular target being queried. As far as the 
overall scale of the biomolecular targets, they can truly be as small as molecular in scale, 
for example peptides, receptors on a protein (for example a binding site on VMAT2), or 
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they can be comprised of entire cellular and systemic scale processes (Drews, J., 2000).  
Once the target has been recognized, it is the overriding goal of the drug design/discovery 
scientists to produce a drug that can be used for further experimental purposes that can 
lead to therapeutic medical intervention.  It is also extremely important that the drug 
designed for the specific target should be designed in such a way that the lead drug 
molecule should not affect any other important biomolecules that are deemed off target, 
as the drug molecule may stray from the designed course of action and produce 
undesirable side effects in the patient. 
 There are at least four primary steps involved in the drug discovery process.  
These are listed here in order of occurrence, but are equally important, and include 1.) 
overall drug design, 2.) synthesis of the designed drug molecule, 3.) pharmacological 
assay evaluation of the targeted and desired physiological/biological effect, and 4.) 
structure-activity relationship (SAR) analysis of the data collected in order to generate the 
subsequent generation of drug compounds that perform even better than the prior 
generation.  The results of SAR analysis are then mined for a better understanding of the 
overall biological workings and mechanisms in place.  It is key that the next generation of 
drug candidates be improved in as many ways as possible, if not all aspects, when 
compared to the first phase of drug synthesis. 
 There are also numerous important facets that must be taken into consideration 
when entering the drug design phase.  The overall structure of the biomolecular target, 
the target’s location within the body, the distinct environmental surroundings in the area 
of the target, the overall number of the biomolecular targets in the area of the body to be 
effected by the drug, the stability of the drug molecule itself, and the potential for binding 
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to other “off-target” sites that may result in side-effects. These are just a few of the 
factors that must be considered when designing small molecule candidates that are to be 
used to produce the desired effect on the targeted biomolecule and therefore on the 
target’s subsequent function. These complications are a part of what makes drug design a 
stimulating yet challenging process.  Many of these challenges can be overcome or 
avoided outright by utilization of the knowledge gathered about the nature of the 
prospective drug target. 
 In the past, most drugs have been discovered by one of two ways.  Either natural 
products were isolated from plant sources that were known to have medicinal properties 
(Sneader, 1985) or through unexpected and or unplanned discoveries in the laboratory 
that reveal that a compound may have the desired effect (Drews, 2000).  Drug design and 
discovery scientists cannot depend on luck to provide the desired drug candidates, 
therefore the most fruitful traditional method for providing promising drug candidates has 
been through isolation and purification of compounds from both newly discovered 
species and traditional medicinal sources such as plants.  Currently there is a marked 
emphasis on more modern strategies for the discovery of new drug entities.  The more 
modern methods consist of rational drug design and high-throughput synthesis and 
subsequent high-throughput pharmacological assays of small organic molecules (Drews, 
2000). 
 Rational drug design is, at its core, based on a thorough understanding of the 
biomolecular target and the overall mechanism of the disease or abuse process and uses 
this knowledge to build molecules that will be likely target specific, with known 
mechanisms of action and prior knowledge of the likely molecular interactions.  In an 
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ideal world, rational drug design would allow for immediate improved drug activity 
profiles, with higher potency and selectivity, while still introducing minimal toxicity into 
the system.  This is due to some prior knowledge of the target and the drug molecule 
libraries that are constructed and customized to interact with the previously known 
structural target. With all previously acquired knowledge of the location, nature of the 
target, and the target’s function, relatively complicated organic synthetic chemistry 
methodology can be used to generate families of compounds within the library that are 
specifically constructed to interact and bind to the known molecular topographic features 
of the target.  Therefore, ideally, rational drug design can, in just one step, improve the 
overall hit rate of the constructed compound library, while improving the lead 
compound’s potency, selectivity, and toxicity profiles. 
 With the utilization of high throughput synthesis coupled to high throughput 
screening methods, the synthesis of a vast number of compounds that can be made in a 
relatively simple manner, with a low number of synthetic steps, with overall yield 
balancing between cost of synthesis and the amount necessary for initial and subsequent 
testing is the focus of synthetic drug discovery chemist.  High throughput synthesis 
coupled to high throughput screening attempts to discover active compounds by applying 
the muscle of large scale library building medicinal chemistry such as parallel organic 
chemistry (used in this work), or microwave based chemistry, to generate a large number 
of compounds that will be screened to afford a small number of candidates.  High 
throughput synthesis must be coupled to high throughput screening methods due to the 
volume of time that it characteristically takes to manage and test large libraries of 
compounds (Drews, 2000).  One major limitation of high throughput synthesis derives 
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from the focus on the large number of compounds generated without initial concern for 
the initial hit rate, drugability factors, or toxicity profile of the compounds generated.  
The utter volume of compounds generated by the high throughput synthesis can offset the 
issues of low initial hit rates and drugability factors.  The number or initial hits and 
preliminary drug candidates can allow for the drugability and toxicity profiles to come 
into play after the preliminary screening.  The ultimate and overriding goal of high 
throughput synthesis and screening is to massively reduce the initial cost of 
distinguishing high quality lead compounds for the desired pharmacological target of 
interest.  Another desirable aspect of high throughput synthesis coupled to high 
throughput screening derives from the creativity possible when generating the compound 
libraries.  Often novel compounds that may have otherwise not been investigated are 
generated when the medicinal chemist is compiling a compound library that lead to 
unforeseen advancements and allow expedited optimization of novel lead drug 
candidates.    
 Pharmacological evaluation processes are required to be developed into a much 
more streamlined procedure when they are part of a large drug discovery process.  Much 
of the time, in the early testing process, the evaluation of compounds is limited to a single 
screening effort where compounds are evaluated for one biological effect.  Compounds 
that show promise in the initial screen are then selected and considered as hits.  These hit 
compounds are then subjected to further biological testing (Drews, 2000).  This is done to 
reduce the number of compounds that require further biological consideration in an effort 
to minimize the testing response time and therefore reducing cost, both in valuable 
scientist hours and in monetary expense.  It is in this manner that compounds deemed 
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ineffectual can be discarded in favor of compounds that obtain a set level of drug 
potential.  This prevents the time-consuming and expensive in-depth pharmacological 
tests from being carried out on compounds that hold little promise of becoming lead 
drugs for the target of interest. 
 An important aspect of high throughput screening is that the data generated, both 
of the positive and negative variety of results, from a large library of compounds is 
invaluable in later compound modification and refinement.  This characterization and 
evaluation of the data generated is known as structure activity relationship (SAR) 
analysis, and can reveal significant features about both the biomolecular target as well as 
the interactions that the lead drug compounds has with the target.  SAR analysis is a key 
tool of the drug design/discovery scientist and is best defined as the science of 
quantifying and evaluating interactions at the molecular level between the drug molecule 
and the target it is interacting with.  Modern SAR efforts require the use of computational 
resources and programs that use mathematical models of the drug molecule and target.  
This part of the drug discovery pathway has become more and more complex as it 
evolves.  Entire research groups are dedicated to the “virtual synthesis” and “virtual 
screening” of molecules and drug targets.  These virtual efforts go hand in hand with 
traditional drug discovery procedures, and are mainly used to support the continuing 
synthetic efforts to make more and more efficient drug candidates.  By taking advantage 
of the information gleaned from prior synthetic efforts and biological experimentation, 
computational SAR can uncover the required molecular features of the lead compounds 
from past generations of synthesis and provide direction and novel ideas for structural 
chemical modification.  
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 The computational methods for computational SAR differ depending on the 
circumstances and information at hand.  The different methods are described as: 1.) 
development of ligand-receptor models also known as docking models, and these are 
used specifically for situations where the receptor or biomolecular target structure has 
been previously identified through methods such as x-ray crystallography, or 2.) 
development of a pharmacophore based model, also known as a ligand based model, 
which consists of SAR modeling based on certain molecular features of the ligand 
molecules from the constructed compound library, and these are used in situations where 
less information is  known about the drug target or when the critical molecular structural 
features of the target are not well defined, as in this case with VMAT2.  Once the nature 
of the molecular interactions between the ligand and the target site has been elucidated, 
SAR based computational models can be further used as a tool to predict new compounds 
and structural motifs that should be improved in their drug candidate qualities.  It is in 
this manner that SAR leads to advancement in the next generation of compounds 
synthesized, and in theory should lead to improvements in all aspects of the next lead 
molecule, including potency and selectivity, and thereby enhance the toxicity and side 
effect profile as well.  It is through these combined efforts that improved 
pharmacotherapies can be discovered to intervene in the disease/abuse process. 
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Figure 1.1  Flow chart  overview of the drug discovery process. Rational design and 
synthesis and high throughput synthesis generate the libraries of compounds that are then 
assayed for activity at the biomolecular target of interest.  Each cycle of the flow chart 
represents a single generation of compounds. SAR analysis can accelerate the cycle time, 
with each generation yielding a new lead compound that is a more suitable drug 
candidate. 
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1.5 Methamphetamine abuse prevalence and limitations of viable therapies and 
treatments 
 Psychostimulant abuse has become a severe worldwide problem that has shown 
no sign of lessening the hold it has on much of mainstream society.  METH is an 
addictive and increasingly popular psychostimulant drug that affects the central nervous 
system.  METH is also known to users of the drug as chalk, ice and crystal.  Currently 
and most significantly there are no effective and accepted pharmacological treatments 
available for addicts who wish to quit.  METH exists in its pure form as a white 
crystalline powder that is odorless, bitter tasting and readily soluble in water or alcohol, 
and can be self-administered by several delivery routes.  Users of METH have various 
methods of delivery that include: nasal inhalation, smoking and inhalation into the lungs, 
or via injection. The oral route of administration has not gained prevalence due to the 
delayed onset of reward, and the relatively low bioavailability when compared to the 
injection route.  While the preferred method of abusing the drug varies by region, 
smoking METH is the most common way of introducing the drug into the body. 
Whatever the route of administration, the users quickly develop a strong desire to 
continue using it due to the false sense of happiness and well-being associated with 
METH’s use. Users report a rush or feeling of strength and invulnerability as well as a 
surge of confidence, hyperactivity, and a drastic increase in energy level.  As with many 
stimulants, METH is often abused in a “binge and crash” manner.  The “rush” felt by 
users of the drug is maintained for a very short amount of time, sometimes only minutes, 
and the users attempt to maintain the high by taking more and more of the drug.  It has 
been documented in many cases that abusers take part in a form of binging known on the 
11 
 
street as a “run”, in which the user forgoes food and sleep for several days while 
continuing to self-administer the drug (National Institute on Drug Abuse, 2013).  In 2012, 
approximately 1.2 million people (about 0.4% of the United States population) reported 
using METH when asked.  While this number is slightly down from previous estimates, 
METH continues to exhibit regional variability, and abuse is strongest on the West coast 
and in parts of the Midwest.  
 METH was developed in the laboratory from the parent drug, amphetamine, and 
is considered the first purely synthetic drug of abuse.  It was developed early in the 
twentieth century and was used for a time as a nasal decongestant and to relieve bronchial 
health issues in the form of an inhalable powder.  METH was first synthesized from 
ephedrine in 1893 by Japanese chemist Nagai Nagayoshi and in 1919 the hydrochloride 
salt was synthesized by the pharmacologist Akira Ogata via a simple reduction of 
ephedrine utilizing red phosphorus (commonly found in certain types of matches) and 
iodine (Vermont, 2013). During World War II, METH was used extensively by the Axis 
forces for its stimulant effects (Defalque, 2011).  METH was synthesized in Germany in 
1937 and subsequently was commercially released in 1938. It quickly became a popular 
stimulant for workers in the “German War Machine” and also gained popularity as a 
recreational drug for young people until the middle of 1941 when it became a controlled 
substance inside Germany as well. METH continued to be  abused by the German armed 
forces during World War II when it was commonly distributed by commanding officers 
(occasionally over the objections of the units' physicians) to prevent or treat the fatigue of 
overworked troops and thus allow them to continue fighting (Defalque, 2011).  
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METH does differ greatly from amphetamine in that, when used at the same 
dosage level, it is a much more potent stimulant as it crosses the blood-brain barrier at a 
greater rate.  Due to the presence of the α−methyl group, it has a longer-lasting effect and 
therefore has greater harmful effects on the central nervous system.  METH has been 
classified as a Schedule II stimulant by the United States Drug Enforcement 
Administration, and while it can be legally prescribed in a non-refillable prescription, it is 
rarely prescribed due mainly to the large abuse liability.  In the medical field, it can still 
be prescribed for the treatment of attention deficit hyperactivity disorder, and narcolepsy, 
and can be utilized as a short-term component of weight loss treatments, albeit at doses 
much lower than those that are readily abused (National Institute on Drug Abuse, 2013).   
   It is widely accepted that the vast majority of the METH abused in the United 
States is illegally manufactured here in the United States or is made in Mexico and 
trafficked into the United States.  One of the major hurdles in combatting the illegal 
manufacture of METH is due to the ease with which it can be prepared.  Multiple 
synthetic methods exist, and are easily found via search engines on the internet.  METH 
is easily made in small, readily mobile, covert “laboratories” (examples include 
automobile trunks, rental storage units, hotel rooms and more recently, recreational 
vehicles).  Requiring inexpensive ingredients such as pseudoephedrine and relatively 
easily to obtain ammonia (a common fertilizer used on farms across the United States), 
combatting METH at its source is problematic, if not impossible. 
 Many users of METH liken its effects to that of cocaine, and the two drugs have 
similar behavioral and physiological effects. There are however, several important 
differences found in the mechanisms by which they produce the reward or “rush” felt by 
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their users. One important aspect in which METH and cocaine differ is the duration of 
time they remain in the body.  The half-life (time it takes for the body to remove half of 
the dose absorbed) of cocaine is roughly one hour; however, the half-life of METH is 
much longer, approximately 12 hours (NIDA, 2013, Barr et al., 2006).  Cocaine is 
relatively quickly removed from the body and much of the dose is completely 
metabolized within in the body in a short time; whereas METH has a much longer 
duration of action, and is more slowly metabolized so that a larger percent of the dose 
absorbed into the body remains unchanged.  METH is metabolized into two primary 
metabolites, amphetamine and 4-hydroxymethamphetamine (Keueger et al., 2005, 
Yamada et al., 1984, Cashman et al., 1999) with amphetamine belonging to the same 
class of stimulant compounds as METH and likely contributes to the pharmacological 
activity felt by the users, while 4-hydroxymethamphetamine (also known as Pholedrine 
as used in a clinical setting) does stimulate the sympathetic nervous system, it is not 
thought to produce the same pharmacological affect as the parent drug, METH (Dasgupta 
et al., 2012).  It is administered in the clinical setting as a topical eye drop form for the 
purpose of dilating the pupil and can be used to diagnose Horner's syndrome (Bates et al., 
1995).  Thus, METH remains in the brain longer, and affords prolonged stimulant and 
rewarding effects.  Both cocaine and METH produce their reward through increased 
levels of dopamine (DA) within the synapse of dopaminergic nerve terminals, but is has 
been shown in studies in animal model that following administration of METH, the levels 
of DA are much higher than when animals are administered cocaine (Barr et al., 2006, 
NIDA, 2013, Wilson et al., 1996).  The structural differences between METH and 
cocaine are shown in Figure 1.2. 
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 Figure 1.2 Chemical Structures of Cocaine and Methamphetamine 
 
 METH has many effects on the human body, and these effects differ greatly 
depending on the length of time a METH user has been abusing the drug.  Short term 
effects from the use of METH, even at what are considered small doses, include 
increased activity, increased attention, increased respiration and rapid and or irregular 
heartbeat, hyperthermia, decreased fatigue, decreased appetite, as well as the main effect 
that METH users desire: quick onset of the rush and euphoria that leads to abuse.  
Hyperthermia (increased core body temperature) and convulsions can occur after using 
METH and are mainly associated with METH overdose, and if not treated by trained 
medical professionals immediately can result in death (NIDA, 2013).  It is widely 
accepted that the main pleasurable effects the users feel when using METH stem from the 
release of large concentrations of DA in the brain.  DA is a neurotransmitter that involved 
in motor function (as seen in Parkinson’s disease), motivation, and the experience of 
pleasure.  It is also believed that the high levels of DA released by METH causes some of 
METH’s harmful effects on dopaminergic neurons in the brain (Barr, et al., 2006, NIDA, 
2013).  The structure of DA is shown in Figure 1.3. 
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 Figure 1.3 Structure of the neurotransmitter dopamine (DA) 
 
The long term effects of METH abuse has many more significant detrimental 
consequences, not the least of which is a strong addiction to the drug.  Addiction is 
defined as the continued repetition of a behavior even though the behavior has strong 
adverse consequences.  Addiction, in the case of METH, is considered a chronic, 
relapsing disease, that is characterized by an overwhelming compulsion to seek out more 
of the drug and is also associated with molecular and functional changes within the 
addict’s brain (NIDA, 2013, Wimalasena, 2011).  Another long term effect of METH, as 
is found with many drugs, is that tolerance develops quickly to METH’s desired 
pleasurable effects when METH is taken repeatedly.   Chronic users of the drug find 
themselves needing to take higher and higher doses of the drug, in more frequent 
administrations, or change the method of administration to achieve the same desired rush 
and euphoria effect.  It is also common for chronic users of METH to be unable to find 
anything in life that provides them pleasure except for the drug, which in turn reinforces 
the need for the METH.  When users are unable to find or afford the drug, or have looked 
for treatment in a clinical atmosphere, users experience extreme withdrawal symptoms 
that include severe depression, fatigue, anxiety, dysphoric mood, increased appetite, 
increased movement or decreased movement, lack of motivation, sleeplessness or 
sleepiness, vivid or lucid dreams, violent behavior, memory loss and of course, an 
intense, overwhelming craving for the drug (Shoptaw, 2009).  Chronic abusers of METH 
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can also display numerous symptoms of psychosis that include paranoia, hallucinations 
and delusions, an example of which is known by a common name “Meth Bugs” in which 
the abuser has an intense sensation of insects crawling beneath their skin.  Skin sores are 
apparent in the users of METH experiencing this specific type of delusion, and are the 
result of the addict scratching and picking at their skin in an attempt to relieve themselves 
from the insects they imagine to be crawling underneath.  These signs of psychosis can 
last for years after a user has been drug free, and even small amounts of stress can bring 
about recurrence of METH psychosis events (Barr et al., 2006, Iyo et al., 1997).  
 These types of symptoms allude to the substantial changes in the brain of abusers 
of METH.  In adults who used METH, magnetic resonance imaging (MRI) has shown 
enlarged striatal volumes (Chang et al., 2005, Chang et al., 2007). In comparison, 
children that have been exposed to prenatal METH show smaller striatal structures 
(Chang, et al., 2007).  Positron emission tomography (PET) studies have revealed that 
several other functional aspects within the striatum have been altered.  These include: 
reduced dopamine transporter (DAT) density and reduced dopamine D(2) receptors in the 
striatum of METH users (Volkow et al., 2001, McCann, et al., 1998, Sekine et al., 2001, 
Iyo et al., 2004).  PET studies also found lower levels of serotonergic transporter density 
and vesicular monoamine transporter (VMAT2) density in the striatum, as well as altered 
brain glucose metabolism (Chang et al., 2007), which were linked with the overall 
severity of psychiatric symptoms in the limbic and orbitofrontal regions of the brain 
(Chang et al., 2007). 
 Some of the changes in the brain of chronic METH abusers do appear to be at 
least partially reversible.  These neuronal recoveries take over a year of abstinence from 
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METH, and were linked with improvements in both motor skills and verbal memory 
examinations.  Substantial damage to some brain regions of addicts does not show 
marked signs of recovery even after the one year abstinence time frame, which indicates 
that some of the METH-induced damage is very long lasting, if not permanent.  Further 
damage to the brain can occur due to an increased risk in METH abusers to experience a 
stroke, which can cause death or in many cases irreversible and severe damage to the 
brain (McIntosh, 2006).  It has also been shown that as a consequence of METH’s effect 
on the levels of DA in the brain, there is a greater occurrence of Parkinson’s disease in a 
population of abusers of METH (Callaghan, 2011). 
 The detrimental effects that derive from METH abuse are numerous and severe.  
The fact that there are currently no effective and accepted pharmacological treatments 
available for the addicts that wish to quit makes it much more difficult to break the cycle 
of addiction.   Medications have been shown effective for treating other substance abuse 
disorders, for example three drugs exist to treat alcoholism: disulfiram, naltrexone, and 
acamprosate.  No medications exist that counteract the effect of METH at the 
biomolecular level or prolong abstinence from or reduce the abuse of METH by an 
individual that has become addicted to the drug (NIDA, 2013).  Currently the most 
effective treatments for METH addiction are behavioral therapies that include cognitive-
behavioral therapy and contingency-management interventions (NIDA, 2013).  Results 
from these behavioral therapies have proven somewhat effective, but treatment depends 
much on the individual addict’s dedication to become drug free.  It is clear that a 
therapeutic treatment for METH abuse is needed, and must be a priority for the future 
treatment of METH addicts. 
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1.6 Methamphetamine Mechanism of Action, and the Role of VMAT2  
 The abuse liability of METH is thought mainly to be a product of an interaction 
and subsequent alteration of the brain’s dopaminergic system.  Inside the presynaptic 
dopaminergic neuron METH interacts with the dopamine transporter (DAT), the 
vesicular monoamine transporter-2 (VMAT2), and with monoamine oxidase (MAO) 
(Dwoskin and Crooks, 2002).  Signal transduction within monoaminergic neurons is 
dependent on monoamine neurotransmission in the synaptic region of the neuron. (Henry 
et al., 1998; Schuldiner et al., 1996; Rudnick, 1998).  Monoamine neurotransmission can 
be apportioned between several principle steps: (1) the initial biosynthesis of 
monoaminergic neurotransmitters from their biochemical precursors within the 
cytoplasm, followed by their active sequestration and accumulation into synaptic storage 
vesicles utilizing an uptake mechanism driven by a proton gradient, (2) the constant 
biosynthetic conversions within the synaptic vesicles, (3) the release of the 
monoaminergic neurotransmitter via exocytosis or diffusion, chiefly the former in 
response to a physiological stimulus, into the synaptic cleft, (4) interaction of the 
neurotransmitter with the target receptor on the postsynaptic membrane (the distinct act 
of signal transduction), and (5) the dissociation of the neurotransmitter molecule from the 
target receptor and the subsequent reuptake into the cytosol of the presynaptic terminal 
by plasma membrane monoamine transporters, of which the dopamine transporter (DAT) 
is an example.  DAT is a membrane spanning protein that functions to pump DA out of 
the synapse back into cytosol, from which VMAT2 sequester DA into vesicles for later 
storage and release.  DA reuptake via DAT provides the primary mechanism through 
which DA is removed from synapses, which effectively terminates the neurotransmitter 
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signal across the neuron’s synaptic cleft, and provides a method for DA to be recycled 
within the neuron rather than repeatedly biosynthesized when needed.  DAT is also 
referred to as a symporter, or a transporter that is involved in the movement of two or 
more species of molecules or ions across a membrane.  Ions that are transported are 
generally moving down the concentration gradient, and that in turn allows the molecule 
being co-transported to be moved against the concentration gradient.  In this case, DAT 
moves DA across the cell membrane by linking the movement of DA to the energetically-
favorable movement of sodium ions moving from high to low concentration into the cell. 
To be specific, the function of DAT requires the sequential binding and co-transport of 
two positively charged sodium ions and one negatively charged chloride ion in order to 
transport one molecule of DA.  The movement of the sodium and chloride ions is 
considered facilitated diffusion, while DA is being actively transported into the 
presynaptic terminal from the synaptic cleft. The overall driving force for DAT-mediated 
DA reuptake is the ion concentration gradient generated by the plasma membrane 
sodium/potassium adenosine triphosphatase (Torres, 2003). 
Those monoaminergic neurotransmitters not taken back up into the presynaptic 
terminal are subject to monoamine metabolizing enzymes in the extracellular space, and 
consequent inactivation, making it necessary for the biosynthesis of the neurotransmitter 
to be repeated.  Metabolizing enzymes are not allocated only within the extracellular 
space, and the neurotransmitter can be metabolized within the cytosol itself by specific 
enzymes, of which monoamine oxidase (MAO) is an example. Accordingly, the efficient 
reuptake of the neurotransmitter from the synaptic cleft via plasma membrane 
monoamine transporters, and their subsequent sequestration and reaccumulation into 
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synaptic vesicles via vesicular monoamine transporters (VMATs), is vital to the process 
of monoamine neurotransmission within monoaminergic synaptic neurons. 
Vesicular monoamine transporters are in control of and responsible for the 
process and mechanism of uptake of cytosolic monoamines into synaptic vesicles found 
within monoaminergic neurons (Wimalasena, 2011).  The VMAT exists as two distinct 
isoforms: VMAT1 and VMAT2 (Erickson and Eiden, 1993; Erickson et al., 1992; Peter 
et al., 1994; Zheng et al., 2006). Remarkably, the distribution of the two isoforms of 
VMAT appears to vary from species to species.  In the human, VMAT1 is primarily 
expressed in neuroindocrine cells which include chromaffin cells of the adrenal medulla, 
as well as enterochromaffin cells of the intestine (Peter et al., 1995; Weihe et al., 1994; 
Stern-Bach et al., 1992; Howell et al., 1994).  While recent studies have shown that the 
VMAT1 isoform is also expressed in the brain (Lohoff et al., 2006), the VMAT2 isoform 
is expressed in sympathetic postganglionic neurons in addition to adult human and 
monoaminergic neurons of the central nervous system (Erickson et al., 1996; Peter et al., 
1995; Weihe et al., 1994; Stern-Bach et al., 1992; Howell et al., 1994) and is considered 
the main transporter protein involved in the sequestration of cytoplasmic 
neurotransmitters into vesicles for storage, as well as their subsequent release.  The 
accumulation and storage of the monoamines dopamine (DA), serotonin, norepinephrine, 
and histamine are essential to the regulatory processes governing the concentrations of 
these endogenous neurotransmitters available in the cytosol of monoaminergic neurons 
(Erikson et al., 1996).  The active transport of cytosolic monoamines into vesicles for 
storage, against a high concentration gradient (synaptic vesicles can contain 
concentrations of monoamines up to 0.5 M), is propelled by the pH gradient across the 
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plasma membrane in vesicles as well as the electrochemical gradient originating from the 
H+-ATPase in the chromaffin granule membrane (Wimalasena, 2011; Eiden et al., 2004; 
Schuldiner, 1994; Gasnier, 2000; Henry et al., 1994). 
VMAT1 and VMAT2 are glycoproteins with a molecular weight of 40 kDa (Liu 
et al. 1992; Erickson and Eiden, 1993; Erickson et al., 1992).  The origin of VMAT1 and 
VMAT2 has been determined to be from two distinct genes; however they show high 
sequence homology (Parsons, 2000; Bravo and Parsons, 2002).  The crystallographic 
structures have not yet been resolved for VMAT1 or VMAT2, the sequences have been 
analyzed and related proteins suggest that their structure is consistent with 
transmembrane proteins consisting of 12 transmembrane spanning domains similar in 
structure to plasma membrane monoamine transporters such as the dopamine transporter 
(DAT).  It is believed that both the C-terminus as well as the N-terminus of the VMAT 
series of transporters are located within the cytoplasmic side of the vesicle, and this is 
supported by studies that show a lack of a cleavable sequence in VMAT2 (Erickson et 
al.,1992). 
Without a crystal structure determination of the crystallized protein, probes into the 
tertiary structure of the protein are inconclusive at this time.  Several studies have 
investigated structure-function relationships of VMAT at the molecular level.  Such 
studies utilize mutations of specific amino acids and determine what effect such a 
mutation has on the binding affinity of the protein for a specific substrate or molecule.  In 
what have been called the original studies in this field, (Shirvan et al., 1994) has shown 
that when His419 (found to be His414 in human VMAT2, and located in the cytoplasmic 
side of the membrane between TMDs X and XI) is mutated to either Arg or to Cys, the 
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accumulation of serotonin (5-HT) and DA drop to zero, and a mutation at the same site 
strongly inhibits the pH-dependent binding of Reserpine (RES) (Wimalasena, 2011).  
These observations have led to the logical conclusion that His419 (His414 in human 
VMAT2) plays a primary role in monoamine transport, likely through aiding the initial 
proton-dependent conformational change of the transporter (Shirvan et al., 1994).  It has 
also been proposed that RES likely binds to this new conformation, and in the mutated 
form of the transporter, the interaction has been impeded. 
Another single-point mutation at the Asp431 (Asp426 in human VMAT2 found in 
TMD XI) with either Glu or Ser again inhibits 5-HT transport without changing the rate 
of RES binding to the preferred RES binding site (Steiner-Mordoch et al., 1996).  Similar 
to conclusions have been drawn from His419 mutations, and it has been postulated that 
Asp431 (Asp426 in human VMAT2) is necessary for the completion of the substrate 
transport cycle, and the concomitant proposed second conformational change of the 
protein releasing the amine into the cytosol, in the same proposed model of VMAT 
function.  In contrast, a mutation replacing Asp404 (Asp399 in human VMAT2) in TMD 
X with Cys or Ser does inhibit 5HT transport and also affects RES binding in rat 
VMAT1, but when Asp404 (Asp399 in human VMAT2) is replaced with Glu, neither 
5HT transport nor the binding of RES and tetrabenazine (TBZ) is altered in a significant 
manner.  The rationale behind this discovery is thought to be the presence of the carboxyl 
moiety shared in Asp and Glu, but lacking in Ser and Cys.  The presence of the carboxyl 
group appears to play a vital function at site 404 (399 in human VMAT2) if VMAT is to 
operate normally (Steiner-Mordoch et al., 1996). 
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Other research has focused on the primary structure of the protein: the VMAT 
sequence homology itself.  Without lengthy mutation studies, it is possible to analyze 
portions of the amino acid sequence, and, when overlaid, to find the portions of the 
sequence that have been conserved between VMATs.  This simple analysis has shown 
that four Asp residues in TMD I, VI, X, and XI as well as a Lys residue found in TMD II 
are conserved among all members of the VMAT protein family.  Since they have been 
dutifully conserved by evolution, it is likely that they have a critical role in both the 
structure and function of this family of VMAT proteins. 
 
1.7 Methamphetamine Mechanism of Action  
 Delving deeper into METH’s mechanism of action at the dopaminergic neuron, 
specifically at DAT, VMAT2 and MAO, Figure 1.4 illustrates the numerous effects that 
METH has at the biomolecular level. 
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 Figure 1.4  Illustration of METH’s effects on the dopaminergic neuron  
(Adapted from G. Zheng, with permission) 
 
 METH effectively reverses the normal function of both DAT and VMAT2, 
greatly increasing the free DA present in the cytosol and in the extracellular 
space/synaptic cleft.  METH also blocks the normal function of MAO, preventing the 
metabolism of the DA into 3,4-dihydroxyphenylacetic acid (DOPAC), such that DA may 
be released from the vesicles into the cytosol and then the extracellular space (Dwoskin 
& Crooks, 2002).   
 VMAT2 is a relevant biomolecular target in the search for a viable treatment for 
METH abuse (Sulzer et al., 2005).  METH inhibits DA uptake at VMAT2 and promotes 
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DA release from vesicles to increase cytosolic DA. Therefore, pharmacological 
compounds that modulate VMAT2 function or effectively redistribute DA from 
presynaptic vesicles, in effect limiting vesicular and cytosolic DA available for METH-
induced reverse transport, should be suitable candidates for the treatment of METH 
addiction. Studies utilizing VMAT2 knockout mice demonstrate reduced drug-seeking 
behavior compared to wild-type rats in locomotor response studies that included an array 
of drugs, including amphetamine and cocaine (Takahashi et al., 1997; Wang et al., 1997). 
 
1.8 Lobeline Background and Mechanism of Action as a Treatment for METH 
abuse 
 (-)-Lobeline (LOB) is the major alkaloidal constituent of Lobelia inflata, which is 
more commonly known as Indian tobacco.  The common name “Indian tobacco” most 
likely originated when Europeans new to the North American continent found that Native 
Americans smoked the dried leaves of the plants (Millspaugh, 1974).  In 1938, Proctor 
prepared a liquid alkaloid extract from the plant and named it lobeline (Millspaugh, 
1974).  Since that time, the alkaloidal extract of Lobelia inflata has been used medically 
as an expectorant, emetic, antiasthmatic, antispasmodic, respiratory stimulant, general 
muscular relaxant, diaphoretic, diuretic, stimulant, and it has even been used to treat 
narcotic overdose (Crooks et al., 2011).  In the Lobelia inflata plant, LOB is by far the 
most abundant alkaloid, as well as the most pharmacologically active constituent of more 
than twenty related piperidine alkaloids (Felpin et al., 2004).  The other alkaloids include, 
but are not limited to, lobelanine, nor-lobelanine, lobelanidine, and nor-lobelanidine.  
The structures of these alkaloids are shown in Figure 1.5.   
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 Figure 1.5  The chemical structures of lobeline (LOB) and structurally related 
alkaloids present in Lobelia inflata. 
  
 The LOB molecule was purified and isolated from the plant extract and 
characterized by Wiedland (Wieland, 1921; Wieland, et al., 1925; Wieland, et al., 1929).  
Wieland followed the purification and isolation of LOB with the subsequent total 
synthesis of the molecule to confirm the structure proposed in 1921 (Wieland, et al., 
1929).  Following Wieland’s total synthesis,  multiple synthetic methods for the 
preparation of LOB have been reported either via racemic methodology (Scheuing, et al., 
1929; Schoepf, et al., 1935) or via the asymmetric synthesis approach (Schoepf, et al., 
1965; Compere, et al., 1999; Felpin, et al., 2002; Klinger, et al., 2006; Birman et al., 
2007). 
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 The free base form of LOB, as well as the sulfate and hydrochloride salt forms of 
LOB, are stable to degradation in the solid, crystalline form.  Conversely, when in 
solution, LOB quickly undergoes a pH-dependent epimerization at carbon-2 (C2) of the 
piperidine ring that yields a mixture of cis-LOB and trans-LOB (Compere, et al., 1999; 
Felpin, et al., 2002; Zheng, et al., 2004).   This epimerization is thought to ensue via the 
transitory retro-aza Michael addition product.  This process is shown in Figure 1.6. 
 
 
Figure 1.6 Likely process of Lobeline epimerization (adapted from Crooks, et al, 2011) 
 
 Compounds possessing a β-aminoketone moiety do have a tendency to exhibit 
stability issues, such as the epimerization process shown in Figure 1.6, as well as an 
elimination process, thought to be due to the molecule’s predisposition to undergo retro-
aza Michael addition processes.  Many of the cases where retro-aza Michael addition 
pathways have been shown to occur happen under acidic conditions (Vazquez, et al., 
2001; Davis, et al., 2005), but the epimerization process does not occur in aqueous 
solutions at a pH of 3.0 (Crooks, et al., 2011).  This is quite useful information, and was 
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used in a “quench” technique (after a set time at a higher pH, an aqueous solution of LOB 
is decreased to a pH below 3.0, effectively terminating the epimerization process at that 
point) (Crooks, et al., 2011).  The quench technique was used to determine the kinetics of 
epimerization and high performance liquid chromatography (HPLC) techniques were 
used to determine the ratio of the two resulting epimers.   
 When in aqueous solution at room temperature, LOB epimerization proceeds to 
afford an approximate 65:35 ratio of cis:trans, and the equilibrium stops at that point. 
Interestingly, when in solution in chloroform, the ratio of cis:trans is 46:54 in favor of 
the trans-isomer.  More surprisingly, the cis:trans ratio within human plasma after 
sublingual administration of LOB sulfate reaches 1:19 in favor of the trans-isomer.  This 
is reversed in rat plasma, after the same sublingual administration of LOB sulfate, i.e. the 
ratio is 16:1 in favor of the cis isomer (Crooks et al., 2011). 
 Several reviews on the pharmacology of LOB exist in the literature (Zheng et al., 
2006; Dwoskin et al., 2002; Felpin et al., 2004; McCurdy et al., 2000).  LOB is known to 
display high affinity for nicotinic acetylcholine receptors (nAChRs) (Court et al., 1994; 
Damaj et al., 1997; Flammia et al., 1999; Miller et al., 2004), and has been shown to have 
many effects similar to nicotine, such as tachycardia (increased heart rate) and 
hypertension (increased blood pressure) (Korczyn et al., 1969), analgesia (Damaj et al., 
1997), nausea (Bevan et al., 1966), improvement in learning and memory tests (Decker et 
al., 1993), anxiolytic activity (Brioni et al., 1993), and hyperalgesic actions (Hamann et 
al., 1994).  In consequence, LOB has been characterized as a nicotinic receptor agonist, 
despite the lack of structural similarities between LOB and nicotine (NIC) and further 
SAR studies do not support LOB and NIC possessing the same pharmacophore profile 
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(Barlow et al., 1989).  It is not thought that LOB and NIC act via the same mechanism, 
and this is supported by studies that show LOB and NIC have different effects in both 
behavioral as well as neurochemical studies (Dwoskin & Crooks, 2002).  In contrast to 
NIC, LOB very marginally supports self-administration in mice (Rasmussen et al., 1998), 
and does not show support for self-administration of any type in rats (Harrod et al., 
2003).  As further evidence that LOB and NIC do not act via the same mechanism, 
chronic administration of LOB does not increase locomotor activity in rats (Fudala et al., 
1986; Stolerman et al., 1995).  In contrast, LOB diminishes hyperactivity induced by 
repeated nicotine administration in rats (Miller et al., 2003).  More specifically, LOB has 
been shown to inhibit NIC-evoked [3H]DA overflow from striatal slices from rat brain 
with an IC50 of approximately 1 µM, which suggests that LOB and NIC not only do not 
act via the same mechanism, but demonstrate that LOB acts as an antagonist at nAChRs 
that mediate NIC-evoked DA release (Miller et al., 2000).  LOB has also been shown to 
bind to α4β2 nAChRs with high affinity (Ki = 4 nM), while inhibiting NIC-evoked 86Rb+ 
(radiolabeled Rubidium) efflux from rat synaptosomes (IC50 = 0.7 µM), which further 
supports contention that LOB is an antagonist at α4β2 nAChRs (Miller et al., 2000).  In 
addition, LOB has been shown to be an antagonist (IC50 = 8.5 µM) at human α7 nAChR 
subtypes expressed in Xenopus oocytes (Briggs et al., 1998).  The combined results from 
the above studies suggest that LOB is not correctly categorized as a nicotinic receptor 
agonist, but that it also acts as a potent, albeit nonselective, nAChR antagonist. 
 Along with the interaction of LOB with nAChRs, LOB also interacts with DAT 
and VMAT2.  LOB inhibits [3H]dihydrotetrabenazine (DTBZ) binding to VMAT2 (IC50 
= 0.9 µM) and also inhibits [3H]DA uptake into vesicle preparations from rat striatum 
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(IC50 = 0.88 µM) (Teng et al., 1997; Teng et al., 1998).  Although LOB does inhibit 
[3H]DA uptake into synaptosomal preparations from rat striatum (IC50 = 80 µM) via 
DAT, it is noteworthy that the inhibition of DAT is of nearly 100-fold weaker in 
comparison to LOB’s inhibition of VMAT2 (Teng et al., 1997).  When VMAT2 and 
DAT are both present on a co-expressed cell line, LOB was shown to induce [3H]DA 
release through its interaction with VMAT2, rather than through an interaction with DAT 
(Wilhelm et al., 2004).  This finding was also supported with later data showing that LOB 
caused a decrease in METH-evoked [3H]DA release  (Wilhelm et al., 2008).  
 Research has shown that LOB inhibits the behavioral consequences of 
amphetamine as well as the neurochemical effects of the drug in both rats and mice.  
LOB decreases amphetamine-induced and METH-induced hyperactivity in rats and mice, 
and has been shown to inhibit amphetamine-evoked DA release from superfused (the 
process by which the maintenance of the normal metabolic or physiological activity of 
the tissue by submitting it to a continuous flow of a sustaining medium over the outside) 
slices from rat brain striatum (Miller et al., 2001).  Most importantly, it was found that 
LOB decreased METH self-administration in rats without acting as a substitute reinforcer  
(Harrod et al., 2001; Harrod et al., 2003), and this is in accord with LOB not supporting 
self-administration in rats (Harrod et al., 2000) suggesting a lack of abuse liability for 
LOB.   
 Further behavioral studies in rats have demonstrated that LOB has significant 
potential as a therapeutic agent for treatment of psychostimulant abuse.  When 
administered as a pretreatment, LOB reduces the intensity of METH-induced stereotypy 
(a repetitive or ritualistic movement, posture, or utterance) in adolescent mice (Tatsuta, et 
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al., 2006).  While, LOB has also been shown to attenuate cocaine self-administration in 
rats (Neugebauer, et al., 2007), the effects that LOB has on cocaine-induced hyperactivity 
in rats are multifaceted and intricate.  When administered acutely, LOB did not decrease 
the effect that cocaine had on hyperactivity in rats.  Conversely, when LOB was given via 
repeated administration, it attenuated cocaine-induced hyperactivity in rats.  LOB was 
also found to prevent rats from becoming sensitized to cocaine (Crooks et al, 2011). 
Phase 1b clinical evaluation of LOB is completed, and found that LOB is safe in human 
METH addicted subjects (Clinical Trial ID #NCT00439504), and awaits investigation in 
Phase II trials as a pharmacological treatment for METH abuse (Crooks et al., 2011).
 The current understanding of the mechanism by which LOB reduces the 
rewarding effects desired by abusers of psychostimulants such as amphetamine and 
METH involves LOB’s alteration of DA concentrations within dopaminergic synapses 
through an interaction with both VMAT2 and DAT (Dwoskin & Crooks, 2002; Crooks et 
al., 2011).  It is more plausible that the interaction between LOB and VMAT2 is more 
essential to LOB’s inhibition of the behavioral effects of psychostimulant abuse, due to 
LOB having an approximate 100-fold greater affinity for VMAT2 than for DAT (Teng, et 
al, 1997; Dwoskin & Crooks, 2002; Crooks et al., 2011).  A distinct and important 
difference between LOB and METH is with respect to their actions on MAO.  LOB does 
not interfere with MAO, allowing the increased levels of DA within the cytosol to be 
oxidized into dihydroxyphenylacetic acid (DOPAC), which does not interact with DA 
receptors on the postsynaptic terminal (Alachar, et al., 2012).  With these data 
considered, the mechanism of action for LOB in the inhibition of METH induced 
behavioral effects is due to the interaction of LOB with the DTBZ allosteric binding site 
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on VMAT2, effectively inhibiting DA uptake into synaptic vesicles while promoting DA 
release from the same storage vesicles within the presynaptic terminals of the 
dopaminergic neuron (Dwoskin & Crooks, 2002; Crooks et al., 2011).  Through this 
mechanism, LOB diminishes the total DA pool available for reverse transport through 
DAT to be released into the synaptic cleft.  In that manner, less DA is available for 
METH to be released from the presynaptic terminal, even if the addict fails to remain 
drug free during treatment.  Figures 1.7 and 1.8 illustrate the mechanism by which LOB 
attenuates METH’s effect at the dopaminergic neuron. 
 
 
Figure 1.7 Lobeline’s Mechanism of Action at the Dopaminergic Neuron 
(Adapted from G. Zheng, With Permission) 
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 Figure 1.8 Lobeline’s inhibition of Methamphetamine 
(Adapted from G. Zheng, With Permission) 
 
1.9 Review of Structural Modifications of Lobeline and Lobelane to afford VMAT2 
Inhibitors 
 The discovery of LOB as a VMAT2 ligand presents a novel scaffold and lead 
molecule with which to explore inhibition of VMAT2, and this section is designed to 
provide background information regarding previous studies that have been conducted in 
this area prior to this author’s entrance into the area of study.  Albeit, LOB is a molecule 
that has been shown to interact with and bind to a number of biomolecular targets, 
including nAChRs (Teng et al., 1997; Dwoskin & Crooks, 2002; Miller et al., 2000; 
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Hillmer et al., 2013; Kaniakova et al., 2011; Hojamat et al., 2010; Horton, et al., 2011), 
opiate receptors (Hart, et al., 2010; Miller et al., 2007; Miller et al., 2011), VMAT2 
(Meyer et al., 2013; Dimatelis, et al., 2012; Horton et al., 2011; Dwoskin & Crooks, 
2002; Crooks et al., 2011; Horton et al., 2011; Nickell et al., 2010; Nickell et al., 2011; 
Hojamat et al., 2010; Varkat et al., 2009; Wilhelm et al., 2004; Wilhelm et al., 2008; 
Zheng et al., 2005; Zheng et al., 2006; Miller et al., 2004; Teng et al, 1998), and DAT 
(Smith, et al., 2012; Horton et al, 2011; Nickell et al., 2010; Wilhelm et al, 2008; Li et al., 
2007;).  Significant quantities of time and effort have been allocated to structurally 
modifying the LOB molecule to improve potency and selectivity at VMAT2 while 
limiting the effects at other neurotransmitter transporters and nAChRs (Crooks, et al.; 
2011).  A review of the studies conducted follows, with a linear timeline of strategies 
attempted.  Some of the first structural modifications attempted on the LOB scaffold 
where oxidation and dehydration reactions under acidic conditions (these reactions are 
shown in Scheme 1.1).  When LOB is subjected to oxidizing conditions, the alcohol 
functionality converts to a ketone (Jones oxidation with chromium (VI) oxide) affording 
lobelanine.  Acid-catalyzed (phosphoric acid) degradation of LOB yields the ketoalkene 
(2-((2R, 6S)-1-methyl-6-styrylpiperidine-2-yl)-1-phenylethanone), and when LOB is 
subjected to mild reduction conditions (sodium borohydride) the keto functionality is 
reduced to afford the stereospecific product, lobelanidine. 
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 Scheme 1.1.  Synthetic routes to lobelanine, lobelanidine, and the ketoalkene [2-((2R, 
6S)-1-methyl-6-styrylpiperidine-2-yl]-1-phenylethanone 
 
 When compared to LOB (data shown in Table 1.1), lobelanine, ketoalkene, and 
lobelanidine all showed decreased binding to α4β2* nAChRs by greater than 100-fold to 
almost 10000-fold differences.  At the α7* nAChRs, affinity was only slightly modified, 
however, a 4-fold increase in affinity for VMAT2 was observed with the ketoalkene 
analog. The radiolabeled ligands are:  [3H]nicotine ([3H]NIC), for the nicotine binding 
site on α4β2* nAChRs, [3H]methyllycaconitine ( [3H]MLA), for the MLA binding site on 
α7* nAChRs, and [3H]methoxytetrabenazine ([3H]MTBZ), for the tetrabenazine (TBZ) 
binding site on VMAT2.  From these data, it can be determined that the presence of a 
second keto moiety in the LOB scaffold causes a decrease in affinity for α4β2* and 
α7*nAChRs, but only slightly improved potency at VMAT2.  Removal of the alcohol 
moiety in LOB results in a ketoalkene analog that  exhibits moderately decreased affinity 
for α4β2* and α7* nAChRs, but exhibits 4-fold increase in affinity for the TBZ binding 
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site on VMAT2.  Reduction of the keto moiety in LOB yields lobelanidine, which has 
two alcohol moieties; when compared to LOB, lobelanidine shows less affinity for α4β2* 
nAChRs, slightly greater affinity than LOB at  α7* nAChRs, and 5-fold less affinity for 
VMAT2 (Crooks, et al., 2011). 
 
Compound 
Values are Ki, µM 
[3H]NIC Binding 
α4β2* nAChR 
[3H]MLA Binding 
α7* nAChR 
[3H]MTBZ 
Binding VMAT2 
LOB 0.004 11.6 5.46 
lobelanine 37.1 22.7 2.41 
ketoalkene (2) 3.10 3.29 25.9 
lobelanidine 0.44 34.2 1.35 
 
Table 1.1. Binding affinity of LOB, lobelanine, ketoalkene, and lobelanidine at α4β2* 
and α7* nAChRs, and at VMAT2. 
 
 With this data in hand, both carboxylate and sulfonate esters of LOB were 
synthesized.  When assayed (data not shown; Hojamat et al., 2010), it was apparent that 
the above modifications of the alcohol moiety of LOB affected the way in which the 
compound bound to both α4β2* and α7* nAChRs, but did not effectively increase affinity 
at VMAT2.   
In order to systematically determine the SAR for the LOB scaffold, the next 
logical step was to reduce/remove the keto functionality completely from the molecule.  
To this end, the reactions outlined in Scheme 1.2 were conducted, and the products 
isolated and characterized (Zheng et al., 2006). 
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 Scheme 1.2.  The synthetic route to des-keto analogs  of lobeline (Adapted from Crooks, 
et al., 2011) 
 
 The aim of the synthetic work described in Scheme 1.2 was to produce a series of 
LOB analogs with the keto group removed.  To afford compound 1, a Clemmenson 
reduction of LOB was used to remove the carboxyl moiety entirely, and this was 
followed by oxidation of the alcohol to a ketone, which was then reduced to afford both 
stereoisomers (R & S) of the corresponding alcohol (3a & 3b), as the synthesis of both 
stereoisomers was desired.  The oxidation step followed by reduction with sodium 
borohydride was done to make it possible to obtain compounds 3a and 3b as a separable 
mixture that each be isolated and purified by silica column chromatography.  A portion of 
the total synthesized amount of compounds 3a and 3b were then subjected to 
hydrogenation conditions (hydrogen gas under pressure with palladium-on-charcoal)  to 
reduce the alkene moiety and afford compounds 5a and 5b, which were also separable via 
silica column chromatography (Zheng, et al., 2006; Crooks et al., 2011).  The process that 
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affords the keto alkene (2) is illustrated in Scheme 1.1. Products 4a and 4b, and 6a and 6b 
can then be synthesized via the same route as used in the preparation of 3a and 3b and 5a 
and 5b (i.e reduction of the ketone to an alcohol, separation and purification, then 
hydrogenation followed by silica column separation and purification).  The pure 
compounds were assayed for biological activity as described in Table 1.1, with one 
exception;  rather than using [3H]methoxytetrabenazine ([3H]MTBZ, as the radioligand 
[3H]dihydroxytetrabenazine ([3H]DTBZ) was used as the radioligand for the 
tetrabenazine (TBZ) binding site on VMAT2, and the two radioligands have been used 
interchangeably as ligands for the TBZ site on VMAT2.  DTBZ is less susceptible to 
metabolism in the periphrery when compared to TBZ and MTBZ, so in in vivo studies, it 
is preferred (Welch et al., 2012).  The biological data for the eight des-keto compounds 
are shown in Table 1.2 (Zheng et al., 2006).    LOB is included as well for comparison. 
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 Compound 
Values are Ki ± SEM, µM 
[3H]NIC Binding 
α4β2* nAChR 
[3H]MLA Binding 
α7* nAChR 
[3H]DTBZ Binding 
VMAT2 
LOB 0.004 ± 0.000 6.26 ± 1.30 2.76 ± 0.64 
3a 9.75 ± 0.91 >100 6.44 ± 0.54 
3b >100 >100 0.59 ± 0.15 
4a 4.19 ± 0.80 1.70 ± 0.32 5.16 ± 0.30 
4b >100 >100 6.06 ± 0.45 
5a 1.77 ± 0.61 39.3 ± 12.9 3.09 ± 0.41 
5b >100 >100 6.60 ± 2.96 
6a 2.36 ± 0.18 1.21 ± 0.09 1.98 ± 0.31 
6b 33.6 ± 8.54 >100 3.01 ± 0.44 
 
Table 1.2. Binding affinity of des-keto LOB analogs at α4β2* and α7* nAChRs, and at 
VMAT2  
   
The data shown in Table 1.2 clearly show that when the keto functionality is 
removed from the LOB scaffold, the affinity for α4β2* and α7* nAChRs dropped 
considerably (in the order of 25000-fold).  Interestingly, when the keto group was 
removed from the LOB molecule, the resultant analogs had affinities for VMAT2 
comparable to that of LOB.  To summarize: the  keto functionality in LOB appears to be 
important for maintaining high affinity for nAChRs, but the same cannot be stated with 
respect to VMAT2.   In continuation of the systematic approach for studying the SAR of 
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the LOB scaffold, the next step was to generate analogs in which of all oxygen 
functionalities in the LOB molecule are removed. 
 
Scheme 1.3.  Synthetic routes to LOB analogs in which all oxygen functionalities have 
been removed (defunctionalized LOB analogs)) (adapted from Crooks et al., 2011). 
 
The synthesis of defunctionalized LOB analogs is described in Scheme 1.3.  It is 
through this synthetic modification of the LOB molecule that a compound of significant 
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interest was discovered, i.e. lobelane (Zheng, et al., 2005).  All synthetic compounds 
generated in Scheme 1.3 began with LOB as the starting material.  The synthesis of 
compounds 7a and 7b began with epimerization of the LOB starting material by 
subjecting LOB to a basic solution via addition of potassium carbonate in methanol.  This 
was followed by reduction with sodium borohydride to yield a mixture of lobelanidine 
isomers (structure of this compound illustrated previously in Scheme 1.1).  The mixture 
of dihydroxyl isomers was treated with phosphoric acid to promote removal of both 
hydroxyl moieties via dehydration to form C-C double bonds.  The resulting mixture of 
7a (meso-transdiene) and 7b ((-)-trans-transdiene) were separable via silica column 
chromatography to afford pure samples of 7a and 7b.  Compounds 7a and 7b were each 
subjected to hydrogenation conditions (hydrogen gas, palladium-on-carbon) to reduce the 
double bonds in the phenethylene linkers, yielding 9a (cis-lobelane) and 9b ((2S,6S)-1-
methyl-2,6-diphenethylpiperidine).   
The synthesis of compounds 10a and 10b also began with LOB as the starting 
material.  The same ketoalkene analog synthesized in Scheme 1.1 was again generated, 
and then subjected to epimerization via potassium carbonate in methanol, yielding a 
mixture of cis-ketoalkene and trans-ketoalkene isomers.  This mixture was subjected to 
catalytic hydrogenation conditions, to yield a mixture of four isomers, which was then 
was subjected to acid catalyzed dehydration with  phosphoric acid, to yield a separable 
mixture of the two products, 10a ((2S,6R)-1-methyl-2-phenethyl-6-styrylpiperidine) and 
10b ((2S,6S)-1-methyl-2-phenethyl-6-styrylpiperidine). 
Starting with LOB, compounds 11a and 11b were prepared via a five step process, 
with Clemmenson reduction followed by Jones oxidation, compound 1 was generated via 
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the same methodology as in Scheme 1.2, and then subjected to epimerization with 
potassium carbonate in methanol.  This mixture of epimers then underwent catalytic 
hydrogenation to yield a mixture of four isomers, which was then subjected to acid 
catalyzed dehydration to yield a mixture of 11a ((2R,6S)-1-methyl-2-phenethyl-6-
styrylpiperidine and 11b ((2R,6R)-1-methyl-2-phenethyl-6-styrylpiperidine) which were 
separable via silica column chromatography to yield the pure samples of each compound. 
The synthesis of compounds 8 and 12 in Scheme 1.3 also began with LOB, and 
followed the same synthetic route, beginning with epimerization of the LOB starting 
material by subjecting LOB to a basic solution via addition of potassium carbonate in 
methanol.  This was followed by reduction with sodium borohydride to yield a mixture of 
lobelanidine isomers (structure of this compound illustrated previously in Scheme 1.1), at 
which point the mixture of epimers was then subjected to reduction via sodium 
borohydride, then to acid catalyzed dehydration of the alcohol with phosphoric acid to 
yield a mixture of compounds 7a and 8.  The isomeric mixture of compounds 7a and 8 
was then purified via silica column chromatography to yield two pure compounds: the 
previously synthesized 7a and 8 ((2R,6R)-1-methyl-2,6-distyrylpiperidine).  When analog 
8 was subjected to catalytic hydrogenation, compound 12 ((2R,6R)-1-methyl-2,6-
diphenethylpiperidine) was obtained.     
 The results for the ten des-oxygen compounds are shown in Table 1.3 (Zheng et 
al., 2005).  LOB is included as well for easy comparison.  Compound 7a (meso-
transdiene; MTD), is an unsaturated, fully deoxygenated analog of LOB, and was found 
to have little to no affinity at either α4β2* (11.6 µM) or α7* (>100 µM) nAChRs, but had 
comparable affinity for VMAT2 as LOB (i.e. less than 4-fold difference).    
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 Compound 
Values are Ki ± SEM, µM 
[3H]NIC Binding 
α4β2* nAChR 
[3H]MLA Binding 
α7* nAChR 
[3H]DTBZ Binding 
VMAT2 
LOB 0.004 ± 0.000 6.26 ± 1.30 2.76 ± 0.64 
7a 11.6 ± 2.01 >100  9.88 ± 2.22 
7b >100 >100 19.4 ±1.25 
8 >100 >100 7.09 ± 2.42 
9a (lobelane) 14.9 ± 1.67 26.0 ± 6.57 0.97 ± 0.19 
9b >100 25.3 ± 4.27 5.32 ± 0.45 
10a >100 >100 2.50 ±0.23 
10b >100 55.1 ± 13.3 5.27 ± 1.32 
11a >100 >100 2.67 ± 0.56 
11b >100 25.2 ± 3.00 >100 
12 >100 40.0 ± 14.1 6.46 ± 1.70 
 
Table 1.3. Binding affinity of “des-oxygen” LOB analogs at α4β2* & α7* nAChRs, and 
at VMAT2 
  
 Compounds 7b [(-)-trans-transdiene] and 8, are the two trans-enantiomers of 
MTD, and both showed no affinity for either α4β2* (>100 µM) or α7* (>100 µM) 
nAChRs, so they were more selective than LOB for VMAT2, but were less potent than 
LOB at VMAT2 with affinities of 19.4 and 7.09 µM respectively.  When MTD and the 
two enantiomers of the trans-transdiene were subjected to hydrogenation, two 
compounds were generated, viz.: 9a (cis-lobelane) and 9b (trans-lobelane).  The cis-
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isomer of lobelane (9a) (hereafter referred to as simply lobelane) showed selectivity for 
VMAT2, with approximately 4000-fold less affinity for α4β2* (14.9 µM) or α7* (26.0 
µM) nAChRs, and had the greatest affinity of any of the compounds in Table 3 for 
VMAT2 (0.97 µM).  The trans-isomer of lobelane, 9b, showed similar selectivity for 
VMAT2, but was not quite as potent (5.32 µM).     
Nearly all the other defunctionalized analogs of LOB followed suit, with one 
exception:  compounds 10a, 10b, 11a and 11b possess little to no affinity at α4β2* or α7* 
nAChRs, and 10a, 10b, and 11a have similar affinities for VMAT2 as does LOB,  
however, 11b, the (2R,6R)-1-methyl-2-phenethyl-6-styrylpiperidine compound lacked 
affinity for VMAT2 (>100 µM).  The TBZ binding site on VMAT2 was unable to 
distinguish between the (2S,6R) stereochemistry of compound 10a, the (2S,6S) 
stereochemistry of compound 10b, and the (2R,6S) stereochemistry of compound 11a, 
but was not as efficient at recognizing the (2R,6R) stereochemistry of compound 11b, 
and it is noteworthy that VMAT2 could differentiate between these subtle changes in 
stereochemistry (Zheng et al., 2005; Crooks et al., 2011).   
Most importantly, for studies focused on targeting VMAT2, a new lead 
compound was identified, lobelane (9a), that was specific for VMAT2 over α4β2* or α7* 
nAChRs, and had greater affinity for the TBZ binding site of VMAT2 than LOB.  At this 
point, emphasis shifted from structural modification of LOB to structural modification of 
the defunctionalized analog, lobelane.  The second iteration of the SAR flowchart cycle 
had begun with lobelane, the second generation lead compound. 
The systematic approach to the alteration of the lobelane scaffold progressed in a 
similar manner to the approach taken with LOB modification; however, a study of greater 
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depth was undertaken for each remaining functionality of the lobelane scaffold.  First, 
synthesis was undertaken that effectively fragmented the lobelane scaffold to better 
determine which portion(s) of the molecule were most important in binding to the TBZ 
site on VMAT2.  Second, the phenyl rings in the lobelane scaffold were modified, either 
by addition of aromatic substituents, or by replacing the phenyl moieties with other 
aromatic ring systems.  Third, the lobelane scaffold was isomerized with respect to the 
location and stereochemistry of the 2,6-substituents on the central piperidine ring.  
Fourth, the length of the ethylene linkers between the central piperidine ring and the 
phenyl groups were varied.  Fifth, the N-methyl substituent of the lobelane molecule was 
modified, either by increasing the length of the methyl group, or by introducing a variety 
of other substituents with greater organic functionality and polarity.  Sixth, the central 
piperidine ring in lobelane was altered by replacement with other heterocycles, e.g. a 
piperazino ring or a five membered pyrrolidine ring, as well as with conformationally 
restricted ring systems, such as the tropane ring.  Each of these structural modifications 
provided important information and the vast amount of work completed has been 
reviewed (Crooks et al., 2011). 
Structural fragmentation of the lobelane scaffold was undertaken to determine if 
the complete lobelane scaffold was necessary to maintain potent binding to the TBZ site 
on VMAT2.  The synthetic methodology used in generating fragmented lobelane analogs 
is shown in Scheme 1.4. 
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Scheme 1.4. Synthetic methods used in generating fragmented  
lobelane analogs (Zheng et al., 2005; Crooks et al., 2011). 
 
The methodology used to generate analogs 13 and 14 in Scheme 4 involved seven 
steps.  Beginning with 2-bromopyridine, Sonogashira coupling chemistry was used to 
couple phenylacetylene to 2-bromopyridine to generate 2-(phenylethynyl)pyridine, which 
was further modified under acidic conditions (sulfuric acid/reflux) to the ketone to yield 
1-phenyl-2-(pyridin-2-yl)ethanone.  The keto compound was hydrogenated with Adam’s 
catalyst (platinum (IV) oxide) to reduce the pyridine ring to a piperidine ring, and set the 
stereochemistry of the phenethyl linker, yielding the nor-(R)-1-phenyl-2-(piperidin-2-
yl)ethanone.  N-methylation via formaldehyde addition afforded the N-methyl analog, 
(R)-2-(1-methylpiperidin-2-yl)-1-phenylethanone.  The keto functionality was then 
reduced with sodium borohydride and dehydrated under acidic conditions with 
phosphoric acid to produce compound 13, (R,E)-1-methyl-2-styrylpiperidine.  A portion 
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of this product was again subjected, in the final step, to hydrogenation conditions 
(hydrogen gas, palladium-on-carbon) to yield the lobelane fragment analog compound 
14, (R)-1-methyl-2-phenethylpiperidine (Zheng, et al., 2005). 
Four acyclic compounds in which the piperidine ring was removed in favor of 
acyclic analogs were also prepared as lobelane fragment analogs.  Two compounds, 15 
((S)-N-methyl-1,9-diphenylnonan-3-amine) and 16 ((R)-N-methyl-1,9-diphenylnonan-3-
amine) were fortuitously formed as side products and separated via silica column 
chromatography from the hydrogenation of the previously discussed compounds 7b ((-)-
trans-transdiene) and compound 8 respectively, formed via ring opening during the 
hydrogenation process.   Two compounds, 17 ((E)-N-cinnamyl-N-methyl-3-phenylprop-
2-en-1-amine) (Blickle et al., 1939) and 18 (N-methyl-3-phenyl-N-(3-
phenylpropyl)propan-1-amine) (Stuhmer et al., 1954) were synthesized via established 
methods.  These four acyclic analogs of lobelane are shown in Figure 1.9. 
 
 
Figure 1.9. Structures of acyclic fragmented lobelane analogs 
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 The biological results for the six fragmented lobelane analogs are shown in Table 
1.4 (Zheng et al., 2005).  Compound 13, the fragmented MTD analog, (R,E)-1-methyl-2-
styrylpiperidine, had no affinity for any of the receptors tested (IC50>100 µM).  
Compound 14, the lobelane fragment analog, (R)-1-methyl-2-phenethylpiperidine, 
showed only slight affinity for the α4β2* nAChR, but had no affinity for the α7* nAChR, 
and surprisingly had no affinity at VMAT2 (IC50>100 µM).  These data indicate that both 
side chain linkers are required for the lobelane scaffold to bind to VMAT2. The acyclic 
fragments of lobelane, compounds 15, 16, 17, and 18 had no affinity for either α4β2* or 
α7* nAChRs, but had similar binding affinity as LOB at VMAT2, but slightly decreased 
affinity for VMAT2 when compared to lobelane.  The combined data from Table 1.4 
indicate that the amine moiety and the two phenethyl moieties are required for binding to 
the TBZ site on VMAT2, and in the case of the acyclic analogs, the data suggests that an 
intact piperidine ring may be needed to maintain affinity for the TBZ site on VMAT2.        
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 Compound 
Values are Ki ± SEM, µM 
[3H]NIC Binding 
α4β2* nAChR 
[3H]MLA Binding 
α7* nAChR 
[3H]DTBZ 
Binding VMAT2 
LOB 0.004 ± 0.000 6.26 ± 1.30 2.76 ± 0.64 
lobelane 14.9 ± 1.67 26.0 ± 6.57 0.97 ± 0.19 
13 >100 >100 >100 
14 4.52 ± 0.58 >100 >100 
15 >100 >100 5.21 ± 1.23 
16 >100 >100 3.96 ± 0.80 
17 >100 >100 2.37 ± 0.55 
18 >100 >100 3.07 ± 1.72 
 
Table 1.4 Binding affinity of acyclic fragmented lobelane analogs 
at α4β2* & α7* nAChRs, and at VMAT2  
 
  The next phase of modification of the lobelane scaffold involved alteration of the 
phenyl rings, either by addition of aromatic substituents, or by replacing the phenyl rings 
with other aromatic ring systems into those positions of the scaffold.  Scheme 1.5 outlines 
the chemistry necessary for the synthesis of symmetrically substituted phenyl ring 
modification of the lobelane scaffold. 
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 Scheme 1.5. Synthetic methods for generation of symmetrically substituted phenyl ring 
analogs of lobelane (Zheng et al., 2005). 
 
 Synthesis of symmetrical substituted phenyl ring analogs of lobelane utilizes 2,6-
methylpyridine as a starting material, which undergoes a condensation type reaction with 
substituted aryl aldehydes when refluxed in acetic anhydride to yield the corresponding 
2,6-distyrylpyridine with a variety of substituted phenyl rings.  The phenyl substituted 
2,6-distyrylpyridine compounds are then subjected to hydrogenation conditions with 
Adam’s catalyst (platinum(IV)oxide) to reduce the central pyridine ring to a piperidine 
ring (affording 2,6-cis-stereochemistry) and the two alkene moieties to alkanes.  At this 
stage of the synthesis, phenyl substituted (2S,6R)-2,6-diphenethylpiperidine is generated.  
If all positions on the phenyl rings are hydrogen rather than other functionalities, the 
compound generated is nor-lobelane, (des-methyl lobelane).  To introduce the N-methyl 
group present in Lobeline and lobelane, the phenyl substituted (2S,6R)-2,6-
diphenethylpiperidine intermediates were exposed to reductive amination conditions with 
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paraformaldehyde and sodium cyanoborohydride in methanol to yield the  corresponding 
phenyl substituted (2S,6R)-1-methyl-2,6-diphenethylpiperidine scaffold.  Symmetrical 
phenyl substituted analogs of both lobelane and nor-lobelane were generated via this 
methodology, and their structures and binding affinities for α4β2* & α7* nAChRs, and for 
VMAT2 are included in Table 1.5. 
 
 
Compound 
Identifier 
 
Compound Structure 
Values are Ki ± SEM, µM 
[3H]NIC 
Binding 
α4β2* 
nAChR 
[3H]MLA 
Binding 
α7* nAChR 
[3H]DTBZ 
Binding 
VMAT2 
VMAT2 
[3H]DA 
Uptake  
 
LOB 
 
N
CH3
OH O
 
 
0.004 ± 
0.000 
 
6.26 ± 1.30 
 
2.76 ± 0.64 
 
0.47 ± 0.045 
 
lobelane 
N
CH3
 
 
14.9 ± 1.67 
 
26.0 ± 6.57 
 
0.97 ± 0.19 
 
0.045± 0.002 
Nor-lobelane 
N
H
 
 
>100 
 
>100 
 
2.31 ± 0.21 
 
0.043 ±0.008 
 
19a 
N
H
F F
 
 
>100 
 
>100 
 
1.60 ± 0.10 
 
0.042±0.011 
 
19b 
N
F F
CH3
 
 
>100 
 
>100 
 
1.07 ± 0.07 
 
0.057± 0.010 
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 20a 
N
H
F F
 
 
>100 
 
49.2 ± 21.3 
 
1.60 ± 0.08 
 
0.036 ±0.006 
 
20b 
N
CH3
F F
 
 
>100 
 
16.6 ± 3.47 
 
0.57 ± 0.07 
 
0.093±0.018 
 
21a 
N
H
F F
 
 
>100 
 
>100 
 
1.25 ± 0.08 
 
0.021± 0.004 
 
21b 
N
CH3F F
 
 
>100 
 
>100 
 
0.98 ± 0.31 
 
0.030± 0.008 
 
22a 
N
H
O
H3C O
H3C
 
 
>100 
 
>100 
 
1.87 ± 0.19 
 
0.026 ± 0.004 
 
22b 
N
CH3
O
H3C O
H3C
 
 
>100 
 
29.7 ± 7.73  
 
0.58 ± 0.04 
 
0.026 ± 0.004 
 
23a 
N
H
O
H3C
O
CH3
 
 
>100 
 
>100 
 
1.67 ± 0.07 
 
0.040± 0.006 
 
23b 
N
CH3
O
H3C
O
CH3
 
 
>100 
 
25.1 ± 2.23  
 
0.43 ± 0.03 
 
0.030± 0.005 
 
24a 
N
H
O O
H3C CH3
 
 
>100 
 
>100 
 
3.32 ± 0.82 
 
0.013±0.003 
 
24b 
N
CH3O O
H3C CH3
 
 
>100 
 
>100 
 
1.73 ± 0.20 
 
0.015 ± 0.002 
 
25a 
N
H
O
O O
O
 
 
>100 
 
>100 
 
2.34 ± 0.16 
 
0.191± 0.146 
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 25b 
N
CH3
O
O O
O
 
 
>100 
 
18.2 ± 6.87  
 
0.52 ± 0.25 
 
0.043± 0.011 
 
26a 
N
H
H3C CH3
 
 
>100 
 
>100 
 
3.23 ± 0.10 
 
0.59 ± 0.010 
 
26b 
N
CH3H3C CH3
 
 
>100 
 
>100 
 
4.36 ± 0.18 
 
0.154± 0.008 
 
27a 
N
H
F3C CF3
 
 
>100 
 
>100 
 
9.90 ± 2.01 
 
0.836± 0.361 
 
27b 
N
CH3
F3C CF3
 
 
>100 
 
>100 
 
1.51 ± 0.07 
 
0.19± 0.015 
 
28a 
N
H
Cl
Cl
Cl
Cl
 
 
>100 
 
>100 
 
1.32 ± 0.18 
 
0.182± 0.005 
 
28b 
N
CH3
Cl
Cl
Cl
Cl
 
 
>100 
 
>100 
 
1.04 ± 0.06 
 
0.016± 0.005 
 
29a 
N
H
Ph Ph
 
 
>100 
 
>100 
 
>100 
 
0.127 ± 0.034 
 
29b 
N
CH3Ph Ph
 
 
>100 
 
>100 
 
10.7 ± 6.60 
 
0.034± 0.008 
 
30  
N
H
O O
O O
 
 
>100 
 
>100 
 
5.96 ± 1.76 
 
0.247± 0.042 
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 31 
N
H
HO OH
 
 
>100 
 
>100 
 
5.26 ± 0.47 
 
0.047± 0.017 
 
32a 
N
H
 
 
>100 
 
>100 
 
4.68 ± 0.70 
 
* 
 
32b 
N
CH3
 
 
>100 
 
>100 
 
0.63 ± 0.16 
 
* 
 
33a 
N
H
 
 
>100 
 
>100 
 
>100 
 
* 
 
33b 
N
CH3
 
 
>100 
 
>100 
 
2.03 ± 0.45 
 
* 
        
Table 1.5 Structures of substituted phenyl analogs of lobelane and assay data from 
[3H]NIC Binding α4β2* nAChR, [3H]MLA Binding α7* nAChR, [3H]DTBZ Binding 
VMAT2, and VMAT2 [3H]DA Uptake 
 
 Twenty eight lobelane analogs with a variety of substitutions in the phenyl rings 
were synthesized in this series.  All of the compounds within this series had either lower 
or comparable affinities at α4β2* & α7* nAChRs when compared to lobelane, with the 
exception of compounds 29a ((2S,6R)-2,6-bis(2-(biphenyl-4-yl)ethyl)piperidine) and 33a 
((2S,6R)-2,6-bis(2-(naphthalen-2-yl)ethyl)piperidine), which were both nor-analogs with 
bulky biphenyl (compound 29a) and 2-naphthyl (compound 33a) analogs, all compounds 
had comparable affinity to lobelane at VMAT2.  Analogs 20b ((2S,6R)-2,6-bis(3-
fluorophenethyl)-1-methylpiperidine), 22b ((2S,6R)-2,6-bis(2-methoxyphenethyl)-1-
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methylpiperidine), and 23b ((2S,6R)-2,6-bis(3-methoxyphenethyl)-1-methylpiperidine)  
had the highest affinity for VMAT2 with Ki values of 0.57, 0.58, and 0.43 µM, 
respectively.  Also the N-methyl analogs consistently exhibited higher affinity at VMAT2 
when compared to their corresponding nor-counterparts.  All in all, modification of the 
phenyl rings in the lobelane scaffold via addition of a variety of aromatic substituents that 
were either electron withdrawing, electron donating, or replacement of the phenyl rings 
with more bulky aromatic moieties was successful in further reducing the affinity of these 
analogs at α4β2* & α7* nAChRs, while maintaining and perhaps slightly improving 
affinity for the TBZ binding site on VMAT2.  The compounds that had the greatest 
affinity for the TBZ binding site on VMAT2 and their corresponding aromatic 
substituents were 19b (2-fluoro substituted phenyl), 20b (3-fluoro substituted phenyl), 
21b (4-fluoro substituted phenyl), 22b (2-methoxy substituted phenyl), 23b (3-methoxy 
substituted phenyl), 24b (4-methoxy substituted phenyl), 25b (3,4-methylenedioxy 
substituted phenyl), and 28b (2,4-dichloro substituted phenyl), each of which possessed 
affinity for the TBZ site on VMAT2 of approximately 1 µM and each possessed a N-
methyl moiety.  This subgroup of eight compounds also had correspondingly potent 
values in the VMAT2 [3H]DA Uptake assay with values ranging from 15-93 nM.  It 
cannot be overstated that the importance of the VMAT2 [3H]DA Uptake assay is much 
greater than that of the TBZ site binding assay.  The TBZ binding assay does determine 
the affinity of the ligand in question for the TBZ binding site on VMAT2, but the 
VMAT2 [3H]DA Uptake assay accurately determines the effect of the ligand on the 
functioning vesicles’ ability to sequester DA into the vesicle for storage and later 
use/release.  More information on these two assays will be addressed in Chapter 5. 
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 Two further synthetic schemes were designed to modify the phenyl moieties 
present in the lobelane scaffold.  Scheme 1.6 outlines the synthesis of lobelane analogs 
possessing heteroaromatic rings in place of the phenyl rings, and Scheme 1.7 outlines the 
synthesis of asymmetric lobelane analogs that possess two different aromatic moieties in 
place of the two phenyl rings of the lobelane scaffold. 
 
 
   
Scheme 1.6 Synthetic methods for generation of symmetrically substituted 
heteroaromatic ring analogs of lobelane (Varkat et al., 2010). 
 
 The synthetic procedure illustrated in Scheme 1.6 began with N-methylated 2,6-
dimethylpyridinium iodide as the staring material.  The starting material underwent a 
condensation reaction with the required heteroaromatic aldehyde to form the conjugated 
backbone of the scaffold.  When subjected to hydrogenation conditions (Adam’s catalyst 
and hydrogen gas), five final products with heteroaromatic moieties in place of the 
phenyl rings found in the lobelane scaffold were generated.  Their structures and binding 
affinities at VMAT2 are included in Table 1.6.  
 Asymmetric lobelane analogs which integrate two non-identical aromatic 
functionalities into the lobelane scaffold were also being prepared.  The synthesis of these 
asymmetric lobelane analogs is outlined in Scheme 1.7.   
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Scheme 1.7 Synthetic methods for the generation of asymmetrical 
 lobelane analogs (Crooks, et al., 2011)  
 
 Two asymmetric analogs were prepared via the chemistry outlined in Scheme 1.7. 
Beginning with 2-bromo-6-pyridinecarboxaldehyde as the starting material, a Wittig 
reaction with a benzyl ylid afforded a cis-trans mixture of 2-bromo-6-styrylpyridine.  
This cis-trans mixture was taken without isolation and subjected to Sonogashira coupling 
chemistry with either 1-ethynylnaphthalene or 3-ethynylanisole to afford the conjugated 
intermediates, 2-(naphthalen-1-ylethynyl)-6-styrylpyridine and 2-((3-
methoxyphenyl)ethynyl)-6-styrylpyridine respectively.    
The two conjugated intermediates (2-(naphthalen-1-ylethynyl)-6-styrylpyridine 
and 2-((3-methoxyphenyl)ethynyl)-6-styrylpyridine) were first subjected to 
hydrogenation conditions with Adam’s catalyst and hydrogen gas, and then N-methylated 
via reductive amination.  The two final products, compound 39, (2S,6R)-1-methyl-2-(2-
(naphthalen-1-yl)ethyl)-6-phenethylpiperidine, and compound 40 (2S,6R)-2-(3-
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methoxyphenethyl)-1-methyl-6-phenethylpiperidine and their binding affinities for 
VMAT2 are included in Table 1.6. 
 
 
Compound 
Identifier 
 
Compound Structure 
Values are Ki ± 
SEM, µM 
[3H]DTBZ Binding 
VMAT2 
 
LOB N
CH3
OH O
 
 
2.76 ± 0.64 
 
lobelane N
CH3  
 
0.97 ± 0.19 
 
34 N
CH3
N N
 
 
5.87 ± 1.72 
 
35 N
CH3
N N
 
 
33.3 ± 16.3 
 
36 N
CH3
N N
 
 
0.96 ± 0.37 
 
37 N
CH3N N  
 
2.64 ± 1.41 
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 38 N
CH3N NCH3 H3C  
 
9.21 ± 1.65 
 
39 N
CH3  
 
1.02 ± 0.30 
 
40 N
CH3
O
CH3
 
 
0.83 ± 0.23 
 
Table 1.6 Structures and Binding affinity of heteroaromatic substituted and asymmetrical 
lobelane analogs for VMAT2  
 
 Of the five analogs that were designed and synthesized to contain two hetero-
aromatic ring substituents instead of rather than the two phenyl rings found in lobelane, 
three (i.e. compounds 34, 35, and 38) will be positively charged due to protonation at 
physiological pH, i.e. nitrogen moieties with pKa’s greater than 7.2-7.4 at three distinct 
sites on the molecule.  The majority of the compounds containing nitrogen atoms 
susceptible to protonation at physiological pH exhibited lower affinities for the TBZ 
binding site on VMAT2 (compounds 34, 35, 37 and 38).  The lone exception was 
compound 36, where the phenyl rings that are found in lobelane have been replaced by 
two 2-quinolinyl moieties; this analog showed similar affinity to lobelane at VMAT2 
(Varkat, et al., 2010).  This is important information, since it shows that the TBZ binding 
site on VMAT2 prefers neutral aryl substituents in order to bind effectively.  
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 The two asymmetric analogs of lobelane (compounds 39 and 40) exhibited similar 
affinities as lobelane at the TBZ binding site on VMAT2.  Compound 39, containing one 
naphthyl ring and one phenyl ring did have slightly less affinity than the symmetrical 
naphthyl analog (1.02 µM vs 0.63 µM, respectively).  Compound 40, containing one 
anisole ring and one phenyl ring also had slightly less affinity for VMAT2 than the 
symmetrical 3-anisolyl analog (0.83 µM vs 0.43 µM).         
 The next two phases of modification of the lobelane scaffold involved altering 
both the location of attachment of the phenethyl linkers on the central piperidine ring as 
well as varying the length of the methylene linkers that connect the aryl rings to the 
central piperidine ring, in order to determine the importance of the intramolecular 
distance between the piperidine ring amine moiety and the phenyl rings (Crooks et al., 
2011).  Schemes 1.8, and 1.9 outline the chemistry used in these modifications of the 
lobelane scaffold.  
 Scheme 1.8 illustrates the synthesis of isomerized lobelane analogs in which the 
phenethyl linkers have been moved from the 2,6 positions of the piperidine ring to the 
1,2-, 1,3-, and 1,4-positions.  Several analogs were also generated that contained a three-
carbon linker between the piperidine ring and the phenyl rings.  The synthesis utilizes an 
appropriate 2-methylpyridine, 3-methylpyridine, or 4-methylpyridine, depending on the 
desired attachment point of the linker on the piperidine ring.  The stating material is 
condensed with benzaldehyde in refluxing acetic anhydride to yield the conjugated 2, 3, 
or 4 substituted (E)-styrylpyridine.  These conjugated products are then subjected to 
hydrogenation conditions with Adam’s catalyst (platinum(IV) oxide) and hydrogen gas to 
yield the appropriate 2, 3, or 4 substituted phenethylpiperidine.   
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Scheme 1.8 Synthetic methods for generation of isomerized lobelane  
analogs (Zheng et al., 2005; Crooks et al., 2011) 
 
The substituted phenethylpiperidines were reacted via one of two methods to 
yield either N1 linked phenethyl analogs or N1 linked phenpropyl analogs.  In the case of 
the N1 substituted phenethyl compounds, the substituted phenethylpiperidines were 
reacted with phenylacetaldehyde and sodium cyanoborohydride to yield the desired series 
of products.  In the case of the N1 substituted phenpropyl compounds, the substituted 
phenethylpiperidines were reacted with trans-cinnamyl bromide with potassium 
carbonate serving as a base, to yield the desired series of products.  The exact structures 
of the analogs generated in Scheme 1.8 and the resultant binding affinities at α4β2* & α7* 
nAChRs, and at VMAT2 are shown in Table 1.7. 
Scheme 1.9 outlines the chemistry used in generating a series of four compounds 
where the phenethyl linkers have been moved to the 2,4 and 3,5 positions of the central 
62 
 
piperidine ring of the lobelane scaffold.  In order to more clearly indicate where the 
amine moiety is in the ring, it has been given a marker labeled as such in the scheme. 
 
 
Scheme 1.9 Synthetic methods for generation of isomerized lobelane analogs with 
phenethyl linkers in the 2,4 and 3,5 position of the piperidine ring (Zheng et al., 2005; 
Crooks et al., 2011) 
 
 The synthesis of the four analogs generated in Scheme 1.9 necessitated two 
different reaction conditions for the appropriate starting materials.  When the starting 
material was 2,4-lutidine, also known as 2,4-dimethylpyridine, the hydrogen atoms on the 
methyl groups were sufficiently acidic to allow condensation reaction to be utilized.  2,4-
Lutidine was subjected to condensation reaction conditions with benzaldehyde in 
refluxing acetic anhydride to yield the desired conjugated intermediate, 2,4-
distyrylpyridine.  However, the presence of the methyl groups in the 3 and 5 positions of 
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the pyridine ring in 3,5-lutidine (also known as 3,5-dimethylpyridine) made the hydrogen 
atoms on the methyl groups less acidic, and a different chemistry was required to 
generate the conjugated intermediate, 3,5-distyrylpyridine.  Starting with 3,5-lutidine, the 
condensation reaction proceeded only with an activated form of benzaldehyde, i.e. N-
benzylidene-4-chloroaniline, using potassium t-butoxide as a base in dimethylformamide.  
The two appropriately substituted conjugated intermediates, 2,4-distyrylpyridine and 3,5-
distyrylpyridine, were then subjected to hydrogenation conditions with Adam’s catalyst 
and hydrogen gas to yield nor-(2S,4S)-2,4-diphenethylpiperidine and nor-(3R,5S)-3,5-
diphenethylpiperidine, respectively.  In order to introduce the N-methyl moiety, the nor-
compounds were exposed to reductive amination conditions with paraformaldehyde and 
sodium cyanoborohydride in methanol to generate analogs (2S,4S)-1-methyl-2,4-
diphenethylpiperidine and (3R,5S)-1-methyl-3,5-diphenethylpiperidine.  The binding 
affinities of the four analogs generated in Scheme 1.9 at α4β2* & α7* nAChRs, and at 
VMAT2 are shown in Table 1.7. 
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 Compound 
Identifier 
 
Compound Structure 
Values are Ki ± SEM, µM 
[3H]NIC 
Binding 
α4β2* nAChR 
[3H]MLA 
Binding α7* 
nAChR 
[3H]DTBZ 
Binding 
VMAT2 
 
LOB 
 
N
CH3
OH O
 
 
0.004 ± 0.000 
 
6.26 ± 1.30 
 
2.76 ± 0.64 
 
lobelane NCH3
 
 
14.9 ± 1.67 
 
26.0 ± 6.57 
 
0.97 ± 0.19 
 
 
41 
N
 
 
 
>100 
 
 
66.9 ± 27.4 
 
 
3.32 ± 0.74 
 
42 N
 
 
>100 
 
>100 
 
3.95 ± 0.61 
 
43 N
 
 
7.62 ± 1.47 
 
>100 
 
1.87 ± 0.25 
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44 
N
 
 
 
>100 
 
 
9.02 ± 1.54 
 
 
3.35 ± 0.80 
 
45 
N
 
 
>100 
 
>100 
 
4.04 ± 1.76 
 
46 
N
 
 
>100 
 
>100 
 
2.47 ± 0.70 
 
 
47 
N
H
 
 
 
>100 
 
 
>100 
 
 
1.36 ± 0.11 
 
 
48 
HN
 
 
 
>100 
 
 
>100 
 
 
6.11 ± 0.92 
Table 1.7 (continued) 
66 
 
  
49 
N
CH3  
 
 
>100 
 
 
>100 
 
 
2.62 ± 0.51 
 
 
50 
N
H3C
 
 
 
>100 
 
 
>100 
 
 
11.7 ± 0.65 
 
Table 1.7 Compound structures and α4β2* & α7* nAChRs, and VMAT2 binding 
affinity of isomerized lobelane analogs with phenethyl linkers in the N1, C2; N1, 
C3; N1, C4;  C2, C4 and C3, C5 positions. 
 
 The above isomerized analogs of lobelane had the low affinities at α4β2* & α7* 
nAChRs, and interestingly maintained similar affinities to lobelane at the TBZ binding 
site on VMAT2 (within one order of magnitude).  Compounds 43, 46, and 49 were 
especially interesting, since they exhibited binding affinity better than most other analogs 
in the table; the linkers in these analogs were in the C2, C4 and N1, C4 positions.  The 
extra carbon in the N1 linker of compound 46 only moderately decreased the analog’s 
affinity for VMAT2.  These data indicate that isomerization of the lobelane scaffold to 
afford compounds with linkers in varying positions of attachment around central 
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piperidine ring does not greatly hinder binding to VMAT2, and allows for interesting 
opportunities involving scaffold optimization and chemical space.   
 The fourth stage of the systematic approach to the alteration of the lobelane 
scaffold comprised of designing analogs with variable methylene linker lengths between 
the central piperidine ring of the scaffold and the phenyl rings, therefore increasing and 
decreasing intramolecular distances between the amine moiety and the phenyl rings.  The 
number of carbon atoms between the piperidine ring and the phenyl rings was varied 
from zero to three in the C2 and C6 positions, affording 17 compounds in this series 
(Zheng et al., 2008; Crooks et al., 2011).  Schemes 1.10, 1.11, and 1.12 outline the 
chemistry designed to produce the three symmetrical scaffolds. 
 
 
Scheme 1.10 Synthesis of a symmetrical lobelane analog with zero methylene groups 
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011) 
 
 Synthesis of the symmetrical lobelane analog with no carbon atoms between the 
piperidine ring and the two phenyl rings (i.e. a molecule which is devoid of methylene 
units between the central piperidine ring and two phenyl rings) was synthesized by initial 
N-methylation of the starting material, 2,6-biphenylpyridine, via reaction with methyl p-
tosylate, generating the quaternary ammonium salt as an intermediate.  Subsequent two 
step reduction of the quaternary ammonium salt with NaBH4, followed by catalytic 
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hydrogenation with palladium- on-carbon and hydrogen gas afforded the desired 
compound, (2S,6R)-1-methyl-2,6-diphenylpiperidine. 
 The synthesis of the symmetrical lobelane analog with one methylene group 
between the piperidine ring and the two phenyl rings is shown in Scheme 1.11. 
 
Scheme 1.11 Synthesis of the symmetrical lobelane analog with one methylene group 
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011) 
 
 The synthesis of the symmetrical analog with one methylene group between the 
piperidine ring and the two phenyl rings utilized 2,6-dibromopyridine as the starting 
material.  
Application of Kumada coupling chemistry, which consists of a cross coupling reaction, 
which is widely used in organic synthesis for generating carbon–carbon bonds by the reaction of 
a Grignard reagent, in this case (3-phenylpropyl)magnesium bromide and an organic halide, 
i.e. 2,6-dibromopyridine . The Kumada coupling procedure uses transition metal 
catalysts, in this case dichloro[1,3-bis(diphenylphosphino)propane]nickel, to couple the 
2,6-dibromopyridine starting material with (3-phenylpropyl)magnesium bromide to 
afford the desired 2,6-dibenzylpyridine intermediate. Reduction of this intermediate via 
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hydrogenation conditions utilizing Adam’s catalyst and hydrogen gas yielded nor-
(2S,6R)-2,6-dibenzylpiperidine. In order to introduce the N-methyl moiety the nor-
compound was exposed to reductive amination conditions with paraformaldehyde and 
sodium cyanoborohydride in methanol to generate lobelane analog (2S,6R)-2,6-dibenzyl-
1-methylpiperidine.     
A similar synthetic strategy for the symmetrical lobelane analog with three 
methylene groups between the piperidine ring and the two phenyl rings is shown in 
Scheme 1.12. 
 
 
Scheme 1.12 Synthesis of the symmetrical lobelane analog with three methylene groups 
between the piperidine ring and the phenyl rings (Zheng et al., 2008; Crooks et al., 2011) 
 
The synthesis of the symmetrical analog with three methylene groups linking the 
piperidine ring and the two phenyl rings also utilized 2,6-dibromopyridine as the starting 
material. Again, via the application of Kumada coupling chemistry to couple the 2,6-
dibromopyridine starting material with (3-phenylpropyl)magnesium bromide afford the 
desired 2,6-bis(3-phenylpropyl)pyridine intermediate.  Reduction of the intermediate via 
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hydrogenation conditions with Adam’s catalyst and hydrogen gas yielded the nor-
(2R,6S)-2,6-bis(3-phenylpropyl)piperidine compound. In order to introduce the N-methyl 
moiety found in the lobelane scaffold, the nor-compounds were exposed to reductive 
amination conditions with paraformaldehyde and sodium cyanoborohydride in methanol 
to generate lobelane analog (2R,6S)-1-methyl-2,6-bis(3-phenylpropyl)piperidine. 
 The asymmetric compounds in this series required more involved chemistry and 
multiple synthetic steps.  The synthesis of the analog containing zero carbons between the 
piperidine ring and the phenyl ring on one side of the molecule and one carbon between 
the piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in 
Scheme 1.13.   
 
 
Scheme 1.13 Synthesis of an asymmetrical lobelane analog with zero carbons and one 
carbon in the linkers between the piperidine ring and the phenyl rings (Zheng et al., 2008; 
Crooks et al., 2011). 
 
 The starting material for the synthesis outlined in Scheme 1.13 was 2-bromo-6-
methoxypyridine.  Application of Kumada coupling chemistry with benzylmagnesium 
chloride afforded the 2-benzyl-6-methoxypyridine intermediate, which was then 
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subjected to reaction with phosphoryl chloride to transform the methoxy group to a 
chlorine functionality, which yielded the 2-benzyl-6-chloropyridine intermediate.  This in 
turn, was subjected to Suzuki coupling with phenylboronic acid catalyzed with [1,3-
bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)-palladium(II) dichloride 
(PEPPSI-IPr) and KOtBu as base in isopropanol, to yield the 2-benzyl-6-phenylpyridine 
intermediate.  Reduction of this intermediate via hydrogenation with Adam’s catalyst and 
hydrogen gas yielded the nor- (2R,6S)-2-benzyl-6-phenylpiperidine.  In order to 
introduce the N-methyl moiety, the nor-compound was exposed to reductive amination 
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to generate 
the lobelane analog (2R,6S)-2-benzyl-1-methyl-6-phenylpiperidine. 
 The synthesis of the analogs containing zero methylene units between the 
piperidine ring and the phenyl ring on one side of the molecule and either two methylene 
units or three methylene units between the piperidine ring and the phenyl ring on the 
opposite side of the molecule is outlined in Scheme 1.14.   
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 Scheme 1.14 Synthesis of asymmetrical lobelane analog with zero methylene units and 
either two or three methylene units in the linkers between the piperidine ring and the 
phenyl rings (Zheng et al., 2008; Crooks et al., 2011). 
 
 The synthesis of both asymmetrical compounds began with 2-bromo-6-
methylpyridine as the starting material, which was reacted with phenylboronic acid under 
Suzuki coupling conditions to yield the common intermediate, 2-methyl-6-
phenylpyridine.  From this point the syntheses diverged.  To make the asymmetrical 
compound with zero and two methylene units in the linkers, the common intermediate 
was subjected to a condensation reaction with benzaldehyde in refluxing acetic 
anhydride.  This afforded the conjugated product (E)-2-phenyl-6-styrylpyridine, which 
was then reduced under hydrogenation conditions to nor-(2R,6S)-2-phenethyl-6-
phenylpiperidine.  The N-methyl group was introduced utilizing reductive amination 
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conditions with paraformaldehyde and sodium cyanoborohydride in methanol to generate 
the desired product, (2R,6S)-1-methyl-2-phenethyl-6-phenylpiperidine.  To prepare the 
asymmetrical compound with zero and three carbons in the linker units, the common 
intermediate 2-methyl-6-phenylpyridine was subjected to deprotonation of the 2-methyl 
group followed by an SN2 reaction with 2-iodoethylbenzene to afford 2-phenyl-6-(3-
phenylpropyl)pyridine,  which was then reduced under hydrogenation conditions to nor-
(2S,6S)-2-phenyl-6-(3-phenylpropyl)piperidine followed by N-methylation to afford the 
desired product, (2S,6S)-1-methyl-2-phenyl-6-(3-phenylpropyl)piperidine. 
 The synthesis of the analog containing one methylene unit between the piperidine 
ring and the phenyl ring on one side of the molecule and two methylene units between the 
piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in 
Scheme 1.15.  Starting with 2-benzyl-6-chloropyridine, Negishi coupling of the starting 
material with 2-phenyl-1-ethylzinc iodide (generated in situ) using PEPPSI-IPr as a 
catalyst afforded 2-benzyl-6-phenethylpyridine, which was then subjected to catalytic 
hydrogenation to yield nor- (2S,6R)-2-benzyl-6-phenethylpiperidine and N-methylated 
with paraformaldehyde and sodium cyanoborohydride in methanol to generate the desired 
product, (2S,6R)-2-benzyl-1-methyl-6-phenethylpiperidine. 
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 Scheme 1.15 Synthesis of the asymmetrical lobelane analog with one methylene units 
and two methylene units in the linkers between the piperidine ring and the phenyl rings 
(Zheng et al., 2008; Crooks et al., 2011). 
 
The synthesis of the analog containing one methylene unit between the piperidine 
ring and the phenyl ring on one side of the molecule and three methylene units between 
the piperidine ring and the phenyl ring on the opposite side of the molecule is outlined in 
Scheme 1.16.  Starting with 2-benzyl-6-chloropyridine, Negishi coupling of the starting 
material with 3-phenyl-1-propylzinc iodide (generated in situ) using PEPPSI-IPr as a 
catalyst afforded 2-benzyl-6-(3-phenylpropyl)pyridine, which was then subjected to 
catalytic hydrogenation to yield nor- (2S,6S)-2-benzyl-6-(3-phenylpropyl)piperidine. N-
methyl under reductive amination conditions with paraformaldehyde and sodium 
cyanoborohydride in methanol afforded the desired product, (2S,6S)-2-benzyl-1-methyl-
6-(3-phenylpropyl)piperidine.  
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  Scheme 1.16 Synthesis of an asymmetrical lobelane analog with one methylene 
unit and two methylene units in the linkers between the piperidine ring and the phenyl 
rings (Zheng et al., 2008; Crooks et al., 2011). 
 
The synthesis of the analog containing two methylene units between the 
piperidine ring and the phenyl ring on one side of the molecule and three methylene units 
between the piperidine ring and the phenyl ring on the opposite side of the molecule is 
outlined in Scheme 1.17.  The starting material,  2,6-lutidine, was subjected to mono-
condensation with benzaldehyde (both mono and disubstituted products were produced, 
and the mono product was separated via column chromatography), to afford the 
conjugated product, (E)-2-methyl-6-styrylpyridine.  The conjugated product was then 
subjected to deprotonation of the 2-methyl group followed by SN2 reaction with (2-
iodoethyl)benzene to yield (E)-2-(3-phenylpropyl)-6-styrylpyridine, which was subjected 
to catalytic hydrogenation to yield nor-(2S,6S)-2-phenethyl-6-(3-phenylpropyl)piperidine 
and N-methylated to afford the desired product,  (2S,6S)-1-methyl-2-phenethyl-6-(3-
phenylpropyl)piperidine.       
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 Scheme 1.17 Synthesis of an asymmetrical lobelane analog with two methylene units and 
three methylene units in the linkers between the piperidine ring and the phenyl rings  
(Zheng et al., 2008; Crooks et al., 2011). 
 
 The 17 lobelane analogs generated in this fourth stage of the systematic approach 
to the alteration of the lobelane scaffold comprised of designing analogs with modified 
lengths between the central piperidine ring of the scaffold, therefore varying the 
intramolecular distance between the amine moiety and the phenyl rings; their binding 
affinities at the TBZ binding site on VMAT2 are shown in Table 1.8. 
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 Compound 
Identifier 
 
Compound Structure 
Values are Ki ± SEM, 
µM 
[3H]DTBZ Binding 
VMAT2 
 
LOB N
CH3
OH O
 
 
2.76 ± 0.64 
 
lobelane N
CH3  
 
0.97 ± 0.19 
 
51 N
CH3  
 
>100 
 
52a NH  
 
7.68 ± 1.44 
 
52b N
CH3  
 
10.5 ± 3.36 
 
53a NH  
 
4.50 ± 1.02 
 
53b N
CH3  
 
1.00 ± 0.23 
 
54a NH
 
 
24.1 ± 6.10 
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 54b N
CH3  
 
13.6 ± 8.14 
 
55a NH
 
 
28.4 ± 7.30 
 
55b N
CH3  
 
16.1 ± 4.07 
 
56a NH
 
 
28.6 ± 2.44 
 
56b N
CH3  
 
62.5 ± 16.6 
 
57a NH
 
 
12.2 ± 0.19 
 
57b N
CH3  
 
2.77 ± 1.77 
 
58a NH  
 
1.13 ± 0.28 
 
58b N
CH3  
 
1.62 ± 0.39 
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 59a NH
 
 
4.60 ± 0.56 
 
59b N
CH3  
 
0.88 ± 0.30 
 
Table 1.8 Compound structures and VMAT2 binding affinity of modified lobelane 
analogs with differing intramolecular distances between the piperidine ring and the 
phenyl rings in the molecule (Zheng et al., 2008; Crooks et al., 2011). 
   
 From the data in Table 1.8, it has been shown that altering the intramolecular 
distance between the piperidine ring and the phenyl rings on the lobelane scaffold has 
dramatic effects on the ability of the analogs to bind to the TBZ binding site on VMAT2.   
The removal of the ethylene linker on both sides of the piperidine ring of lobelane to 
afford compound 51 resulted in a complete loss of affinity for the TBZ binding site on 
VMAT2.  When the linkers are one methylene unit in length some of the affinity for 
VMAT2 returns, but then only moderately, as compound 52b still exhibited a 10-fold 
decrease in affinity compared to lobelane.  In order to bind to the TBZ site on VMAT2, it 
appears that it is necessary to extend the length of the methylene linkers between the 
piperidine ring and the phenyl rings to at least two carbons (the distance found in 
lobelane) or longer.  Compound 53b, which is a symmetrical analog of lobelane (three 
carbons in each linker), exhibits the same affinity for VMAT2 as does lobelane (Ki = 1.00 
µM).  The asymmetric analog 59b also had an affinity similar to lobelane (Ki = 0.88 µM), 
80 
 
and the linkers between the piperidine ring and the phenyl rings were two and three 
methylene units in length.   
 In the fifth stage of the systematic approach to alteration of the lobelane scaffold , 
the N-methyl group of lobelane was modified, either by increasing the length of the alkyl-
moiety, or by replacing the methyl group with a variety of other N-substituents with 
greater organic functionality and polarity.  The seven compounds generated in this series 
of structural modifications and their affinities for the TBZ binding site on VMAT2 are 
shown in Table 1.9. 
 
 
Compound 
Identifier 
 
Compound Structure 
Values are Ki ± SEM, 
µM 
[3H]DTBZ Binding 
VMAT2 
 
LOB N
CH3
OH O
 
 
2.76 ± 0.64 
 
lobelane N
CH3  
 
0.97 ± 0.19 
 
60 N
H3C  
 
3.41 ± 0.67 
 
61 N
CH3  
 
1.87 ± 0.25 
Table 1.9 (continued) 
81 
 
 62 N
N
H3C CH3  
 
>100 
 
63 N
N  
 
22.6 ± 0.23 
 
64 N
NH2  
 
5.59 ± 0.94 
 
65 N
N
CH3H3C  
 
9.59 ± 1.47 
 
66 N
HO
HO  
 
0.56 ± 0.08 
 
Table 1.9 Compound structures and VMAT2 binding affinity of modified lobelane 
analogs  (Crooks et al., 2011) 
 
 In compounds 60 and 61 the length of the N-methyl substituent has been 
increased from methyl to ethyl and propyl.  The N-ethyl and N-propyl analogs exhibited 
slightly lower affinity at VMAT2 compared to lobelane.  By replacing the N-methyl 
group with a dimethylhydrazine moiety, as in compound 62, led to a complete loss of 
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affinity for the TBZ site on VMAT2.  When the N-methyl group was replaced with a 
cyanomethyl moiety (compound 63), aminoethyl (compound 64), or a 
dimethylaminoethyl moiety (compound 65), the affinity for VMAT2 was also reduced by 
about one order of magnitude (5-20 fold) when compared to lobelane (Crooks et al., 
2011).  One very interesting compound was discovered in this series (compound 66), in 
which the N-methyl group was replaced with a 1,2(R)-dihydroxypropyl moiety.  
Compound 66, (R)-3-((2S,6R)-2,6-diphenethylpiperidin-1-yl)propane-1,2-diol, exhibited 
slightly better affinity than lobelane for the TBZ binding site on VMAT2, and was much 
more water soluble than lobelane, which is a highly desirable characteristic in compounds 
selected for further study in animals and humans. 
 In the sixth phase of the systematic approach to structural changes in the lobelane 
scaffold, the central piperidine ring was subjected to structural modification.  The 
piperidine ring was altered by incorporating an additional heteroatom, to afford a 
piperazine ring system.  The piperidine ring was also replaced with a smaller five-
membered pyrrolidine ring, as well as with a larger conformationally restricted tropane 
ring system.  The synthesis of the piperazine ring analogs is outlined in Scheme 1.18. 
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 Scheme 1.18 Synthetic outline for generation of piperazine analogs of lobelane 
 
 Two compounds were constructed in the piperazine series of analogs, viz:, 
(2R,6S)-2,6-diphenethylpiperazine and (2R,6S)-1,4-dimethyl-2,6-diphenethylpiperazine.  
The chemistry involved in making these two compounds differs only in the starting 
material when compared to the synthesis of the piperidine analogs in Scheme 1.5, since 
2,6-dimethylpyrazine is used in place of 2,6-dimethylpyridine.  The two piperazine 
compounds generated in this series and their affinities for the TBZ binding site on 
VMAT2 are shown in Table 1.9.  
 The piperidine ring was also replaced with a five-membered pyrrolidine ring, and 
the structures and affinities of such compounds at the TBZ binding site on VMAT2 are 
also shown in Table 1.9. 
 Finally, the piperidine ring was replaced with a more conformationally restricted 
tropane ring.  The outline of the chemistry used to synthesize the seven compounds in 
this series is shown in Schemes 1.19 and 1.20. 
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 Scheme 1.19 Synthesis of tropane analogs of lobelane (Zheng et al., 2005) 
 
 
Scheme 1.20 Synthesis of tropane analogs of lobelane with extended linkers  
(Zheng et al., 2005) 
 
 Briefly, the synthesis of the seven analogs in the tropane series began with 
tropinone as the starting material, which was subjected to an Aldol condensation reaction 
with either aryl aldehydes or trans-cinnamaldehyde.  Clemmenson reduction of the 
conjugated Aldol products followed by catalytic hydrogenation with palladium-on-carbon 
and hydrogen gas afforded the substituted (2R,4S)-2,4-dibenzyl-8-methyl-8-
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azabicyclo[3.2.1]octane and (2R,4S)-8-methyl-2,4-bis(3-phenylpropyl)-8-
azabicyclo[3.2.1]octane analogs of lobelane. 
 
 
Compound 
Identifier 
 
Compound Structure 
Values are Ki ± SEM, 
µM 
[3H]DTBZ Binding 
VMAT2 
 
LOB N
CH3
OH O
 
 
2.76 ± 0.64 
 
lobelane N
CH3  
 
0.97 ± 0.19 
 
67 
N
H
H
N
 
 
37.6 ± 20.3 
 
68 
N
N
CH3
CH3  
 
6.09 ± 0.19 
 
69 
N
H  
 
1.50 ± 0.22 
 
70 
N
CH3  
 
14.5 ± 2.13 
 
71 
N
H  
 
3.02 ± 0.17 
Table 1.10 (continued) 
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 72 
N
CH3  
 
8.80 ± 2.30 
 
73 N
H3C
 
 
1.30 ± 0.21 
 
74 N
H3C
 
 
>100 
 
 
75 
N
H3C
F
F
 
 
 
1.38 ± 0.20 
 
 
76 
N
H3C
F
F
 
 
 
>100 
Table 1.10 (continued)  
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77 NH3C
O
O
H3C
H3C
 
 
 
4.80 ± 1.70 
 
 
78 NH3C
O
O
H3C
H3C  
 
 
3.88 ± 0.90 
 
 
 
79 
N
H3C
 
 
 
 
3.95 ± 0.54 
 
Table 1.10 Structures and VMAT2 binding affinities of modified lobelane analogs   
(Zheng et al., 2005; Crooks et al., 2011) 
 
 In the piperazine series of compounds, only compound 68 ((2R,6S)-1,4-dimethyl-
2,6-diphenethylpiperazine) had similar affinity to lobelane at VMAT2.  In the pyrrolidine 
series of analogs, affinities for VMAT2 were lower in all compounds, but interestingly 
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the nor-compounds had higher affinities than their N-methyl counterparts, which 
contrasts greatly compared to the previous piperidine series of lobelane analogs.  In the 
tropane series of analogs,, compounds 73 and 75 had affinities similar to lobelane, while 
their saturated counterparts had no affinity for VMAT2 (IC50>100 µM).  The double 
bond present in the tropane ring of compounds 73 and 75 appear to be important in 
providing the correct configuration of the tropane ring, as well as the orientations of the 
two phenethyl side chains. 
 
1.10 Portions of the lobelane scaffold that are critical in binding to VMAT2 
 From the library of compounds designed, synthesized, and evaluated for their 
affinity for VMAT2, it is possible to infer which portions of the lobelane scaffold is 
essential for the molecule to bind to VMAT2.  A graphical representation of each section 
of the molecule that must be conserved in order to maintain affinity for VMAT2 is shown 
in Figure 1.9. 
 
 
Figure 1.10 Graphical representation of the lobelane scaffold depicting the parts of the 
molecule that are essential for binding to VMAT2 
 
 Three distinct sections of the lobelane scaffold have been shown to be important 
with respect to binding to VMAT2.  First, a cationic nitrogen moiety must be present 
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(depicted in Figure 1.9 in blue), and preferably the nitrogen atom is located inside a 
cyclic system such as the piperidine ring.  Second, two hydrophobic moieties must be 
present (depicted in Figure 1.9 in green), preferably both phenyl rings.  Substitution of 
the phenyl rings with fluoro or methoxy moieties can improve affinity for the VMAT2 
binding site.  Third, the cationic site and the two hydrophobic sites must be linked 
together via methylene linkers (depicted in Figure 1.9 in red) of at least two methylene 
units in length.  The methylene linkers can be attached at the 2,6 or 1,4 positions on the 
central nitrogen containing ring without a decrease in binding affinity for the VMAT2 
binding site. 
 
 1.11 Modification and optimization of the lobelane scaffold  
 
 With the data from all six stages of lobelane scaffold modifications in hand, three 
structural groups within the library of compounds appear to be prime candidates for 
optimization and further exploration.  These three areas are 1.) further studies on the 
design and synthesis of structural analogs of lobelane that maintain the 2,6-substituted 
piperidine scaffold but introduced preferred moieties, i.e. chloro, fluoro, or methoxy 
moieties, into the phenyl rings present in lobelane, 2.)  further studies into structural 
analogs of lobelane that move the phenethyl linkers present in the 2,6-substituted position 
on the piperidine ring in lobelane to the 1,4-substituted position could be designed and 
synthesized that also include the preferred moieties, i.e. chloro, fluoro, or methoxy 
moieties to enhance their affinity and function at VMAT2 , and 3.) further studies into 
lobelane analogs that introduce an additional nitrogen atom into the piperidine ring of the 
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lobelane scaffold that would increase water- solubility while maintaining similar affinity 
for VMAT2.  These three areas are explored in Chapters 2, 3, and 4, and have become the 
main focus of this work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © John P. Culver 2015 
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Chapter 2.   
Synthesis of  2,6-disubstituted piperidine analogs structuraly related to  lobelane 
2.1 Prior studies with this scaffold 
 As discussed in Chapter 1 of this dissertation, (section 1.8), a series of 28 
symmetrical 2,6-substituted lobelane analogs have previously been synthesized and their 
affinities at α4β2* & α7* nAChRs and at the TBZ binding site on VMAT2 have been 
evaluated.  All of the compounds within this series had either lower or comparable 
affinities at α4β2* & α7* nAChRs when compared to lobelane, with the exception of 
compounds 29a ((2S,6R)-2,6-bis(2-(biphenyl-4-yl)ethyl)piperidine) and 33a ((2S,6R)-2,6-
bis(2-(naphthalen-2-yl)ethyl)piperidine), which were both nor-analogs with bulky 
biphenyl (compound 29a) and 2-naphthyl (compound 33a) aromatic rings incorporated 
into the molecule in place of the phenyl moieties. These compounds had comparable 
affinity to lobelane at VMAT2.  Analogs 20b ((2S,6R)-2,6-bis(3-fluorophenethyl)-1-
methylpiperidine), 22b ((2S,6R)-2,6-bis(2-methoxyphenethyl)-1-methylpiperidine), and 
23b ((2S,6R)-2,6-bis(3-methoxyphenethyl)-1-methylpiperidine)  had the highest affinity 
for VMAT2 with Ki values of 0.57, 0.58, and 0.43 µM respectively.  Also the N-methyl 
analogs consistently exhibited higher affinity at VMAT2 when compared to the 
corresponding nor-counterparts.   
 
2.2 Design and synthesis of the 2,6-disubstituted piperidine scaffold  
Further optimization and study was needed to ascertain if addition of different 
substituents into the phenyl ring would enhance binding affinity at VMAT2.  Addition of 
two substituents into the phenyl ring was also explored in order to determine if multiple 
substituents could also improve affinity.  The synthesis of eighteen compounds in this 
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series was accomplished.  The general synthetic scheme that was utilized is shown in 
Scheme 2.1, and the structures and analytical data follow in Figures 2.1 through 2.18. 
 
Scheme 2.1 Synthesis of the 2,6-substituted piperidine analog scaffold of lobelane  
  
 The general synthetic scheme begins with 2,6-dimethylpyridine as the starting 
material, which is subjected to condensation reaction conditions with the appropriate 
mono-substituted or di-substituted aryl aldehyde.  This affords the appropriate crude 2,6-
distyrylpyridine compound (purified by crystallization or via silica column 
chromatography), which was then exposed to acidic hydrogenation conditions with 
Adam’s catalyst (platinum(IV)oxide) and hydrogen gas in acetic acid.  After 18-72 hours, 
depending on the aromatic substitution pattern of the distyrylpyridine, the reaction yields 
the appropriate nor-(2S,6R)-2,6-diphenethylpiperidine (purified via silica column 
chromatography), as the meso-isomer (cis stereochemistry at the C2 and C6 positions on 
the piperidine ring.  N-methylation was accomplished by exposing the nor-compounds to 
reductive amination conditions with paraformaldehyde and sodium cyanoborohydride in 
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methanol to generate lobelane analogs containing the N-methyl moiety (purified by silica 
column chromatography). The structures of the compounds synthesized in this series and 
the structural analytical data for each compound are shown in Figures 2.1 through 2.20.  
NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of three 
Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm 
relative to either TMS as internal standard or as relative to the solvent peak present in 
13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an 
Agilent 7683 autosampler and an Agilent 5973 MSD. All compounds were converted to 
their hydrochloric acid salts prior to submission for pharmacological evaluation.  A 
detailed example of the procedure used in the synthesis of the 2,6-substituted piperidine 
series of lobelane analogs follows (example procedure is for the synthesis of JPC-001 and 
JPC-011. 
 
Condensation reaction procedure: To a clean, dry 250 ml round bottom flask equipped 
with a magnetic stirbar and a water jacketed condenser was added 3.772 grams (0.0352 
moles) of 2,6-lutidine, 10.0 grams (0.071 moles) of 3,5-difluorobenzaldehyde, and 10 ml 
of acetic anhydride.  The reaction mass was heated to reflux and maintained at reflux for 
72 hours.  The reaction was then cooled to room temperature and the excess solvent was 
removed under vacuum.  The gummy residue was purified via silica column 
chromatography (300 grams of 400 mesh silica) utilizing a 10:1 mixture of hexane:ethyl 
acetate.  The excess solvent was removed from the product fraction via vacuum, and a 
solid white product was isolated.  The product (2,6-bis(3,5-difluorostyryl)pyridine) was 
isolated in 52% yield (6.5 grams (0.0183 moles)). 
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 Hydrogenation reaction procedure: 2.0 grams (5.63 mmol) of the product of the 
condensation reaction (2,6-bis(3,5-difluorostyryl)pyridine) was placed in a clean, dry 250 
ml Parr hydrogenation flask and brought into solution with 50 ml of concentrated acetic 
acid.  To this was added 0.5 mole % (6.3 mg (0.0282 mmol)) of Adam’s catalyst 
(platinum (IV) oxide).  This heterogeneous catalyst reaction mass was placed on a Parr 
hydrogenator and purged three times with hydrogen gas with shaking.  The reaction was 
then pressurized to 50 psi (3.45 atm) with hydrogen gas under room temperature.  The 
Parr hydrogenator’s shaking function was used and the reaction allowed to proceed for 18 
hours.  The pressure was then released and the reaction was filtered through a pad of 
celite to remove the platinum catalyst.  The remaining filtrate was subjected to reduced 
pressure under vacuum to remove excess acetic acid.  The reaction mass was then 
basified with a saturated solution of sodium bicarbonate in water, and extracted three 
times with dichloromethane.  The organic layer was dried with sodium sulfate, filtered, 
and the dichloromethane removed under reduced pressure.  The remaining gummy 
residue was purified via column chromatography (60 grams of silica (400 mesh)) 
utilizing a solvent mixture of 50:1:0.2 chloroform: methanol: ammonium hydroxide.  The 
product fractions were combined, and the solvent removed via vacuum to yield 1.52 
grams (4.16 mmol (73.9% isolated yield) of (2S,6R)-2,6-bis(3,5-
difluorophenethyl)piperidine (JPC-001) as a gummy material.  The purified product was 
converted to the hydrochloride salt by dissolving the gum residue in a minimum amount 
of dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise 
until a precipitate formed.  This reaction mass was stirred for four hours at room 
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temperature and the excess solvent removed via reduced pressure.  The residue was 
triturated in dry diethyl ether until a white powder of the hydrochloride salt of the product 
formed.  The powder was filtered off and dried under vacuum overnight to yield 1.35 
grams (3.36 mmol) of (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidinium chloride in 
80.75% isolated yield. 
Reductive amination procedure: 1.0 grams (2.49 mmol) of (2S,6R)-2,6-bis(3,5-
difluorophenethyl)piperidinium chloride product was added to a clean, dry 50 ml round 
bottom flask and brought into solution with 10 ml of methanol.  210 mg (2.49 mmol) of 
dry sodium bicarbonate was added to the solution and stirred for thirty minutes to convert 
the hydrochloride salt to the freebase form.  To the reaction mass was added five 
equivalents of sodium cyanoborohydride (783 mg (12.45 mmol)) and ten equivalents 
(748 mg (24.9 mmol)) of paraformaldehyde, and this reaction was stirred under room 
temperature for 18 hours.  The excess solvent was then removed via reduced pressure and 
the reaction mass was subjected to extraction with saturated sodium chloride in water and 
dichloromethane three times.  The organic layer was then collected, combined, and dried 
with sodium sulfate and filtered.  The excess dichloromethane was removed under 
reduced pressure to yield a gummy residue which was purified via silica column 
chromatography (30 grams of silica (400 mesh)) via a solvent mixture of 50:1:0.2 
chloroform:methanol: ammonium hydroxide.  The product fractions were combined, and 
the solvent removed via reduced pressure to yield the pure product (2S,6R)-2,6-bis(3,5-
difluorophenethyl)-1-methylpiperidine (JPC-011) as a gummy material.  The yield of the 
product was (746 mg (1.97 mmol) or 79% yield.  The freebase product was a gummy, 
oily residue and was therefore brought up in a minimum volume of dichloromethane to 
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which 1.0 M hydrochloric acid is dry diethyl ether was added until a precipitate began to 
form.  This mixture was stirred under room temperature for four hours at which time the 
solvent was removed via reduced pressure.  The residue was triturated with dry diethyl 
ether until a white powder of the hydrochloride salt formed.  The powder was filtered off 
and dried under vacuum to yield 594 mg (1.43 mmol) of (2S,6R)-2,6-bis(3,5-
difluorophenethyl)-1-methylpiperidinium chloride resulting in a 72.5% isolated yield for 
the hydrochloride salt formation.   
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Figure 2.1 Structure of (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001) 
Chemical Formula: C21H23F4N Molecular Weight: 365.41 
 
This molecule was designed to evaluate the effect of 3,5-difluoro substituents on 
VMAT2 binding.  Since the fluoro-moieties are very electronegative they cause inductive 
withdrawal, or withdrawal of electrons from the phenyl rings, but since the fluoro-
moieties have non-bonding electrons they can donate electron density through pi bonding 
or resonance donation. The synthesis utilized 2,6-dimethylpyridine as the starting 
material, which was subjected to Aldol condensation with 3,5-difluorobenazldehyde to 
yield 2,6-bis(3,5-difluorostyryl)pyridine.  Catalytic hydrogenation of the styryl 
intermediate afforded (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001).   
1H NMR (500 MHz, CDCl3):   δ 1.28-1.81 (m, 10H), 2.11 (s, 1H), 2.33-2.41 (m, 2H), 
2.70 (t, 4H), 6.53-6.62 (m, 2H), 6.68-6.73 (m, 4H) ppm. 
 13C NMR (125 MHz, CDCl3):  δ 25.3, 31.9, 32.3, 35.6, 63.1, 101.8, 113.6, 147.1, 164.2 
ppm. 
 MS (EI) m/z 365 (M+). 
 
 
 
 
 
98 
 
  
Figure 2.2 Structure of (2S,6R)-2,6-bis(3,5-difluorophenethyl)-1-methylpiperidine 
 (JPC-011) Chemical Formula: C22H25F4N  Molecular Weight: 379.43 
 
This molecule was designed to evaluate the effect of 3,5-difluoro substitution of 
lobelane  on VMAT2 binding similar to JPC-001, but to also preserve the N-methyl 
substituent on the amine.  (2S,6R)-2,6-bis(3,5-difluorophenethyl)piperidine (JPC-001) 
was N-methylated by exposed to reductive amination conditions with paraformaldehyde 
and sodium cyanoborohydride in methanol to provide N-methylated (2S,6R)-2,6-bis(3,5-
difluorophenethyl)-1-methylpiperidine (JPC-011). 
1H NMR (500 MHz, CDCl3):   δ 1.31-1.84 (m, 10H), 2.14 (s, 3H), 2.36-2.40 (m, 2H), 
2.66 (t, 4H), 6.59-6.64 (m, 2H), 6.71-6.74 (m, 4H) ppm. 
13C NMR (125 MHz, CDCl3):  δ 25.5, 31.8, 32.3, 35.9, 40.5, 62.4, 101.5, 111.6, 147.4, 
164.5 ppm. 
 MS (EI) m/z 379 (M+). 
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Figure 2.3 Structure of (2S,6R)-2,6-bis(3-chlorophenethyl)piperidine (JPC-002) 
Chemical Formula: C21H25Cl2N  Molecular Weight: 362.34 
 
This molecule was designed to evaluate the effect of the 3-chloro substitution of 
lobelane on VMAT2 binding.  The chlorine atom is an electron-withdrawing aromatic 
substituent and can cause similar inductive and resonance based electron effects on the 
phenyl rings as the fluoro substituent, however the chlorine atom is larger in radius, and 
slightly more polarizable than the fluoro moiety. The synthesis began with 2,6-
dimethylpyridine as the starting material, which was subjected to Aldol condensation 
with 3-chlorobenzaldehyde to yield 2,6-bis(3-chlorostyryl)pyridine.  Subsequent catalytic 
hydrogenation afforded (2S,6R)-2,6-bis(3-chlorophenethyl)piperidine (JPC-002). 
However, during hydrogenation, reductive dechlorination occurred, leading to a difficult 
separation and very little JPC-002 was isolated, even when scaled up to larger reaction 
amounts.  For this reason alone, the N-methyl analog was not prepared. 
1H NMR (300 MHz, CDCl3): δ 1.37-1.78 (m, 10H), 2.11 (s, 1H), 2.33-2.41 (m, 2H), 2.60 
(t, 4H), 7.13-7.21 (m, 2H), 7.34-7.46 (m, 4H), 7.51, (s, 2H) ppm. 
13C NMR (75 MHz, CDCl3):  δ 22.3, 30.5, 32.8, 35.8, 58.1, 121.6, 121.9, 128.5, 129.1, 
136.3, 142.2 ppm. 
MS (EI) m/z 361 (M+). 
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Figure 2.4 Structure of 3,3'-(2,2'-((2S,6R)-piperidine-2,6-diyl)bis(ethane-2,1-
diyl))dianiline (JPC-008) Chemical Formula: C21H29N3 Molecular Weight: 323.48 
 
This molecule was designed to evaluate the effect of introducing a 3-amino 
substituent into the lobelane scaffold on VMAT2 binding.  The amino moiety is an 
electron donating group that donates some of its electron density into the conjugated π 
system of the phenyl ring.  The 2,6-dimethylpyridine starting material was subjected to 
Aldol condensation reaction conditions with 3-nitrobenazldehyde to yield 2,6-bis(3-
nitrostyryl)pyridine.  Subsequent catalytic hydrogenation afforded the desired compound, 
3,3'-(2,2'-((2S,6R)-piperidine-2,6-diyl)bis(ethane-2,1-diyl))dianiline (JPC-008). 
1H NMR (300 MHz, CDCl3): δ 1.35-1.83 (m, 10H), 2.08 (s, 1H), 2.56 (t, 4H), 2.71 (m, 
2H), 5.24 (s, 4H), 6.43-6.48 (m, 2H), 6.59-6.67 (m, 4H), 7.10, (m, 2H)ppm. 
 13C NMR (75 MHz, CDCl3):  δ 21.5, 29.7, 32.3, 35.9, 54.8, 111.6, 114.7, 117.3, 127.1, 
138.2, 147.5 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 2.5 Structure of (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine (JPC-003) 
Chemical Formula: C21H39N Molecular Weight: 305.54 
 
This molecule was designed to evaluate the effect of complete saturation of the 
phenyl rings in nor-lobelane to cyclohexyl moieties on VMAT2 binding (Note, this 
compound and the N-methyl derivative has been prepared previously) (Zheng et al., 
2005).   2,6-Dimethylpyridine was the starting material, which was subjected to Aldol 
condensation reaction conditions with benzaldehyde to yield the intermediate 2,6-
bis(styryl)pyridine.  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded of the desired compound, (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine 
(JPC-003).   
 1H NMR (300 MHz, CDCl3): δ 1.37-2.38 (m, 36H), 2.05 (s, 1H), 2.67 (m, 2H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 20.7, 24.7, 25.3, 28.6, 29.8, 32.7, 33.0, 33.1, 49.8 ppm. 
MS (EI) m/z 305 (M+). 
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Figure 2.6 Structure of (2S,6R)-2,6-bis(2-cyclohexylethyl)-1-methylpiperidine (JPC-007) 
Chemical Formula: C22H41N  Molecular Weight: 319.57 
 
This molecule was designed to evaluate the effect of complete saturation of the 
phenyl rings in Lobeline to cyclohexyl moieties, while preserving the N-methyl 
substituent, on VMAT2 binding.  (2S,6R)-2,6-bis(2-cyclohexylethyl)piperidine (JPC-003) 
was exposed to reductive amination conditions with paraformaldehyde and sodium 
cyanoborohydride in methanol to afford N-methylated (2S,6R)-2,6-bis(2-
cyclohexylethyl)-1-methylpiperidine (JPC-007). 
1H NMR (300 MHz, CDCl3): δ 1.45-2.34 (m, 36H), 2.08 (m, 2H). 2.17 (s, 3H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 21.1, 24.9, 25.6, 28.7, 29.6, 32.9, 33.4, 33.9, 38.8, 54.6 
ppm. 
MS (EI) m/z 319 (M+). 
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Figure 2.7 Structure of (2S,6R)-2,6-bis(2,4-difluorophenethyl)piperidine (JPC-130a) 
Chemical Formula: C21H23F4N Molecular Weight: 365.41 
 
This molecule was designed to evaluate the effect of introducing 2,4-difluoro 
aromatic substituents into the nor-lobelane structure on VMAT2 binding.  Again, since 
the fluoro-substituents are electronegative they cause inductive withdrawal of electrons 
from the aromatic ring, but since the fluoro-moieties have non-bonding electrons they can 
also donate electron density through pi bonding or resonance donation. Synthesis began 
with 2,6-dimethylpyridine as the starting material, which was subjected to Aldol 
condensation reaction conditions with 2,4-difluorobenzaldehyde to yield 2,6-bis(2,4-
difluorostyryl)pyridine.  Catalytic hydrogenation with Adam’s catalyst (PtO2) and 
hydrogen gas afforded the desired product, (2S,6R)-2,6-bis(2,4-
difluorophenethyl)piperidine (JPC-130a).   
1H NMR (500 MHz, CDCl3):   δ 1.28-1.73 (m, 10H), 2.17 (s, 1H), 2.30-2.41 (m, 2H), 
2.73 (t, 4H), 6.60-6.67 (m, 2H), 6.87-6.95 (m, 2H), 7.17-7.23 (m, 2H) ppm. 
 13C NMR (125 MHz, CDCl3):  δ 24.3, 25.6, 31.7, 32.3, 60.3, 101.8, 109.4, 120.9, 128.9, 
161.1, 164.2 ppm. 
 MS (EI) m/z 365 (M+). 
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Figure 2.8 Structure of (2S,6R)-2,6-bis(2,4-difluorophenethyl)-1-methylpiperidine  
(JPC-130b) Chemical Formula: C22H25F4N  Molecular Weight: 379.43 
 
 This molecule was designed to evaluate the effect of introducing 2,4-
difluoro aromatic substituents into lobelane on VMAT2 binding, while retaining the N-
methyl substituent on the piperidine ring.  (2S,6R)-2,6-bis(2,4-
difluorophenethyl)piperidine (JPC-130a) was exposed to reductive amination conditions 
with paraformaldehyde and sodium cyanoborohydride in methanol to provide the desired 
compound,  N-methylated (2S,6R)-2,6-bis(2,4-difluorophenethyl)-1-methylpiperidine 
(JPC-130b). 
1H NMR (500 MHz, CDCl3):  δ 1.35-1.76 (m, 10H), 2.15 (s, 3H), 2.35 (m, 2H), 2.65 (t, 
4H), 6.73-6.78 (m, 4H), 7.13-7.15 (m, 2H) ppm. 
 13C NMR (125 MHz, CDCl3):  δ 25.1, 25.2, 26.8, 29.9, 34.9, 62.6, 103.7, 111.0, 122.7, 
131.3, 160.6, 162.5 ppm. 
 MS (EI) m/z 379 (M+).   
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 Figure 2.9 Structure of (2S,6R)-2,6-bis(3,5-dimethoxyphenethyl)piperidine (JPC-004) 
Chemical Formula: C25H35NO4  Molecular Weight: 413.55 
 
This molecule was designed to evaluate the effect of introducing  3,5-dimethoxy 
aromatic substituents into the nor-lobelane molecule on VMAT2 binding.  Since the 
methoxy substituents are electronegative they cause inductive withdrawal, or withdrawal 
of electrons from the carbon atom of benzene, but since they also have non-bonding 
electrons they can donate electron density through pi bonding or resonance donation.   
The methoxy group is substantially larger than fluoro group in the previous compounds, 
and will provide some steric effects at the binding site of VMAT2, if space on the site is 
limited around the phenyl ring binding regions. The starting material, 2,6-
dimethylpyridine was reacted with 3,5-dimethoxybenazldehyde under Aldol 
condensation reaction conditions to yield 2,6-bis(3,5-dimethoxystyryl)pyridine.  Catalytic 
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas eafforded (2S,6R)-2,6-
bis(3,5-dimethoxyphenethyl)piperidine (JPC-004).  
1H NMR (300 MHz, CDCl3): δ 1.33-1.82 (m, 10H), 2.20 (s, 1H), 2.41 (m, 2H), 2.65 (t, 
4H), 3.78 (s, 12H), 6.52-6.64 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 21.6, 29.6, 32.6, 39.9, 55.6, 58.3, 97.2, 106.3, 143.9, 160.1 
ppm. 
MS (EI) m/z 413 (M+). 
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 Figure 2.10 Structure of (2S,6R)-2,6-bis(3,5-dimethoxyphenethyl)-1-methylpiperidine  
(JPC-010) Chemical Formula: C26H37NO4 Molecular Weight: 427.58 
 
This molecule was designed to evaluate the effect of introducing 3,5-dimethoxy 
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the 
N-methyl substituent on the piperidine ring.  (2S,6R)-2,6-bis(3,5-
dimethoxyphenethyl)piperidine (JPC-004) was exposed to reductive amination conditions 
with paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6-
bis(3,5-dimethoxyphenethyl)-1-methylpiperidine (JPC-010). 
1H NMR (300 MHz, CDCl3): δ 1.26-1.87 (m, 10H), 2.22 (s, 3H), 2.35 (m, 2H), 2.63 (t, 
4H), 3.78 (s, 12H), 6.31-6.36 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 21.6, 29.6, 30.9, 32.6, 33.1, 39.9, 55.2, 97.9, 106.2, 144.8, 
160.6 ppm. 
MS (EI) m/z 427 (M+). 
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Figure 2.11 Structure of (2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)piperidine (JPC-033) 
Chemical Formula: C25H35NO4  Molecular Weight: 413.55 
 
This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy 
aromatic substituents into the nor-lobelane scaffold on VMAT2 binding.  Synthesis 
began with 2,6-dimethylpyridine as the starting material, which was subjected to Aldol 
condensation with 3,4-dimethoxybenazldehyde to yield 2,6-bis(3,4-
dimethoxystyryl)pyridine.  Catalytic hydrogenation afforded (2S,6R)-2,6-bis(3,4-
dimethoxyphenethyl)piperidine (JPC-033).  
1H NMR (300 MHz, CDCl3): δ 1.30-1.75 (m, 10H), 2.17 (s, 1H), 2.49 (m, 2H), 2.57 (t, 
4H), 3.79 (s, 12H), 6.72-6.87 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 23.6, 29.3, 31.2, 35.9, 55.3, 62.4, 107.9, 111.5, 119.9, 
134.5, 146.2, 148.1 ppm 
MS (EI) m/z 413 (M+). 
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Figure 2.12 Structure of (2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)-1-methylpiperidine  
(JPC-034) Chemical Formula: C26H37NO4 Molecular Weight: 427.58 
 
This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy 
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the 
N-methyl moiety on the piperidine ring.   The synthesis utilized (2S,6R)-2,6-bis(3,4-
dimethoxyphenethyl)piperidine (JPC-033) which was exposed to reductive amination 
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to afford 
(2S,6R)-2,6-bis(3,4-dimethoxyphenethyl)-1-methylpiperidine (JPC-034). 
1H NMR (300 MHz, CDCl3): δ 1.30-1.95 (m, 10H), 2.20 (s, 3H), 2.45 (m, 2H), 2.61 (t, 
4H), 3.86 (s, 12H), 6.76 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 24.8, 26.3, 30.2, 31.9, 36.3, 55.7, 62.4, 110.9, 111.5, 
119.9, 135.0, 146.7, 148.4 ppm. 
MS (EI) m/z 427 (M+). 
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Figure 2.13 Structure of (2S,6R)-2,6-bis(2,3-dimethoxyphenethyl)piperidine (JPC-035) 
Chemical Formula: C25H35NO4  Molecular Weight: 413.55 
 
This molecule was designed to evaluate the effect of introducing 2,3-dimethoxy 
aromatic substituents into the nor-lobelane scaffold on VMAT2 binding. The starting 
material, 2,6-dimethylpyridine, was subjected to Aldol condensation with 2,3-
dimethoxybenzaldehyde to yield 2,6-bis(2,3-dimethoxystyryl)pyridine.  Catalytic 
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded (2S,6R)-2,6-
bis(2,3-dimethoxyphenethyl)piperidine (JPC-035). 
1H NMR (300 MHz, CDCl3): δ 1.30-1.85 (m, 10H), 2.13 (s, 1H), 2.41 (m, 2H), 2.62 (t, 
4H), 3.81 (s, 12H), 6.77-6.94 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 23.4, 25.7, 27.8, 33.1, 55.9, 60.7, 62.2, 111.2, 121.1, 
123.0, 130.1, 146.1, 152.0 ppm. 
MS (EI) m/z 413 (M+). 
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Figure 2.14 Structure of (2S,6R)-2,6-bis(2,3-dimethoxyphenethyl)-1-methylpiperidine 
(JPC-036) Chemical Formula: C26H37NO4 Molecular Weight: 427.58 
 
This molecule was designed to evaluate the effect of introducing 2,3-dimethoxy 
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the 
N-methyl moiety on the piperidine ring.  (2S,6R)-2,6-bis(2,3-
dimethoxyphenethyl)piperidine (JPC-035) was exposed to reductive amination conditions 
with paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6-
bis(2,3-dimethoxyphenethyl)-1-methylpiperidine (JPC-036). 
1H NMR (300 MHz, CDCl3): δ 1.30-1.95 (m, 10H), 2.27 (s, 3H), 2.45 (m, 2H), 2.68 (t, 
4H), 3.83 (s, 12H), 6.77-6.98 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 24.6, 26.4, 27.0, 31.0, 35.2, 55.5, 60.5, 63.2, 109.8, 121.7, 
123.6, 136.1, 146.7, 152.4 ppm 
MS (EI) m/z 427 (M+). 
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Figure 2.15 Structure of (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)piperidine (JPC-041) 
Chemical Formula: C25H35NO4  Molecular Weight: 413.55 
 
This molecule was designed to evaluate the effect of introducing 2,5-dimethoxy 
aromatic substituents into nor-lobelane on VMAT2 binding.  2,6-Dimethylpyridine was 
subjected to Aldol condensation with 2,5-dimethoxybenzaldehyde to yield 2,6-bis(2,5-
dimethoxystyryl)pyridine.  Catalytic hydrogenation with Adam’s catalyst (PtO2) and 
hydrogen gas afforded (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)piperidine (JPC-041). 
1H NMR (300 MHz, CDCl3): δ 1.39-1.85 (m, 10H), 2.21 (s, 1H), 2.35 (m, 2H), 2.65 (t, 
4H), 3.74 (s, 12H), 6.63-6.76 (m, 6H) ppm.   
13C NMR (75 MHz, CDCl3): δ 22.3, 26.2, 31.9, 34.9, 55.1, 55.7, 62.9, 110.4, 110.6, 
110.8, 116.0, 132.3, 151.4, 153.1 ppm. 
MS (EI) m/z 413 (M+). 
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Figure 2.16 Structure of (2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)-1-methylpiperidine 
(JPC-042) Chemical Formula: C26H37NO4 Molecular Weight: 427.58 
 
This molecule was designed to evaluate the effect of introducing 2,5-dimethoxy 
aromatic substituents into the lobelane scaffold on VMAT2 binding, while retaining the 
N-methyl moiety on the piperidine ring.  (2S,6R)-2,6-bis(2,5-
dimethoxyphenethyl)piperidine (JPC-041) which was exposed to reductive amination 
conditions with paraformaldehyde and sodium cyanoborohydride in methanol to afford 
(2S,6R)-2,6-bis(2,5-dimethoxyphenethyl)-1-methylpiperidine (JPC-041). 
1H NMR (300 MHz, CDCl3): δ 1.25-1.90 (m, 10H), 2.20 (s, 3H), 2.35 (m, 2H), 2.63 (t, 
4H), 3.72 (s, 12H), 6.63-6.76 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 25.0, 27.0, 27.2, 31.2, 34.7, 55.4, 55.7, 62.9, 110.4, 110.8, 
116.0, 132.3, 151.4, 153.1 ppm. 
MS (EI) m/z 427 (M+). 
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Figure 2.17 Structure of (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)piperidine 
(JPC-161b)Chemical Formula: C23H29F2NO2  Molecular Weight: 389.48 
 
 This molecule was designed to evaluate the effect of introducing 4 fluoro,3-
methoxy aromatic substituents on VMAT2 binding. 2,6-Dimethylpyridine was subjected 
to Aldol condensation with 4-fluoro-3-methoxybenzaldehyde to yield 2,6-bis(4-fluoro-3-
methoxystyryl)pyridine.  Subsequent catalytic hydrogenation with Adam’s catalyst 
(PtO2) and hydrogen gas afforded (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)- 
piperidine (JPC-161b). 
1H NMR (300 MHz, CDCl3): δ 1.30-1.75 (m, 10H), 2.09 (s, 1H), 2.53 (m, 2H), 2.62 (t, 
4H), 3.81 (s, 6H), 6.72-7.10 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 22.6, 29.9, 32.3, 36.5, 55.3, 61.4, 109.7, 114.1, 123.9, 
136.1, 148.4, 148.6 ppm. 
MS (EI) m/z 389 (M+). 
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Figure 2.18 Structure of (2S,6R)-2,6-bis(4-fluoro-3-methoxyphenethyl)-1-
methylpiperidine (JPC-161c) 
 Chemical Formula: C24H31F2NO2  Molecular Weight: 403.51 
 
This molecule was designed to evaluate the effect of introducing 4 fluoro,3-
methoxy aromatic substituents into the lobelane scaffold on VMAT2 binding while 
retaining the N-methyl moiety on the piperidine ring.  (2S,6R)-2,6-bis(4-fluoro-3-
methoxy- phenethyl)piperidine (JPC-161b) was exposed to reductive amination with 
paraformaldehyde and sodium cyanoborohydride in methanol to afford (2S,6R)-2,6-bis(4-
fluoro-3-methoxyphenethyl)-1-methylpiperidine (JPC-161c). 
1H NMR (300 MHz, CDCl3): δ 1.35-1.75 (m, 10H), 2.17 (s, 3H), 2.43 (m, 2H), 2.58 (t, 
4H), 3.87 (s, 6H), 6.70-7.10 (m, 6H) ppm. 
13C NMR (75 MHz, CDCl3): δ 21.9, 30.2, 31.9, 34.5, 38.2, 55.8, 61.9, 111.3, 114.0, 
123.7, 138.1, 148.2, 148.5 ppm. 
MS (EI) m/z 403 (M+). 
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2.3 Summary of the 2,6-disubstituted  piperidine analog series 
 
In summary, eighteen compounds were designed and synthesized in the 2,6-
disubstituted piperidine scaffold of lobelane, fourteen of which contained two 
substituents in each of the phenyl rings.  These substituents consisted of difluoro-, 
dimethoxy-, and 4-fluoro-3-methoxyphenyl substituents.  Seven of the compounds were 
analogs of the nor-lobelane scaffold, and seven analogs were analogs of the lobelane 
scaffold.  Their affinities for the TBZ site of VMAT2, as well as their functional ability to 
prevent DA uptake into the vesicles of the dopaminergic neuron are discussed in Chapter 
5. 
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Chapter 3. 
Design and Synthesis of 1,4-Disubstituted Piperidine Analogs of lobelane 
 
3.1  Prior studies with the 1,4-disubstituted scaffold  
 As discussed in Chapter 1, (section 1.8), a series of isomerized lobelane analogs 
have been designed and synthesized. These analogs have different positions of 
attachment of the phenethyl moieties around the central piperidine ring.  Of these 
structural modifications, the analogs with phenethyl moieties in the N1 and C4 positions 
of the piperidine ring showed more promise for optimization and further study, since their 
binding affinities at VMAT2 were quite similar to lobelane, and they exhibited little to no 
affinity for α4β2* & α7* nAChRs.  The symmetry present in the 1,4-substituted scaffold 
allows for the relatively fast synthesis of a library of compounds with a variety of 
substituents in the phenyl rings, and also provides opportunities to explore the 
introduction of non-aromatic functionalities in place of one of the phenyl rings in 
lobelane, resulting in analogs with higher polarity improved water solubility 
characteristics, which is a desirable property in the development of drugs with improved 
bioavailability over lobelane. 
 
 3.2 Design and Synthesis of 1,4-substituted piperidine scaffold analogs 
Further optimization and study was needed to ascertain if addition of different 
substituents into the phenyl rings of the 1,4-substituted lobelane scaffold would enhance 
binding affinity at VMAT2.  Addition of multiple aromatic substituents into the phenyl 
rings was also explored in order to determine if multiple substituents could also improve 
affinity.  The synthesis of 43 compounds in this series were designed and synthesized.  
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The general synthetic scheme is shown in Scheme 3.1, and the structures and analytical 
data follow in Figures 3.1 through 3.43. 
 
Scheme 3.1  Synthetic route to the 1,4-disubstituted piperidine analogs of lobelane 
 
 The general synthetic route to the 1,4-disubstituted piperidine analogs of lobelane 
began with 4-picoline (also known as 4-methylpyridine) as the starting material.  Similar 
chemistry to that used in the 2,6-disubstituted  piperidine scaffold was utilized. The 
starting material was subjected to Aldol condensation with the appropriately substituted 
benzaldehyde in refluxing acetic anhydride to afford the corresponding (E)-4-
styrylpyridine intermediate.  After purification via silica gel column chromatography, this 
intermediate was subjected to catalytic hydrogenation with Adam’s catalyst and hydrogen 
gas in acetic acid to afford the appropriately substituted 4-phenethylpiperidine 
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intermediate, which was then subjected to a SN2 reaction with potassium carbonate and 
the appropriately substituted bromoethylbenzene to yield the final 1,4-disubstituted 
piperidine analogs of lobelane.  A detailed example of the procedure used in the synthesis 
of the 1,4-disubstituted piperidine analogs of lobelane is given below (example is for 
JPC-077 (1,4-bis(2-methoxyphenethyl)piperidine ).  The exact structures of the 
compounds synthesized and the analytical data for each compound are shown in Figures 
3.1 through 3.43.  NMR spectra were recorded in either CDCl3 or DMSO-d6 (as 
designated) on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as 
indicated are reported in ppm relative to either TMS as internal standard or as relative to 
the solvent peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 
6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD.  All 
compounds were converted into their hydrochloride or fumarate salt forms prior to use in 
pharmacological assay experiments.    
 
Condensation reaction procedure: To a clean, dry 250 ml round bottom flask equipped 
with a magnetic stirbar and a water jacketed condenser was added 2.30 grams (0.0247 
moles) of 3-picoline, 5.044 grams (0.0371 moles) of 2-methoxybenzaldehyde, and 25 ml 
of acetic anhydride.  The reaction mass was heated to reflux and maintained at reflux for 
72 hours.  The reaction was then cooled to room temperature and the excess solvent was 
removed under vacuum.  The gummy residue was purified via silica column 
chromatography (200 grams of 400 mesh silica) utilizing a 5:1 mixture of hexane:ethyl 
acetate.  The excess solvent was removed from the product fraction via vacuum, and a 
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solid off-white product isolated.  The product (E)-4-(2-methoxystyryl)pyridine was 
isolated in 54% yield (2.81 grams (0.0133 moles)). 
 
Hydrogenation reaction procedure: 2.0 grams (9.47 mmol) of the product of the 
condensation reaction ((E)-4-(2-methoxystyryl)pyridine) was placed in a clean, dry 250 
ml Parr hydrogenation flask and brought into solution with 50 ml of concentrated acetic 
acid.  To this was added 0.5 mole % (10.75 mg (0.0473 mmol)) of Adam’s catalyst 
(platinum (IV) oxide).  This heterogeneous catalyst reaction mass was placed on a Parr 
hydrogenator and purged three times with hydrogen gas and shaking.  The reaction was 
then pressurized to 50 psi (3.45 atm) with hydrogen gas under room temperature.  The 
Parr hydrogenator’s shaking function was used and the reaction was allowed to proceed 
for 72 hours.  The pressure was then released and the reaction was filtered through a pad 
of celite to remove the platinum catalyst.  The remaining filtrate was subjected to reduced 
pressure under vacuum to remove excess acetic acid.  The reaction mass was then 
basified with a saturated solution of sodium bicarbonate in water, and extracted three 
times with dichloromethane.  The organic layer was dried with sodium sulfate, filtered, 
and the dichloromethane removed under reduced pressure.  The remaining gummy 
residue was purified via column chromatography (60 grams of silica (400 mesh)) 
utilizing a solvent mixture of 10:1:0.2 dichloromethane: methanol: ammonium 
hydroxide.  The product fractions were combined, and the solvent removed via vacuum 
to yield 1.39 grams (6.35 mmol (67.0% isolated yield) of 4-(2-
methoxyphenethyl)piperidine as a gummy material.  The purified product was converted 
to the hydrochloride salt by dissolving the gum residue in a minimum amount of 
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dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise until a 
precipitate formed.  This reaction mass was stirred for four hours at room temperature 
and the excess solvent was removed via reduced pressure.  The residue was triturated in 
dry diethyl ether until a white powder of the hydrochloride salt of the product formed.  
The powder was filtered off and dried under vacuum overnight to yield 1.27 grams (4.97 
mmol) of 4-(2-methoxyphenethyl)piperidinium chloride in 78.2% isolated yield. 
N-alkylation reaction procedure (SN2 reaction): To a clean, dry 100 ml round bottomed 
flask that has been purged with argon gas and equipped with a magnetic stirbar and a 
water jacketed condenser was added 350 mg (1.37 mmol) of 4-(2-
methoxyphenethyl)piperidinium chloride (from the hydrogenation reaction above), 325 
mg (1.51 mmol) of 2-methoxyphenethylbromide, and 10 ml of dimethylformamide 
(DMF) as solvent.  To this reaction mass was added 500 mg (3.43 mmol) of potassium 
carbonate and 11.6 mg (0.07 mmol) of potassium iodide.  Under an argon atmosphere the 
reaction mass was heated in an oil bath (with stirring) to 60° C and maintained at that 
temperature for 18 hours.  The reaction flask was then subjected to reduced pressure 
while maintaining the heat in the oil bath in order to remove excess DMF from the 
reaction mixture.  The residue from this procedure was subjected to extraction with 
dichloromethane and saturated sodium chloride (brine solution) in water three times.  The 
organic layers are combined, dried with sodium sulfate, filtered, and the combined filtrate 
was subjected to reduced pressure to remove the dichloromethane solvent.  The residue 
from this procedure was purified via silica column chromatography (20 g of silica (400 
mesh)) utilizing a 20:1 mixture of dichloromethane: methanol.  The fractions containing 
the product were combined and the solvents removed under reduced pressure.  The 
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residue of the pure compound JPC-077 (1,4-bis(2-methoxyphenethyl)piperidine) (356 
mg, 1.01 mmol , 73.7% yield) was a thick oil at this stage, so the purified product was 
converted to the hydrochloride salt by dissolving the gum residue in a minimum amount 
of dichloromethane and adding 1.0 M hydrochloric acid in dry diethyl ether dropwise 
until a precipitate formed.  This reaction mass was stirred for four hours at room 
temperature and the excess solvent was removed via reduced pressure.  The residue was 
triturated in dry diethyl ether until a white powder of the hydrochloride salt of the product 
formed.  The powder was filtered off and dried under vacuum overnight to yield 276 mg 
(0.702 mmol) of  (1,4-bis(2-methoxyphenethyl)piperidinium chloride in 70.2% yield. 
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Figure 3.1 Structure of 1-(2-methoxyphenethyl)-4-phenethylpiperidine (JPC-57) 
Chemical Formula: C22H29NO  Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of introducing a 2-methoxy 
substituent into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4-
disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine was subjected to 
Aldol condensation with benzaldehyde in refluxing acetic anhydride to yield (E)-4-
styrylpyridine (which was purified via silica column chromatography before use).  
Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-
phenethylpiperidine (purified via silica column chromatography before use), which was 
then reacted via an SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-2-
methoxybenzene to yield the final product, 1-(2-methoxyphenethyl)-4-
phenethylpiperidine (JPC-57) (purified via column chromatography). . 
1H NMR (300 MHz, CDCl3): δ 1.38-1.80 (m, 7H), 2.52-3.01 (m, 10H). 3.78 (s, 3H), 
6.83-7.31(m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 27.8, 32.7, 34.1, 35.4, 37.0, 54.2, 55.1, 61.1, 110.2, 
120.9, 127.1, 127.9, 128.8, 128.9, 129.6, 131.4, 140.7, 157.2 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.2 Structure of 1-(3,4-dimethoxyphenethyl)-4-phenethylpiperidine (JPC-058) 
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing 3,4-dimethoxy 
substituents into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4-
disubstituted piperidine scaffold on VMAT2 binding.  Synthesis began with the common 
intermediate 4-phenethylpiperidine prepared previously, which was reacted via an SN2 
reaction with potassium carbonate and 1-(2-bromoethyl)-3,4-dimethoxybenzene to yield 
the final product 1-(3,4-dimethoxyphenethyl)-4-phenethylpiperidine (JPC-058) after 
purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.19-2.07 (m, 10H), 2.51-3.07 (m, 7H). 3.81 (s, 6H), 
6.70-6.76(m, 5H), 7.11-7.21 (m, 3H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 29.7, 32.6, 34.1, 35.8, 37.6, 54.0, 55.1, 61.7, 110.4, 
111.6, 114.7, 114.8, 120.7, 121.3, 129.1, 129.3, 140.4, 144.1, 157.3 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.3 Structure of 1-(3-methoxyphenethyl)-4-phenethylpiperidine (JPC-059) 
Chemical Formula: C22H29NO Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of the introducing the 3-
methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4-
disubstituted piperidine scaffold on VMAT2 binding.  Synthesis began with the common 
intermediate 4-phenethylpiperidine, which was reacted with potassium carbonate and 1-
(2-bromoethyl)-3-methoxybenzene to yield the final product 1-(3-methoxyphenethyl)-4-
phenethylpiperidine (JPC-059) after was purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.24-1.98 (m, 10H), 2.51-2.98 (m, 7H). 3.80 (s, 3H), 
6.73-7.23 (m, 9H) ppm. 
13C NMR (100 MHz, CDCl3):  δ 28.7, 29.3, 32.0, 32.6, 37.2, 38.9, 51.6, 55.0, 56.5, 112.2, 
114.3, 120.8, 125.7, 128.2, 128.3, 129.6, 138.9, 141.9, 159.4 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.4 Structure of 1-(4-methoxyphenethyl)-4-phenethylpiperidine (JPC-060) 
Chemical Formula: C22H29NO  Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of introducing the 4-methoxy 
substituent into the phenyl ring of the phenethyl moiety attached to N1 in the 1,4-
substituted piperidine scaffold on VMAT2 binding.  Synthesis began with the common 
intermediate 4-phenethylpiperidine, which was reacted via a SN2 reaction with potassium 
carbonate and 1-(2-bromoethyl)-4-methoxybenzene to yield the final product 1-(4-
methoxyphenethyl)-4-phenethylpiperidine (JPC-060) after purification via silica gel 
column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.18-1.94 (m, 10H), 2.38-2.95 (m, 7H). 3.82 (s, 3H), 
6.78-7.21 (m, 9H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.4, 28.7, 32.0, 32.6, 37.2, 38.9, 51.6, 55.0, 56.9, 
114.0, 125.7, 128.2, 128.3, 129.1, 129.6, 141.9, 158.0 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.5 Structure of 1-(2-chlorophenethyl)-4-phenethylpiperidine (JPC-072) 
Chemical Formula: C21H26ClN Molecular Weight: 327.89 
 
This molecule was designed to evaluate the effect of introducing the 2-chloro 
substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4-
substituted piperidine scaffold on VMAT2 binding 4-Phenethylpiperidine was reacted 
with potassium carbonate and 1-(2-bromoethyl)-2-chlorobenzene to afford the final 
product 1-(2-chlorophenethyl)-4-phenethylpiperidine (JPC-072) after purification via 
silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.39-1.77 (m, 7H), 2.10-3.09 (m, 10H), 7.08-7.28 (m, 9H) 
ppm. 
 13C NMR (75 MHz, CDCl3):  δ 31.0, 31.9, 33.3, 35.2, 38.4, 53.9, 58.6, 125.8, 127.1, 
127.9, 128.5, 129.6, 131.1, 134.0, 142.6 ppm. 
MS (EI) m/z 327 (M+). 
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Figure 3.6 Structure of 1-(4-fluorophenethyl)-4-phenethylpiperidine (JPC-073) 
Chemical Formula: C21H26FN Molecular Weight: 311.44 
 
This molecule was designed to evaluate the effect of the introducing a 4-chloro 
substituent into the phenyl ring of the phenethyl linker attached to N1 in the 1,4-
disubstituted piperidine scaffold on VMAT2 binding.  4-Phenethylpiperidine was reacted 
with potassium carbonate and 1-(2-bromoethyl)-4-fluorobenzene to yield the final 
product, 1-(4-fluorophenethyl)-4-phenethylpiperidine (JPC-073) after purification via 
silica column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.32-2.01 (m, 10H), 2.51-3.01 (m, 7H), 6.93-6.99 (m, 
2H), 7.12-7.31 (m, 7H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.6, 33.3, 33.4, 35.6, 38.7, 54.2, 61.3, 115.1, 115.4, 
125.8, 128.4, 130.1, 130.2, 136.2, 142.9 ppm. 
MS (EI) m/z 311 (M+). 
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Figure 3.7 Structure of 4-(2-methoxyphenethyl)-1-phenethylpiperidine (JPC-078) 
Chemical Formula: C22H29NO  Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of introducing a 2-methoxy 
substituent into the phenyl ring of the phenethyl moiety attached to C4 in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine 
was subjected to Aldol condensation with 2-methoxybenzaldehyde in refluxing acetic 
anhydride to yield (E)-4-(2-methoxystyryl)pyridine (purified via silica column 
chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded 4-(2-methoxyphenethyl)piperidine  (purified via silica column 
chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product, 4-(2-methoxyphenethyl)-1-
phenethylpiperidine (JPC-078) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.32-1.98 (m, 7H), 2.54-2.98 (m, 10H). 3.81 (s, 3H), 
6.83-7.31(m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 27.6, 32.7, 34.2, 35.9, 37.0, 54.3, 55.5, 61.4, 110.4, 
120.5, 126.1, 126.9, 128.5, 128.8, 129.7, 131.4, 140.8, 157.5 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.8 Structure of 1,4-bis(2-methoxyphenethyl)piperidine (JPC-077) 
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(2-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-methoxybenzene to yield the final product, 1,4-bis(2-methoxyphenethyl)- 
piperidine (JPC-077) after was purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.32-2.02 (m, 7H), 2.52-3.06 (m, 10H). 3.83 (s, 6H), 
6.84-7.27 (m, 8H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 27.6, 28.3, 32.7, 35.9, 37.0, 54.2, 55.5, 59.5, 110.4, 
110.5, 120.5, 120.6, 126.9, 127.4, 129.7, 130.4, 131.4, 157.5, 157.6 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.9 Structure of 4-(2-methoxyphenethyl)-1-(3-
methoxyphenethyl)piperidine (JPC-094)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  
Synthesis began with 4-(2-methoxyphenethyl)piperidine which was reacted with 
potassium carbonate and 1-(2-bromoethyl)-3-methoxybenzene to yield the final product, 
4-(2-methoxyphenethyl)-1-(3-methoxyphenethyl)- piperidine (JPC-094) which was 
purified via column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.27-1.98 (m, 7H), 2.48-3.04 (m, 10H). 3.82 (s, 6H), 
6.89-7.22 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.5, 28.7, 29.3, 32.9, 35.8, 51.6, 55.0, 55.21, 55.22, 
56.5, 109.5, 110.6, 112.2, 114.3, 120.3, 120.8, 124.4, 127.1, 129.6, 138.9, 157.0, 159.4 
ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.10 Structure of 4-(2-methoxyphenethyl)-1-(4-
methoxyphenethyl)piperidine (JPC-095)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  
Synthesis began with the common intermediate 4-(2-methoxyphenethyl)piperidine that 
had been prepared previously, which was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-methoxybenzene to yield the final product 4-(2-methoxyphenethyl)-1-(4-
methoxyphenethyl) piperidine (JPC-095) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.28-2.04 (m, 7H), 2.44-2.91 (m, 10H). 3.80 (s, 6H), 
6.81-7.30 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 26.5, 28.4, 28.7, 32.9, 35.8, 43.3, 51.6, 55.0, 55.2, 
56.9, 109.4, 110.6, 120.3, 127.1, 129.1, 129.5, 129.7, 157.0, 158.0 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.11 Structure of 4-(2-methoxyphenethyl)-1-(2-
chlorophenethyl)piperidine (JPC-096)  
Chemical Formula: C22H28ClNO Molecular Weight: 357.92 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1 and a 
2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding. The 
combination of methoxy and chloro substituents had not previously been investigated in 
any lobelane scaffold thus far.  4-(2-Methoxyphenethyl)piperidine was reacted with 
potassium carbonate and 1-(2-bromoethyl)-2-chlorobenzene to yield the final product 4-
(2-methoxyphenethyl)-1-(2-chlorophenethyl)piperidine (JPC-096) after purification via 
silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.30-1.97 (m, 10H), 2.48-2.94 (m, 7H). 3.81 (s, 3H), 
6.80-7.28 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 26.5, 27.8, 28.7, 32.8, 35.8, 43.3, 51.6, 54.9, 55.2, 
110.6, 120.2, 127.1, 127.6, 128.9, 129.4, 129.5, 129.7, 131.1, 133.0, 134.8, 157.0 ppm. 
MS (EI) m/z 357 (M+). 
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Figure 3.12 Structure of 4-(2-methoxyphenethyl)-1-(4-fluorophenethyl)piperidine 
(JPC-097) Chemical Formula: C22H28FNO Molecular Weight: 341.46 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1 and a 
2-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(2-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-fluorobenzene to yield the final product, 4-(2-methoxyphenethyl)-1-(4-
fluorophenethyl)piperidine (JPC-097) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.30-1.97 (m, 10H), 2.50-3.00 (m, 7H). 3.81 (s, 3H), 
6.82-7.25(m, 8H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 27.6, 32.7, 33.3, 35.9, 37.0, 54.3, 55.5, 61.4, 110.3, 
115.1, 115.3, 120.5, 127.0, 129.6, 130.1, 130.2, 131.3, 136.3, 136.4, 157.4, 163.0 ppm. 
MS (EI) m/z 341 (M+). 
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Figure 3.13 Structure of 4-(3-methoxyphenethyl)-1-phenethylpiperidine 
(JPC-079) Chemical Formula: C22H29NO  Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of introducing a 3-methoxy 
substituent into the phenyl ring of the phenethyl linker attached to C4 in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine 
was subjected to Aldol condensation with 3-methoxybenzaldehyde in refluxing acetic 
anhydride to yield (E)-4-(3-methoxystyryl)pyridine (purified via silica column 
chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded 4-(3-methoxyphenethyl)piperidine  (purified via silica column 
chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product, 4-(3-methoxyphenethyl)-1-
phenethylpiperidine (JPC-079) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.25-2.03 (m, 7H), 2.55-3.03 (m, 10H). 3.80 (s, 3H), 
6.71-7.31 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3) δ 25.6, 30.7, 34.1, 36.3, 37.0, 49.3, 55.6, 59.9, 110.9, 113.8, 
120.5, 126.1, 128.5, 128.8, 129.7, 139.4, 140.8, 159.5 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.14 Structure of 1-(2-methoxyphenethyl)-4-(3-
methoxyphenethyl)piperidine (JPC-080)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 and 
a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3-
methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-methoxybenzene to yield the final product 1-(2-methoxyphenethyl)-4-(3-
methoxyphenethyl)- piperidine (JPC-080) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-2.04 (m, 10H), 2.42-3.07 (m, 7H), 3.77 (s, 6H), 
6.65-6.89(m, 4H), 7.11-7.21 (m, 4H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 28.3, 32.7, 33.5, 35.7, 38.6, 53.7, 54.1, 55.4, 55.5, 59.5, 
110.4, 111.0, 114.3, 120.5, 120.9, 127.3, 129.1, 129.4, 130.3, 144.6, 157.6, 159.7 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.15 Structure of 1,4-bis(3-methoxyphenethyl)piperidine (JPC-081) 
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3-
Methoxyphenethyl) was reacted with potassium carbonate and 1-(2-bromoethyl)-3-
methoxybenzene to yield the final product 1,4-bis(3-methoxyphenethyl)- piperidine 
(JPC-081) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.19-2.07 (m, 10H), 2.51-3.07 (m, 7H). 3.79 (s, 6H), 
6.73-6.76(m, 5H), 7.15-7.21 (m, 3H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.7, 33.5, 34.2, 35.6, 38.6, 54.2, 55.4, 61.2, 111.0, 
111.4, 114.3, 114.7, 120.9, 121.3, 129.4, 129.5, 142.4, 144.6, 159.7 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.16 Structure of 1-(4-methoxyphenethyl)-4-(3-
methoxyphenethyl)piperidine (JPC-082)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-methoxybenzene to yield the final product, 1-(4-methoxyphenethyl)-4-(3-
methoxyphenethyl)piperidine (JPC-082) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-1.96 (m, 7H), 2.41-2.97 (m, 10H). 3.82 (s, 6H), 
6.81-7.23 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.2, 28.7, 32.0, 32.6, 37.1, 43.3, 51.6, 54.9, 55.0, 
56.9, 109.5, 111.1, 113.9, 114.0, 120.5, 129.0, 129.3, 129.6, 143.6, 158.1, 159.3 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.17 Structure of 1-(2-chlorophenethyl)-4-(3-
methoxyphenethyl)piperidine (JPC-083)  
Chemical Formula: C22H28ClNO Molecular Weight: 357.92 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and a 
3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-chlorobenzene to yield the final product 1-(2-chlorophenethyl)-4-(3-
methoxyphenethyl)piperidine (JPC-083) was after  purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.22-1.94 (m, 10H), 2.43-2.99 (m, 7H). 3.80 (s, 3H), 
6.88-7.32 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.4, 28.3, 28.9, 32.1, 37.2, 43.4, 51.8, 55.0, 111.2, 
114.1, 120.6, 127.7, 129.4, 131.2, 133.2, 134.1, 134.9, 143.7, 159.3, 166.4 ppm. 
MS (EI) m/z 357 (M+). 
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Figure 3.18 Structure of 1-(4-fluorophenethyl)-4-(3-methoxyphenethyl)piperidine 
(JPC-084) Chemical Formula: C22H28FNO Molecular Weight: 341.46 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and a 
3-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted scaffold on VMAT2 binding.  4-(3-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-fluorobenzene to yield the final product 1-(4-fluorophenethyl)-4-(2-
chlorophenethyl)piperidine (JPC-084) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.24-1.96 (m, 10H), 2.46-3.02 (m, 7H). 3.80 (s, 3H), 
6.83-7.21(m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.4, 28.7, 32.0, 32.6, 37.1, 43.3, 51.6, 54.9, 56.6, 
111.1, 113.9, 115.2, 115.4, 120.5, 129.3, 130.5, 130.6, 133.5, 143.6, 159.3, 162.3 ppm. 
 MS (EI) m/z 341 (M+). 
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Figure 3.19 Structure of 4-(4-methoxyphenethyl)-1-phenethylpiperidine  
(JPC-085) Chemical Formula: C22H29NO  Molecular Weight: 323.47 
 
This molecule was designed to evaluate the effect of introducing a 4-methoxy 
substituent into the phenyl ring of the phenethyl linker attached to C4 in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine 
was subjected to Aldol condensation with 4-methoxybenzaldehyde in refluxing acetic 
anhydride to yield (E)-4-(4-methoxystyryl)pyridine (purified via silica gel column 
chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded 4-(4-methoxyphenethyl)piperidine  (purified via silica gel column 
chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product 4-(4-methoxyphenethyl)-1-
phenethylpiperidine (JPC-085) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-1.97 (m, 10H), 2.36-2.91 (m, 7H). 3.83 (s, 3H), 
6.81-7.24 (m, 9H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.7, 29.3, 31.0, 32.5, 37.4, 43.3, 51.6, 54.9, 56.6, 
109.5, 113.7, 126.7, 128.60, 128.61, 129.1, 133.72, 137.4, 157.3 ppm. 
MS (EI) m/z 323 (M+). 
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Figure 3.20 Structure of 1-(2-methoxyphenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-086)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(4-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-methoxybenzene to yield the final product 1-(2-methoxyphenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-086) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.27-2.06 (m, 7H), 2.48-3.05 (m, 10H). 3.84 (s, 6H), 
6.87-7.30 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.3, 28.7, 31.0, 32.5, 37.4, 43.3, 51.5, 54.9, 55.3, 
55.4, 110.9, 113.7, 120.5, 124.4, 125.0, 128.3, 129.1, 130.0, 133.7, 157.0, 157.3 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.21 Structure of 1-(3-methoxyphenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-087)  
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted scaffold on VMAT2 binding.  4-(4-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-3-methoxybenzene to yield the final product 1-(3-methoxyphenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-087), after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.23-1.98 (m, 7H), 2.38-2.94 (m, 10H). 3.81 (s, 6H), 
6.87-7.28 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.7, 29.3, 31.0, 32.5, 37.4, 43.3, 51.6, 54.9, 55.0, 
56.5, 112.2, 113.7, 114.3, 120.8, 129.1, 129.6, 133.7, 138.9, 157.3, 159.4 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.22 Structure of 1,4-bis(4-methoxyphenethyl)piperidine (JPC-088) 
Chemical Formula: C23H31NO2 Molecular Weight: 353.50 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(4-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-methoxybenzene to yield the final product 1-(4-methoxyphenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-088) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-2.05 (m, 7H), 2.38-2.91 (m, 10H). 3.82 (s, 6H), 
6.76-7.23 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.4, 28.7, 31.1, 32.6, 37.5, 51.6, 54.95, 55.04, 56.9, 
109.5, 113.7, 114.0, 124.4, 129.08, 129.12, 129.7, 133.8, 157.4, 158.1 ppm. 
MS (EI) m/z 353 (M+). 
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Figure 3.23 Structure of 1-(2-chlorophenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-089) 
Chemical Formula: C22H28ClNO Molecular Weight: 357.92 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and a 
4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(4-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-089) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.26-1.95 (m, 10H), 2.41-3.02 (m, 7H). 3.81 (s, 3H), 
6.84-7.33 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.2, 28.7, 31.1, 32.5, 37.4, 43.3, 51.6, 55.0, 109.5, 
113.7, 124.4, 127.6, 128.9, 129.3, 131.1, 133.1, 133.8, 134.8, 157.4, 165.9 ppm. 
MS (EI) m/z 357 (M+). 
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Figure 3.24 Structure of 1-(4-fluorophenethyl)-4-(4-methoxyphenethyl)piperidine 
(JPC-090) Chemical Formula: C22H28FNO Molecular Weight: 341.46 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and a 
4-methoxy substituent into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(4-
Methoxyphenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-fluorobenzene to yield the final product 1-(4-fluorophenethyl)-4-(4-
methoxyphenethyl)piperidine (JPC-090) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-1.94 (m, 10H), 2.49-3.07 (m, 7H). 3.83 (s, 3H), 
6.87-7.28(m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.4, 28.7, 31.0, 32.5, 37.4, 51.6, 54.9, 56.5, 113.7, 
115.2, 115.4, 124.4, 129.1, 130.5, 130.6, 133.50, 133.53, 133.7, 159.9, 162.3 ppm. 
 MS (EI) m/z 341 (M+). 
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Figure 3.25 Structure of 4-(2,4-difluorophenethyl)-1-phenethylpiperidine  
(JPC-098) Chemical Formula: C21H25F2N Molecular Weight: 329.43 
 
This molecule was designed to evaluate the effect of introducing 2,4-difluoro 
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine 
ring of the 1,4-disubstituted scaffold on VMAT2 binding.  4-Methylpyridine was 
subjected to Aldol condensation with 2,4-difluorobenzaldehyde in refluxing acetic 
anhydride to yield (E)-4-(2,4-difluorostyryl)pyridine (purified via silica gel column 
chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded 4-(2,4-difluorophenethyl)piperidine  (purified via silica gel column 
chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product 4-(2,4-difluorophenethyl)-1-
phenethylpiperidine (JPC-098) was after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.31-1.95 (m, 9H), 2.44-3.02 (m, 8H). 6.65-6.91(m, 6H), 
7.13-7.30 (m, 2H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.7, 28.6, 29.3, 32.7, 35.9, 43.29, 43.30, 51.6, 56.6, 
103.6, 109.5, 111.4, 124.4, 126.7, 128.6, 131.7, 137.3, 142.2 ppm. 
MS (EI) m/z 329 (M+). 
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Figure 3.26 Structure of 4-(2,4-difluorophenethyl)-1-(2-
methoxyphenethyl)piperidine (JPC-099)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(2,4-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-methoxybenzene to yield the final product, 4-(2,4-difluorophenethyl)-1-
(2-methoxyphenethyl)piperidine (JPC-099) after purification via silica gel  column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.28-2.02 (m, 9H), 2.51-3.00 (m, 8H). 3.81 (s, 3H), 6.65-
6.81(m, 5H), 7.11-7.26 (m, 2H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.3, 24.7, 28.6, 32.6, 35.8, 43.3, 51.5, 55.3, 55.4, 
103.5, 109.5, 110.9, 111.2, 120.5, 124.4, 125.0, 128.3, 130.0, 157.1 ppm. 
MS (EI) m/z 359 (M+). 
 
 
148 
 
  
Figure 3.27 Structure of 4-(2,4-difluorophenethyl)-1-(3-
methoxyphenethyl)piperidine (JPC-100)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 2,4-difluoro substituents in the phenyl ring of the phenethyl linker attached to C4 of 
the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(2,4-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-3-methoxybenzene to yield the final product, 4-(2,4-difluorophenethyl)-1-
(3-methoxyphenethyl)piperidine (JPC-100) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.31-2.01 (m, 9H), 2.57-3.05 (m, 8H). 3.79 (s, 3H), 6.72-
6.81(m, 5H), 7.11-7.26 (m, 2H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 25.9, 32.3, 34.0, 35.5, 37.2, 54.1, 55.4, 61.0, 103.7, 
111.1, 111.2, 111.4, 114.6, 121.2, 129.5, 130.8, 130.88, 130.91, 142.1, 159.7 ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.28 Structure of 4-(2,4-difluorophenethyl)-1-(4-methoxyphenethyl)piperidine 
(JPC-101) Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(2,4-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-methoxybenzene to yield the final product 4-(2,4-difluorophenethyl)-1-(4-
methoxyphenethyl)piperidine (JPC-101) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.32-1.98 (m, 9H), 2.57-3.04 (m, 8H). 3.83 (s, 3H), 6.69-
6.84(m, 5H), 7.09-7.21 (m, 2H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.7, 28.4, 28.6, 32.7, 35.9, 43.3, 51.5, 55.0, 56.9, 
103.5, 111.1, 111.3, 114.0, 124.4, 124.7, 124.8, 129.1, 129.6, 129.1, 131.6, 158.0 ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.29 Structure of 1-(2-chlorophenethyl)-4-(2,4-difluorophenethyl)piperidine 
(JPC-102) Chemical Formula: C21H24ClF2N Molecular Weight: 363.87 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1 and 
2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(2,4-
Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(2,4-
difluorophenethyl)piperidine (JPC-102) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.31-1.97 (m, 9H), 2.46-2.94 (m, 8H), 6.65-7.26 (m, 7H) 
ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.7, 27.2, 28.6, 32.6, 35.8, 42.4, 43.3, 51.5, 54.9, 
103.6, 109.5, 111.2, 124.6, 127.6, 128.9, 129.4, 131.1, 131.7, 133.0, 134.8, 159.5 ppm. 
MS (EI) m/z 363 (M+). 
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Figure 3.30 Structure of 4-(2,4-difluorophenethyl)-1-(4-fluorophenethyl)piperidine  
(JPC-103) Chemical Formula: C21H24F3N Molecular Weight: 347.42 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and 
2,4-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(2,4-
Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-fluorobenzene to yield the final product 4-(2,4-difluorophenethyl)-1-(4-
fluorophenethyl)piperidine (JPC-103) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.34-2.02 (m, 9H), 2.41-3.06 (m, 8H), 6.61-7.29 (m, 7H) 
ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.7, 28.5, 32.7, 35.9, 37.6, 42.1, 43.3, 51.6, 56.5, 
103.6, 109.5, 111.3, 115.2, 115.4, 124.4, 124.7, 130.6, 131.6, 133.5, 159.9, 162.0 ppm. 
MS (EI) m/z 347 (M+). 
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Figure 3.31 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-phenethylpiperidine 
(JPC-104) Chemical Formula: C22H28FNO Molecular Weight: 341.46 
 
This molecule was designed to evaluate the effect of introducing 2-fluoro-4-
methoxy substituents into the phenyl ring of the phenethyl linker attached to C4 in the 
piperidine ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
Methylpyridine was subjected to Aldol condensation with 2-fluoro-4-methoxy 
benzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-fluoro-4-methoxy 
styryl)pyridine (purified via silica gel column chromatography).  Catalytic hydrogenation 
with Adam’s catalyst (PtO2) and hydrogen gas  afforded 4-(2-fluoro-4-
methoxyphenethyl)piperidine  (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and (2-bromoethyl)benzene to yield the final 
product 4-(2-fluoro-4-methoxyphenethyl)-1-phenethylpiperidine (JPC-104) after 
purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.27-1.89 (m, 9H), 2.38-2.94 (m, 8H), 3.82 (s, 3H), 6.74-
7.38 (m, 8H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.6, 28.7, 29.3, 32.6, 36.1, 43.3, 51.6, 55.5, 56.6, 
101.5, 109.5, 110.1, 120.1, 126.7, 128.6, 130.9, 131.0, 137.3, 157.2, 158.8, 158.9 ppm. 
MS (EI) m/z 341 (M+). 
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Figure 3.32 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(2-
methoxyphenethyl)piperidine (JPC-105)  
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and  2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached 
to C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 
binding.  4-(2-Fluoro-4-methoxyphenethyl)piperidine  was reacted with potassium 
carbonate and 1-(2-bromoethyl)-2-methoxybenzene to yield the final product, 4-(2-
fluoro-4-methoxyphenethyl)-1-(2-methoxyphenethyl)piperidine (JPC-105) after 
purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-1.97 (m, 9H), 2.41-2.99 (m, 8H), 3.81 (s, 6H), 6.71-
7.35 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.1, 25.7, 26.2, 27.0, 36.2, 43.1, 55.2, 56.6, 58.1, 
101.5, 111.2, 120.5, 126.7, 130.2, 130.5, 132.6, 158.1, 159.4, 161.2 ppm. 
MS (EI) m/z 371 (M+). 
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Figure 3.33 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(3-
methoxyphenethyl)piperidine (JPC-106)  
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached 
to C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 
binding.  4-(2-Fluoro-4-methoxyphenethyl)piperidine  was reacted with potassium 
carbonate and 1-(2-bromoethyl)-3-methoxybenzene to yield the final product, 4-(2-
fluoro-4-methoxyphenethyl)-1-(3-methoxyphenethyl)piperidine (JPC-106) was after 
purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.21-1.98 (m, 9H), 2.40-2.92 (m, 8H), 3.80 (s, 6H), 6.78-
7.31 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 24.2, 25.2, 26.3, 36.1, 38.0, 55.1, 57.6, 60.3, 101.5, 
109.5, 112.0, 114.2, 128.1, 130.5, 142.7, 157.7, 159.9, 160.7 ppm. 
MS (EI) m/z 371 (M+). 
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Figure 3.34 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(4-
methoxyphenethyl)piperidine (JPC-107)  
Chemical Formula: C23H30FNO2 Molecular Weight: 371.49 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1 and 
e2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to 
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  
4-(2-Fluoro-4-methoxy phenethyl)piperidine  was reacted with potassium carbonate and 
1-(2-bromoethyl)-4-methoxybenzene to yield the final product, 4-(2-fluoro-4-
methoxyphenethyl)-1-(4-methoxyphenethyl)piperidine (JPC-107) after purification via 
silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.27-1.97 (m, 9H), 2.32-3.04 (m, 8H), 3.82 (s, 6H), 6.71-
7.21 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 23.7, 24.9, 26.0, 34.1, 36.0, 55.1, 55.2, 60.7, 101.3, 
109.2, 113.9, 130.0, 130.1, 130.3, 132.7, 157.5, 158.3, 159.2 ppm. 
MS (EI) m/z 371 (M+). 
 
 
 
156 
 
  
Figure 3.35 Structure of 1-(2-chlorophenethyl)-4-(2-fluoro-4-
methoxyphenethyl)piperidine (JPC-108)  
Chemical Formula: C22H27ClFNO Molecular Weight: 375.91 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and 
2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to 
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  
4-(2-Fluoro-4-methoxyphenethyl)piperidine  was reacted with potassium carbonate and 
1-(2-bromoethyl)-2-chlorobenzene to yield the final product, 1-(2-chlorophenethyl)-4-(2-
fluoro-4-methoxyphenethyl)piperidine (JPC-108) was after purification via silica gel 
column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.29-2.07 (m, 9H), 2.48-2.98 (m, 8H), 3.82 (s, 3H), 6.65-
7.39 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.0, 28.1, 30.9, 31.2, 36.1, 53.1, 55.6, 56.0, 102.1, 
109.9, 127.7, 129.9, 130.1, 131.0, 131.7, 134.2, 158.2, 159.1 ppm. 
MS (EI) m/z 375 (M+). 
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Figure 3.36 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(4-
fluorophenethyl)piperidine (JPC-109)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and 
2-fluoro-4-methoxy substituents into the phenyl ring of the phenethyl linker attached to 
C4 of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  
4-(2-Fluoro-4-methoxyphenethyl)piperidine was reacted with potassium carbonate and 1-
(2-bromoethyl)-4-fluorobenzene to yield the final product, 4-(2-fluoro-4-
methoxyphenethyl)-1-(4-fluorophenethyl)piperidine (JPC-109) after purification via 
silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.28-2.09 (m, 9H), 2.45-3.01 (m, 8H), 3.79 (s, 3H), 6.69-
7.37 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.1, 28.0, 30.5, 32.7, 36.0, 52.7, 55.7, 57.1, 101.9, 
110.3, 114.2, 114.3, 129.8, 129.9, 130.3, 158.5, 159.9, 160.2 ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.37 Structure of 4-(3,5-difluorophenethyl)-1-phenethylpiperidine  
(JPC-110) Chemical Formula: C21H25F2N Molecular Weight: 329.43 
 
This molecule was designed to evaluate the effect of introducing 3,5-difluoro 
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine 
was subjected to Aldol condensation with 3,5-difluorobenzaldehyde in refluxing acetic 
anhydride to yield (E)-4-(3,5-difluorostyryl)pyridine (purified via silica gel column 
chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen 
gas afforded 4-(3,5-difluorophenethyl)piperidine  (purified via silica gel column 
chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product 4-(3,5-difluorophenethyl)-1-
phenethylpiperidine (JPC-110) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.31-1.95 (m, 9H), 2.44-3.02 (m, 8H). 6.71-7.34 (m, 8H) 
ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.7, 30.7, 32.3, 33.0, 34.9, 52.9, 59.3, 107.7, 112.9, 
126.5, 127.9, 128.7, 162.1 ppm. 
MS (EI) m/z 329 (M+). 
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Figure 3.38 Structure of 4-(3,5-difluorophenethyl)-1-(2-
methoxyphenethyl)piperidine (JPC-111)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(3,5-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-methoxybenzene to yield the final product, 4-(3,5-difluorophenethyl)-1-
(2-methoxyphenethyl)piperidine (JPC-111) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.28-1.97 (m, 9H), 2.47-3.08 (m, 8H). 3.80 (s, 3H), 6.63-
7.31 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.1, 29.2, 29.9, 30.6, 34.3, 51.7, 54.2, 57.0, 107.9, 
110.5, 113.7, 120.1, 129.9, 130.3, 130.6, 158.0, 162.4 ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.39 Structure of 4-(3,5-difluorophenethyl)-1-(3-
methoxyphenethyl)piperidine (JPC-112)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 3-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(3,5-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-3-methoxybenzene to yield the final product, 4-(3,5-difluorophenethyl)-1-
(3-methoxyphenethyl)piperidine (JPC-112) after purified via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.29-2.03 (m, 9H), 2.56-3.03 (m, 8H). 3.79 (s, 3H), 6.68-
6.76(m, 5H), 7.13-7.29 (m, 2H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.6, 33.16, 34.13, 35.5, 38.0, 54.1, 55.4, 61.1, 100.9, 
101.3, 101.6, 111.0, 111.32, 114.6, 121.2, 129.4, 142.3, 146.7, 154.6, 157.9, 161.3, 164.6 
ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.40 Structure of 4-(3,5-difluorophenethyl)-1-(4-
methoxyphenethyl)piperidine (JPC-113)  
Chemical Formula: C22H27F2NO Molecular Weight: 359.45 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-methoxy substituent into the phenyl ring of the phenethyl linker attached to N1, 
and 3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 
of the piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-
(3,5-Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-methoxybenzene to yield the final product 4-(3,5-difluorophenethyl)-1-(4-
methoxyphenethyl)piperidine (JPC-113) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.22-2.03 (m, 9H), 2.41-3.02 (m, 8H). 3.82 (s, 3H), 6.59-
7.32 (m, 7H) ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.9, 30.5, 31.8, 33.9, 36.1, 53.0, 55.1, 59.4, 108.4, 
114.9, 116.0, 124.1, 159.9, 161.8 ppm. 
MS (EI) m/z 359 (M+). 
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Figure 3.41 Structure of 1-(2-chlorophenethyl)-4-(3,5-
difluorophenethyl)piperidine (JPC-114)  
Chemical Formula: C21H24ClF2N Molecular Weight: 363.87 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 2-chloro substituent into the phenyl ring of the phenethyl linker attached to N1, and 
3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3,5-
Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-2-chlorobenzene to yield the final product 1-(2-chlorophenethyl)-4-(3,5-
difluorophenethyl)piperidine (JPC-114) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.30-1.99 (m, 9H), 2.51-3.07 (m, 8H), 6.68-7.29 (m, 7H) 
ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 27.9, 30.1, 31.0, 31.9, 34.7, 51.1, 54.8, 107.6, 114.2, 
127.2, 127.4, 128.9, 129.7, 131.5, 161.7 ppm. 
MS (EI) m/z 363 (M+). 
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Figure 3.42 Structure of 4-(3,5-difluorophenethyl)-1-(4-
fluorophenethyl)piperidine (JPC-115)  
Chemical Formula: C21H24F3N Molecular Weight: 347.42 
 
This molecule was designed to evaluate the effect of introducing the combination 
of a 4-fluoro substituent into the phenyl ring of the phenethyl linker attached to N1, and 
3,5-difluoro substituents into the phenyl ring of the phenethyl linker attached to C4 of the 
piperidine ring in the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-(3,5-
Difluorophenethyl)piperidine  was reacted with potassium carbonate and 1-(2-
bromoethyl)-4-fluorobenzene to yield the final product, 4-(3,5-difluorophenethyl)-1-(4-
fluorophenethyl)piperidine  (JPC-115) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.27-1.99 (m, 9H), 2.43-3.01 (m, 8H), 6.63-7.31 (m, 7H) 
ppm. 
13C NMR (100 MHz, DMSO-d6):  δ 28.1, 30.95, 31.7, 32.9, 34.9, 51.9, 59.7, 106.8, 
111.90, 112.0, 113.8, 113.93, 129.7, 161.2, 161.5 ppm. 
MS (EI) m/z 347 (M+). 
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 Figure 3.43 Structure of 1-phenethyl-4-(2,4,5-trimethoxyphenethyl)piperidine 
(JPC-068)  
Chemical Formula: C24H33NO3 Molecular Weight: 383.52 
 
This molecule was designed to evaluate the effect of introducing 2,4,5-trimethoxy 
substituents into the phenyl ring of the phenethyl linker attached to C4 in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Methylpyridine 
was subjected to Aldol condensation with 2,4,5-trimethoxybenzaldehyde in refluxing 
acetic anhydride to yield (E)-4-(2,4,5-trimethoxystyryl)pyridine (purified via silica gel 
column chromatography).  Catalytic hydrogenation with Adam’s catalyst (PtO2) and 
hydrogen gas afforded 4-(2,4,5-trimethoxyphenethyl)piperidine  (purified via silica gel 
column chromatography), which was reacted with potassium carbonate and (2-
bromoethyl)benzene to yield the final product, 1-phenethyl-4-(2,4,5-
trimethoxyphenethyl)piperidine (JPC-068) after purification via silica gel column 
chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.24-1.97 (m, 7H), 2.47-2.98 (m, 10H). 3.72 (s, 3H), 3.77 
(s, 3H), 3.80 (s, 3H), 6.44 (s, 1H), 6.62 (s, 1H), 7.12-7.24 (m, 5H) ppm. 
 13C NMR (75 MHz, CDCl3) δ 27.1, 32.6, 34.0, 35.8, 37.5, 54.3, 56.5, 56.7, 61.3, 114.1, 
126.1, 128.5, 128.8, 140.6, 142.9, 147.6, 151.5 ppm. 
MS (EI) m/z 383 (M+). 
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 A series of 1,4-disubstituted piperidine analogs were prepared with shorter alkane 
linker units between the C4 position of the piperidine ring and the phenyl moiety, while 
maintaining a substituted phenethyl linker at the N1 position of the piperidine ring, to 
determine the ability of the TBZ binding site on VMAT2 to recognize compounds with 
shorter linkers and less degrees of freedom of rotation The synthetic route for generating 
these compounds is shown in Scheme 3.2, and a total of four compounds were 
synthesized via a one-step synthesis. 
 
 
Scheme 3.2 Synthetic route to the phenethyl substituted 4-benzyl-1-phenethylpiperidine 
analogs of lobelane  
 
 Starting with 4-benzylpiperidine, which was readily available from Sigma 
Aldrich, a simple SN2 reaction with potassium carbonate and the appropriately substituted 
(2-bromoethyl)benzene afforded the desired 4-benzyl-1-phenethylpiperidine product, 
which was purified by silica gel column chromatography.  The four compounds designed 
and synthesized in this series, their structures, and analytical data follow in Figures 3.44 
through 3.47.  NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) 
on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are 
reported in ppm relative to either TMS as internal standard or as relative to the solvent 
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peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC 
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD. 
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Figure 3.44 Structure of 4-benzyl-1-(2-methoxyphenethyl)piperidine (JPC-061)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
  
 This molecule was designed to evaluate the effect of incorporating a shorter 
methylene linker between the C4 position of the piperidine ring and the phenyl moiety, 
while maintaining a 2-methoxyphenethyl unit on the N1 position in the piperidine ring of 
the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Benzylpiperidine was 
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-2-
methoxybenzene to yield the final product 4-benzyl-1-(2-methoxyphenethyl)piperidine 
(JPC-061). 
1H NMR (300 MHz, CDCl3): δ 1.30-1.91 (m, 5H), 2.47-2.61 (m, 6H), 2.75-2.78 (m, 4H), 
3.82 (s, 3H) 6.74-7.35 (m, 9H) ppm. 
MS (EI) m/z 309 (M+). 
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Figure 3.45 Structure of 4-benzyl-1-(3-methoxyphenethyl)piperidine (JPC-062)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
 
This molecule was designed to evaluate the effect of incorporating a shorter 
methylene linker between the C4 position of the piperidine ring and the phenyl moiety 
while, maintaining a 3-methoxyphenethyl unit on the N1 position in the piperidine ring of 
the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Benzylpiperidine was 
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-3-
methoxybenzene to yield the final product, 4-benzyl-1-(3-methoxyphenethyl)piperidine 
(JPC-062). 
1H NMR (300 MHz, CDCl3): δ 1.32-1.95 (m, 5H), 2.43-2.60 (m, 6H), 2.77-2.82 (m, 4H), 
3.81 (s, 3H) 6.71-7.32 (m, 9H) ppm. 
MS (EI) m/z 309 (M+). 
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Figure 3.46 Structure of 4-benzyl-1-(3,4-dimethoxyphenethyl)piperidine  
(JPC-063) Chemical Formula: C22H29NO2 Molecular Weight: 339.47 
 
This molecule was designed to evaluate the effect of incorporating a shorter 
methylene linker between the C4 position of the piperidine ring and the phenyl moiety, 
while maintaining a 3,4-dimethoxyphenethyl unit on the N1 position in the piperidine 
ring of the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Benzylpiperidine 
was subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-3,4-
dimethoxybenzene to yield the final product, 4-benzyl-1-(3,4-
dimethoxyphenethyl)piperidine (JPC-063). 
1H NMR (300 MHz, CDCl3): δ 1.34-1.87 (m, 5H), 2.41-2.57 (m, 6H), 2.71-2.80 (m, 4H), 
3.80 (s, 6H) 6.71-7.30 (m, 8H) ppm. 
MS (EI) m/z 339 (M+). 
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Figure 3.47 Structure of 4-benzyl-1-(4-methoxyphenethyl)piperidine (JPC-064)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
 
This molecule was designed to evaluate the effect of incorporating a shorter 
methylene linker between the C4 position of the piperidine ring and the phenyl moiety, 
while maintaining a 4-methoxyphenethyl unit on the N1 position in the piperidine ring of 
the 1,4-disubstituted piperidine scaffold on VMAT2 binding.  4-Benzylpiperidine was 
subjected to SN2 reaction with potassium carbonate and 1-(2-bromoethyl)-4-
methoxybenzene to yield the final product, 4-benzyl-1-(4-methoxyphenethyl)piperidine 
(JPC-064). 
1H NMR (300 MHz, CDCl3): δ 1.28-1.98 (m, 5H), 2.46-2.62 (m, 6H), 2.75-2.84 (m, 4H), 
3.82 (s, 3H) 6.75-7.37 (m, 9H) ppm. 
MS (EI) m/z 309 (M+). 
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A series of 1,4-substituted piperidine analogs with shorter methylene linkers 
between the N1 position of the piperidine ring and the substituted phenyl moiety, while 
maintaining a substituted phenethyl linker on the C4 position, were prepared to further 
analyze the ability of the TBZ binding site on VMAT2 to recognize compounds with 
shorter linkers and less degrees of freedom of rotation (one carbon shorter) at the N1 
position.  The synthetic route for generating these compounds is shown in Scheme 3.3, 
and a total of six compounds were synthesized via a one-step synthesis. 
 
 
Scheme 3.3 Synthetic route to the substituted 1-benzyl-4-phenethylpiperidine  
analogs of lobelane. 
 
 4-Phenethylpiperidine, which had been previously prepared in earlier syntheses, 
was subjected to a reductive amination reaction with an appropriately substituted 
benzaldehyde and sodium cyanoborohydride in methanol to yield the appropriate 1-
benzyl-4-phenethylpiperidine product, which was purified by silica gel column 
chromatography.  The six compounds designed and synthesized in this series, their 
structures, and analytical data follow in Figures 3.48 through 3.53.  NMR spectra were 
recorded in either CDCl3 or DMSO-d6 (as designated) on one of three Varian instruments 
(300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm relative to either 
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TMS as internal standard or as relative to the solvent peak present in 13C spectra. GC-
mass spectra were recorded on an Agilent 6890 GC incorporating an Agilent 7683 
autosampler and an Agilent 5973 MSD. 
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Figure 3.48 Structure of 1-benzyl-4-phenethylpiperidine (JPC-152)  
Chemical Formula: C20H25N Molecular Weight: 279.42 
 
This molecule was designed to evaluate the effect that a shorter methylene linker 
(one carbon) between the N1 position on the piperidine ring and the phenyl ring, while 
maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4-
disubstituted piperidine scaffold would have on VMAT2 binding.  4-Phenethylpiperidine, 
which had been previously prepared in earlier syntheses, was subjected to reductive 
amination conditions with benzaldehyde and sodium cyanoborohydride in methanol to 
afford the final product 1-benzyl-4-phenethylpiperidine (JPC-152). 
1H NMR (300 MHz, CDCl3): δ 1.05-1.92 (m, 9H), 2.58-2.86 (m, 4H). 3.48 (s, 2H), 7.15-
7.32 (m, 10H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 26.8, 32.6, 33.4, 35.65, 38.7, 54.1, 63.8, 125.7, 127.0, 
128.25, 128.4, 128.5, 129.4, 138.8, 142.95 ppm. 
MS (EI) m/z 279 (M+). 
 
 
 
 
 
174 
 
  
Figure 3.49 Structure of 1-(2-methoxybenzyl)-4-phenethylpiperidine (JPC-153)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
 
This molecule was designed to evaluate the effect that a shorter methylene linker 
(one carbon) between the N1 position of the piperidine ring and a 2-methoxyphenyl ring, 
while maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4-
disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine 
was subjected to reductive amination conditions with 2-methoxybenzaldehyde and 
sodium cyanoborohydride in methanol to afford the final product 1-(2-methoxybenzyl)-4-
phenethylpiperidine (JPC-153). 
1H NMR (300 MHz, CDCl3): δ 1.28-2.05 (m, 9H), 2.58-2.94 (m, 4H). 3.55 (s, 2H), 3.81 
(s, 3H) 6.84-7.37 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 26.8, 32.7, 33.5, 35.6, 38.8, 54.1, 55.7, 56.6, 110.55, 
120.4, 125.7, 127.9, 128.4, 128.5, 130.7, 157.9 ppm. 
MS (EI) m/z 309 (M+). 
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Figure 3.50 Structure of 1-(3-methoxybenzyl)-4-phenethylpiperidine (JPC-154)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
 
This molecule was designed to evaluate the effect that a shorter methylene linker 
(one carbon) between the N1 position of the piperidine ring and a 3-methoxyphenyl ring, 
while maintaining a phenethyl linker at the C4 position in the piperidine ring of the 1,4-
disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine 
was subjected to reductive amination conditions with 3-methoxybenzaldehyde and 
sodium cyanoborohydride in methanol to afford the final product, 1-(3-methoxybenzyl)-
4-phenethylpiperidine (JPC-154). 
1H NMR (300 MHz, CDCl3): δ 1.28-2.00 (m, 9H), 2.59-2.90 (m, 4H). 3.46 (s, 2H), 3.81 
(s, 3H) 6.77-7.29 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.6, 33.4, 35.6, 38.7, 54.1, 55.5, 63.7, 112.5, 114.8, 
121.7, 125.7, 128.4, 128.5, 129.2, 141.7, 159.9 ppm. 
MS (EI) m/z 309 (M+). 
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Figure 3.51 Structure of 1-(4-methoxybenzyl)-4-phenethylpiperidine (JPC-155)  
Chemical Formula: C21H27NO Molecular Weight: 309.45 
 
This molecule was designed to evaluate the effect that a shorter methylene linker 
(one carbon) between the N1 position of the piperidine ring and a 4-methoxyphenyl ring, 
while maintaining a phenethyl linker at the C4 position of the piperidine ring of the 1,4-
disubstituted piperidine scaffold would have on VMAT2 binding 4-Phenethylpiperidine 
was subjected to reductive amination conditions with 4-methoxybenzaldehyde and 
sodium cyanoborohydride in methanol to afford the final product 1-(4-methoxybenzyl)-4-
phenethylpiperidine (JPC-155). 
1H NMR (300 MHz, CDCl3): δ 1.29-1.97 (m, 9H), 2.58-2.90 (m, 4H). 3.44 (s, 2H), 3.80 
(s, 3H) 6.83-7.32 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 26.8, 32.5, 33.4, 35.6, 38.7, 53.94, 55.51, 63.1, 113.7, 
125.7, 128.41, 128.44, 130.6, 142.92, 159.5 ppm. 
MS (EI) m/z 309 (M+). 
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Figure 3.52 Structure of 1-(2-chlorobenzyl)-4-phenethylpiperidine (JPC-156)  
Chemical Formula: C20H24ClN Molecular Weight: 313.86 
 
This molecule was designed to evaluate the effect that a shorter methylene linker 
(one carbon) between the N1 position of the piperidine ring and a 2-chlorophenyl ring, 
while maintaining a phenethyl linker at the C4 position of the piperidine ring of the 1,4-
disubstituted piperidine scaffold would have on VMAT2 binding.  4-Phenethylpiperidine 
was subjected to reductive amination conditions with 2-chlorobenzaldehyde and sodium 
cyanoborohydride in methanol to afford the final product, 1-(2-chlorobenzyl)-4-
phenethylpiperidine (JPC-156). 
1H NMR (300 MHz, CDCl3): δ 1.25-2.01 (m, 9H), 2.58-2.89 (m, 4H). 3.57 (s, 2H), 7.18-
7.57 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.73, 33.5, 35.6, 38.8, 54.3, 59.8, 125.7, 126.7, 128.0, 
128.41, 128.44, 129.4, 130.4, 134.2, 136.3, 143.6 ppm. 
MS (EI) m/z 313 (M+). 
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Figure 3.53 Structure of 1-(4-fluorobenzyl)-4-phenethylpiperidine (JPC-157)  
Chemical Formula: C20H24FN Molecular Weight: 297.41 
 
This molecule was designed to evaluate the effect that of a shorter methylene 
linker (one carbon) between the N1 position of the piperidine ring and a 4-fluorophenyl 
ring, while maintaining a phenethyl linker at the C4 position of the piperidine ring of the 
1,4-disubstituted piperidine scaffold of analog would have on VMAT2 binding.  4-
Phenethylpiperidine was subjected to reductive amination conditions with 4-
fluorobenzaldehyde and sodium cyanoborohydride in methanol to afford the final product 
1-(4-fluorobenzyl)-4-phenethylpiperidine (JPC-157). 
1H NMR (300 MHz, CDCl3): δ 1.05-1.65 (m, 7H), 2.31-2.73 (t, 6H). 3.60 (s, 2H), 7.18-
7.47 (m, 9H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 32.4, 32.8, 35.9, 38.3, 52.9, 53.14, 61.3, 114.63, 124.7, 
127.7, 127.9, 130.45, 132.2, 142.6, 159.9 ppm. 
MS (EI) m/z 309 (M+). 
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Similarly, another series of 1,4-disubstituted piperidine analogs combined these 
factors with shorter linkers between the N1 position of the piperidine ring and the phenyl 
moiety, while maintaining a substituted phenethyl linker on the C4 position;  or with 
shorter linkers between the C4 position of the piperidine ring and the phenyl moiety, 
while maintaining a substituted phenethyl linker at the N1 position, were prepared to 
further analyze the ability of the TBZ binding site on VMAT2 to recognize compounds 
with shorter linkers and less degrees of freedom of rotation (one carbon shorter) at the N1 
position.  This series of compounds incorporated an alkylbranch in the N1 alkyl linker to 
afford a racemic 1-phenylpropan-2-yl moiety attached to N1 of the piperidine ring.  The 
combined synthetic routes for generating these compounds is shown in Scheme 3.4, and a 
total of four compounds were prepared via a one-step synthesis. 
 
Scheme 3.4 Synthesis of the 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine and 4-
benzyl-1-(1-phenylpropan-2-yl)piperidine series of lobelane analogs 
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 4-Benzylpiperidine or 4-phenethylpiperidine were each subjected to reductive 
amination conditions with the appropriately substituted 1-phenylpropan-2-one and 
sodium cyanoborohydride in methanol.  This afforded the desired 4-phenethyl-1-(1-
phenylpropan-2-yl)piperidine and 4-benzyl-1-(1-phenylpropan-2-yl)piperidine scaffolds, 
respectively.  This synthetic route to these series of molecules also allowed for the 
introduction of a bromo substituted phenyl moiety into the scaffold.  The final products 
were purified via silica gel column chromatography. The structures of four compounds 
from this series together with their analytical data are shown in Figures 3.54 through 
3.57.  NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of 
three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in 
ppm relative to either TMS as internal standard or as relative to the solvent peak present 
in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an 
Agilent 7683 autosampler and an Agilent 5973 MSD. 
 
 
 
 
 
 
 
181 
 
  
Figure 3.54 Structure of racemic 4-benzyl-1-(1-phenylpropan-2-yl)piperidine 
(JPC-174) Chemical Formula: C21H27N Molecular Weight: 293.45 
 
4-Benzylpiperidine was subjected to reductive amination conditions with 1-
phenylpropan-2-one and sodium cyanoborohydride in methanol to afford the final 
product, (±)-4-benzyl-1-(1-phenylpropan-2-yl)piperidine (JPC-174). 
1H NMR (300 MHz, CDCl3): δ 0.97 (d, 3H), 1.02-1.88 (m, 5H), 2.21-2.96 (m, 8H). 3.10 
(m, 1H), 7.15-7.36 (m, 10H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 14.5, 26.7, 32.8, 33.9, 38.6, 39.4, 43.5, 48.8, 49.5, 53.7, 
62.0, 125.87, 125.93, 128.2, 128.3, 129.2, 129.4, 139.7, 140.8 ppm. 
MS (EI) m/z 293 (M+). 
 
 
 
 
 
 
182 
 
  
Figure 3.55 Structure of racemic 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine 
 (JPC-175) Chemical Formula: C22H29N Molecular Weight: 307.47 
 
4-Phenethylpiperidine was subjected to reductive amination conditions with 1-
phenylpropan-2-one and sodium cyanoborohydride in methanol to afford the final 
product (±)-4-phenethyl-1-(1-phenylpropan-2-yl)piperidine (JPC-175). 
1H NMR (300 MHz, CDCl3): δ 0.96 (d, 3H), 1.22-1.92 (m, 7H), 2.21-2.96 (m, 8H). 3.07 
(m, 1H), 7.18-7.34 (m, 10H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 14.6, 33.0, 33.1, 33.4, 36.0, 38.8, 39.5, 48.9, 49.5, 62.0, 
125.7, 125.9, 128.3, 128.4, 128.43, 128.51, 128.57, 129.4, 141.0, 142.9, 149.8 ppm. 
MS (EI) m/z 307 (M+). 
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Figure 3.56 Structure of racemic 4-benzyl-1-(1-(4-bromophenyl)propan-2-
yl)piperidine (JPC-171)  
Chemical Formula: C21H26BrN Molecular Weight: 372.34 
 
4-Benzylpiperidine was subjected to reductive amination conditions with 1-(4-
bromophenyl)propan-2-one and sodium cyanoborohydride in methanol to afford the final 
product (±)-4-benzyl-1-(1-(4-bromophenyl)propan-2-yl)piperidine 
(JPC-171). 
1H NMR (300 MHz, CDCl3): δ 0.97 (d, 3H), 1.07-1.84 (m, 5H), 2.25-2.99 (m, 8H). 3.15 
(m, 1H), 7.15-7.46 (m, 7H), 7.86-7.90 (m, 2H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 14.6, 33.0, 33.1, 33.4, 36.0, 38.8, 39.5, 48.9, 49.5, 62.0, 
125.7, 125.9, 128.3, 128.4, 128.43, 128.51, 128.57, 129.4, 141.0, 142.9, 149.8 ppm. 
MS (EI) m/z 372 (M+). 
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Figure 3.57 Structure of racemic 1-(1-(4-bromophenyl)propan-2-yl)-4-
phenethylpiperidine (JPC-172)  
Chemical Formula: C22H28BrN Molecular Weight: 386.37 
 
4-Phenethylpiperidine was subjected to reductive amination conditions with 1-(4-
bromophenyl)propan-2-one and sodium cyanoborohydride in methanol to afford the final 
product, (±)-1-(1-(4-bromophenyl)propan-2-yl)-4-phenethylpiperidine  
(JPC-172). 
1H NMR (300 MHz, CDCl3): δ 0.98 (d, 3H), 1.22-1.80 (m, 7H), 2.28-2.94 (m, 8H). 3.13 
(m, 1H), 7.24-7.65 (m, 9H) ppm. 
13C NMR (75 MHz, CDCl3):  δ 13.5, 31.2, 33.1, 35.1, 36.8, 37.3, 37.9, 38.5, 47.9, 50.3, 
53.7, 62.4, 120.3, 124.0, 125.9, 126.3, 128.4, 129.5, 131.1, 131.6, 142.3, 149.7 ppm. 
MS (EI) m/z 386 (M+). 
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 The final series of 1,4-disubstituted piperidine analogs was designed to increase 
the water-solubility of the scaffold by replacing the phenyl ring at the N1 phenethyl 
linker with saturated heterocyclic moieties, i.e. either piperidine or morpholine, and to 
study what effect the introduction of a more polar moiety would have on binding affinity 
at the TBZ site of VMAT2.  Utilizing synthetic methods similar to those used in Scheme 
3.1, 11 analogs were designed and synthesized in this series.  The chemistry by which 
this series of compounds were generated is shown in Scheme 3.5. 
 
Scheme 3.5 Synthesis of the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine and 4-(2-
(4-phenethylpiperidin-1-yl)ethyl)morpholine series of lobelane analogs 
 
The general synthetic scheme to the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine 
and 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine analogs of lobelane utilizes 4-
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methylpyridine as the starting material.  Similar to chemistry used to construct the  2,6-
substituted  scaffold, 4-methylpyridine was subjected to Aldol condensation with an 
appropriately substituted benzaldehyde in refluxing acetic anhydride to afford the 
corresponding (E)-4-styrylpyridine intermediate.  After purification via silica gel column 
chromatography, the conjugated intermediate was then subjected to catalytic 
hydrogenation with Adam’s catalyst and hydrogen gas in acetic acid, to afford the 
appropriate substituted 4-phenethylpiperidine intermediate.  The 4-phenethylpiperidine 
intermediate was then subjected to a SN2 reaction with potassium carbonate and either 1-
(2-chloroethyl)piperidine or 4-(2-chloroethyl)morpholine, to yield respectively the final 
products of the 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine and 4-(2-(4-
phenethylpiperidin-1-yl)ethyl)morpholine series of lobelane analogs.  The exact 
structures of the above compounds and the analytical data for each compound are shown 
in Figures 3.58 through 3.68.  NMR spectra were recorded in either CDCl3 or DMSO-d6 
(as designated) on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as 
indicated are reported in ppm relative to either TMS as internal standard or as relative to 
the solvent peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 
6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD. 
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Figure 3.58 Structure of 4-phenethyl-1-(2-(piperidin-1-yl)ethyl)piperidine  
(JPC-116) Chemical Formula: C20H32N2 Molecular Weight: 300.48 
 
4-Methylpyridine was subjected to Aldol condensation with benzaldehyde in 
refluxing acetic anhydride to yield (E)-4-styrylpyridine (purified via silica gel column 
chromatography).  Subsequent catalytic hydrogenation with Adam’s catalyst (PtO2) and 
hydrogen gas afforded 4-phenethylpiperidine (purified via silica gel column 
chromatography), which was then reacted with potassium carbonate and 1-(2-
chloroethyl)piperidine in DMF to yield the final product, 4-phenethyl-1-(2-(piperidin-1-
yl)ethyl)piperidine (JPC-116)  after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.43-1.78 (m, 13H), 2.31-2.65 (m, 14H), 7.23-7.43 (m, 
5H) ppm. 
MS (EI) m/z 300 (M+). 
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Figure 3.59 Structure of 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine 
(JPC-117) Chemical Formula: C19H30N2O Molecular Weight: 302.45 
 
4-Methylpyridine was subjected to Aldol condensation with benzaldehyde in 
refluxing acetic anhydride to yield (E)-4-styrylpyridine (purified via silica gel column 
chromatography).  Subsequent catalytic hydrogenation with Adam’s catalyst (PtO2) and 
hydrogen gas afforded 4-phenethylpiperidine (purified via silica gel column 
chromatography), which was reacted with potassium carbonate and 4-(2-
chloroethyl)morpholine in DMF to yield the final product 4-(2-(4-phenethylpiperidin-1-
yl)ethyl)morpholine (JPC-117) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.35-1.68 (m, 7H), 2.37-2.70 (m, 14H), 3.43-3.51 (m, 4H) 
7.23-7.41 (m, 5H) ppm. 
MS (EI) m/z 300 (M+). 
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Figure 3.60 Structure of 4-(2-methoxyphenethyl)-1-(2-(piperidin-1-
yl)ethyl)piperidine (JPC-118)  
Chemical Formula: C21H34N2O Molecular Weight: 330.51 
 
4-Methylpyridine was subjected to Aldol condensation with 2-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield 
the final product 4-(2-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-118) 
after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.47-1.68 (m, 13H), 2.30-2.67 (m, 14H), 3.82 (s, 3H), 
6.81-7.23 (m, 4H) ppm. 
MS (EI) m/z 330 (M+). 
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Figure 3.61 Structure of 4-(2-(4-(2-methoxyphenethyl)piperidin-1-
yl)ethyl)morpholine (JPC-119)  
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48 
 
4-Methylpyridine was subjected to Aldol condensation with 2-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield 
the final product 4-(2-(4-(2-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC-
119) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.32-1.64 (m, 7H), 2.44-2.68 (m, 14H), 3.48-3.58 (m, 
4H), 3.81 (s, 3H), 6.81-7.23 (m, 4H) ppm. 
MS (EI) m/z 332 (M+). 
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Figure 3.62 Structure of 4-(3-methoxyphenethyl)-1-(2-(piperidin-1-
yl)ethyl)piperidine (JPC-120)  
Chemical Formula: C21H34N2O Molecular Weight: 330.51 
 
4-Methylpyridine was subjected to Aldol condensation with 3-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(3-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(3-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield 
the final product, 4-(3-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-
120) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.42-1.66 (m, 13H), 2.32-2.64 (m, 14H), 3.81 (s, 3H), 
6.83-7.27 (m, 4H) ppm. 
MS (EI) m/z 330 (M+). 
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Figure 3.63 Structure of 4-(2-(4-(3-methoxyphenethyl)piperidin-1-
yl)ethyl)morpholine (JPC-121)  
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48 
 
4-Methylpyridine was subjected to Aldol condensation with 3-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(3-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(3-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield 
the final product 4-(2-(4-(3-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC-
121) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.38-1.67 (m, 7H), 2.44-2.67 (m, 14H), 3.47-3.60 (m, 
4H), 3.82 (s, 3H), 6.78-7.19 (m, 4H) ppm. 
MS (EI) m/z 332 (M+). 
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Figure 3.64 Structure of 4-(4-methoxyphenethyl)-1-(2-(piperidin-1-
yl)ethyl)piperidine (JPC-122)  
Chemical Formula: C21H34N2O Molecular Weight: 330.51 
 
4-Methylpyridine was subjected to Aldol condensation with 4-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(4-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(4-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield 
the final product, 4-(4-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-
122) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.35-1.68 (m, 13H), 2.36-2.62 (m, 14H), 3.80 (s, 3H), 
6.80-7.22 (m, 4H) ppm. 
MS (EI) m/z 330 (M+). 
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Figure 3.65 Structure of 4-(2-(4-(4-methoxyphenethyl)piperidin-1-
yl)ethyl)morpholine (JPC-123)  
Chemical Formula: C20H32N2O2 Molecular Weight: 332.48 
 
4-Methylpyridine was subjected to Aldol condensation with 4-
methoxybenzaldehyde in refluxing acetic anhydride to yield (E)-4-(4-
methoxystyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(4-
methoxyphenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield 
the final product 4-(2-(4-(4-methoxyphenethyl)piperidin-1-yl)ethyl)morpholine (JPC-
123) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.31-1.62 (m, 7H), 2.48-2.70 (m, 14H), 3.45-3.62 (m, 
4H), 3.84 (s, 3H), 6.73-7.26 (m, 4H) ppm. 
MS (EI) m/z 332 (M+). 
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Figure 3.66 Structure of 4-(2,4-difluorophenethyl)-1-(2-(piperidin-1-
yl)ethyl)piperidine (JPC-124)  
Chemical Formula: C20H30F2N2 Molecular Weight: 336.46 
 
4-Methylpyridine was subjected to Aldol condensation with 2,4-
difluorobenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2,4-
difluorostyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2,4-
difluorophenethyl)piperidine (purified via silica gel column chromatography), which was 
reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield the 
final product, 4-(2,4-difluorophenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-124) 
after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.38-1.69 (m, 13H), 2.40-2.65 (m, 14H), 6.61-7.27 (m, 
3H) ppm. 
MS (EI) m/z 336 (M+). 
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Figure 3.67 Structure of 4-(2-(4-(2,4-methoxyphenethyl)piperidin-1-
yl)ethyl)morpholine (JPC-125)  
Chemical Formula: C19H28F2N2O Molecular Weight: 338.44 
 
4-methylpyridine was subjected to Aldol condensation with 2,4-
difluorobenzaldehyde in refluxing acetic anhydride to yield (E)-4-(2,4-
difluorostyryl)pyridine (purified via silica gel column chromatography).  Subsequent 
catalytic hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2,4-
difluorophenethyl)piperidine (purified via silica gel column chromatography), which was 
reacted with potassium carbonate and 4-(2-chloroethyl)morpholine in DMF to yield the 
final product 4-(2-(4-(2,4-difluorophenethyl)piperidin-1-yl)ethyl)morpholine (JPC-125) 
after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.35-1.63 (m, 7H), 2.38-2.63 (m, 14H), 3.48-3.55 (m, 4H) 
6.64-7.23 (m, 3H) ppm. 
MS (EI) m/z 338 (M+). 
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Figure 3.68 Structure of 4-(2-fluoro-4-methoxyphenethyl)-1-(2-(piperidin-1-
yl)ethyl)piperidine  (JPC-126)  
Chemical Formula: C21H33FN2O Molecular Weight: 348.50 
 
4-Methylpyridine was subjected to Aldol condensation with 2-fluoro-4-methoxy 
benzaldehyde in refluxing acetic anhydride to yield (E)-4-(2-fluoro-4-methoxy 
styryl)pyridine (purified via silica gel column chromatography). Subsequent catalytic 
hydrogenation with Adam’s catalyst (PtO2) and hydrogen gas afforded 4-(2-fluoro-4-
methoxy phenethyl)piperidine (purified via silica gel column chromatography), which 
was reacted with potassium carbonate and 1-(2-chloroethyl)piperidine in DMF to yield 
the desired 4-(2-fluoro-4-methoxyphenethyl)-1-(2-(piperidin-1-yl)ethyl)piperidine (JPC-
126) after purification via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.35-1.62 (m, 13H), 2.37-2.70 (m, 14H), 3.80 (s, 3H) 
6.73-7.27 (m, 3H) ppm. 
MS (EI) m/z 348 (M+). 
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3.3 Summary of the 1,4-disubstituted piperidine analog series 
 
In summary, 68 compounds were designed and synthesized in the 1,4-
disubstituted piperidine scaffold series as analogs of lobelane utilizing five distinct 
chemical schemes. Of the total number of compounds prepared, 43 were of the 1,4-
substituted scaffold of lobelane, with a large variety of substituent combinations in the 
two phenyl rings, that included methoxy, fluoro, and chloro moieties.  Another series of 
11 compounds belonging to the 1,4-disubstituted piperidine scaffold were  designed and 
synthesized for the purpose of increasing the water solubility of the scaffold by replacing 
the phenyl ring on the N1 phenethyl moiety with saturated heterocyclic moieties, such as 
piperidine or morpholine, and to study what effect the introduction of these more polar 
moieties would have on binding affinity at the TBZ binding site on VMAT2.  The 
remaining 14 compounds were of three smaller series of analogs in which a change in the 
intramolecular distance between the substituted phenyl rings and the central piperidine 
ring was made.  The pharmacological assay data for the above 68 compounds from these 
different scaffolds are discussed in Chapter 5. 
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Chapter 4. 
Design and Synthesis of 1,4-disubstituted piperazine and 1,4-diazapane analogs of 
lobelane 
4.1  Experiments in the 1,4-disubstituted piperazine scaffold 
 As discussed in Chapter 1, (section 1.8), a series of isomerized lobelane analogs 
have been designed and synthesized in which  compounds with different attachment 
positions of the phenethyl linkers on the central piperidine ring were constructed.  Of 
these structural modifications, the analogs with the phenethyl linkers in the N1, C4 
positions of the piperidine ring showed more promise for optimization and further study 
(data shown in Table 1.7), since their binding affinities for VMAT2 were quite similar to 
lobelane, while maintaining little to no affinity for α4β2* & α7* nAChRs (data shown in 
Table 1.7).  The symmetry present in the 1,4-disubstituted scaffold allowed for a 
relatively fast and efficient synthesis of a library of compounds with substituents in the 
phenyl rings.  Several series of compounds were explored in Chapter 3 that possessed a 
central piperidine ring, and further studies into a similar scaffold were explored that 
inserted an additional nitrogen atom into the central piperidine ring, affording 1,4-
piperazine and 1,4-diazapane scaffolds.  The addition of another nitrogen atom into the 
central piperidine ring is predicted to improve the water solubility characteristics of the 
scaffold, which is a desirable property in the development of drugs with higher 
bioavailability than lobelane, and several series of compounds were designed and 
synthesized to explore these possibilities, resulting in the generation of 21 compounds.  
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The scheme by which the 1,4-piperazine compounds were synthesized is shown in 
Scheme 4.1. The structures of the compounds and the supporting analytical data are 
provided in Figures 4.1 through 4.21.  The compounds were converted to their 
hydrochloride or tartrate salts (di-salts in the case of the piperazine and diazapane 
scaffold) prior to being submitted for pharmacological assay, and the assay data is 
presented in Chapter 5. 
 
Scheme 4.1 Synthesis of the symmetrical 1,4-substituted piperazine analog scaffold. 
 
 A simple one-step reaction was used to generate six initial compounds in the 
symmetrical 1,4-substituted piperazine analog series.  The starting material for this 
reaction was 1.4-piperazine (for ease of handling, the dihydrochloride salt of 1,4-
piperazine was also used), which was then subjected to SN2 reaction conditions with the 
appropriately substituted phenethylbromide and excess potassium carbonate as base in 
dimethylformamide as solvent.  2.2 equivalents of the appropriately substituted (2-
bromoethyl)benzene was added drop-wise into the reaction mixture.  The reaction was 
then heated to 70-80° Celsius for 12-18 hours until the 1,4-piperazine starting material 
was no longer visible by TLC chromatography (visualized with Dragendorff’s reagent).  
The reaction was cooled, excess solvent removed under reduced pressure, adsorbed onto 
silica gel, and purified via silica gel chromatography to yield the desired 1,4-substituted 
piperazine product. 
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Figure 4.1 Structure of 1,4-diphenethylpiperazine (JPC-134) 
Chemical Formula: C20H26N2 Molecular Weight: 294.43 
 
 This compound incorporates a second nitrogen atom into the central ring of the 
1,4-piperidine scaffold, while retaining the two phenethyl linkers that were present in 
lobelane.  1,4-Piperazine (readily available from Sigma Aldrich Chemical Company) was 
reacted via a SN2 reaction with potassium carbonate and 2.2 equivalents of (2-
bromoethyl)benzene in DMF to yield the desired product, 1,4-diphenethylpiperazine 
(JPC-134).  The final product was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.59-2.65 (m, 12H), 2.80-2.85 (m, 4H), 7.20-7.32 (m, 
10H) ppm. 
MS (EI) m/z 294 (M+). 
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Figure 4.2 Structure of 1,4-bis(2-methoxyphenethyl)piperazine (JPC-135) 
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49 
 
This compound incorporates 2-methoxy substituents into the two phenethyl 
linkers that are present in lobelane.  1,4-Piperazine was reacted with potassium carbonate 
and 2.2 equivalents of 1-(2-bromoethyl)-2-methoxybenzene in DMF to yield the desired 
product, 1,4-bis(2-methoxyphenethyl)piperazine (JPC-135).  The final product was 
purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.56-2.72 (m, 12H), 2.81-2.87 (m, 4H), 3.82 (s, 6H), 
6.83-7.26 (m, 8H) ppm. 
13C NMR (75 MHz, CDCl3):  δ 28.2, 53.4, 55.5, 59.0, 110.4, 120.5, 127.4, 128.8, 130.4, 
157.5 ppm. 
MS (EI) m/z 354 (M+). 
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Figure 4.3 Structure of 1,4-bis(3-methoxyphenethyl)piperazine (JPC-137) 
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49 
 
This compound incorporates 3-methoxy substituents into the two phenethyl 
linkers that are present in lobelane.  1,4-Piperazine was reacted with potassium carbonate 
and 2.2 equivalents of 1-(2-bromoethyl)-3-methoxybenzene in DMF to yield the desired 
product, 1,4-bis(3-methoxyphenethyl)piperazine (JPC-137).  The final product was 
purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.59-2.67 (m, 12H), 2.77-2.80 (m, 4H), 3.80 (s, 6H), 
6.74-6.82 (m, 6H), 7.18-7.26 (m, 2H) ppm. 
MS (EI) m/z 354 (M+). 
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Figure 4.4 Structure of 1,4-bis(4-methoxyphenethyl)piperazine (JPC-138) 
Chemical Formula: C22H30N2O2 Molecular Weight: 354.49 
 
This compound incorporated 4-methoxy substituents into the two phenethyl 
linkers that are present in lobelane.  1,4-Piperazine was reacted with potassium carbonate 
and 2.2 equivalents of 1-(2-bromoethyl)-4-methoxybenzene in DMF to yield the desired 
product 1,4-bis(4-methoxyphenethyl)piperazine (JPC-138).  The final product was 
purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.56-2.62 (m, 12H), 2.74-2.81 (m, 4H), 3.79 (s, 6H), 
6.82-6.85 (m, 2H), 7.11-7.26 (m, 4H) ppm. 
MS (EI) m/z 354 (M+). 
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Figure 4.5 Structure of 1,4-bis(2-chlorophenethyl)piperazine (JPC-139) 
Chemical Formula: C20H24Cl2N2 Molecular Weight: 363.32 
 
This compound incorporated 2-chloro substituents into the two phenethyl linkers 
that are present in lobelane.  1,4-Piperazine was reacted with potassium carbonate and 2.2 
equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the desired product, 
1,4-bis(2-chlorophenethyl)piperazine (JPC-139).  The final product was purified via 
silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.61-2.66 (m, 12H), 2.89-2.99 (m, 4H), 7.17-7.33 (m, 8H) 
ppm. 
MS (EI) m/z 362 (M+). 
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Figure 4.6 Structure of 1,4-bis(4-fluorophenethyl)piperazine (JPC-140) 
Chemical Formula: C20H24F2N2 Molecular Weight: 330.41 
 
This compound incorporated 4-fluoro substituents into the two phenethyl linkers 
that are present in lobelane.  1,4-Piperazine was reacted with potassium carbonate and 2.2 
equivalents of 1-(2-bromoethyl)-4-fluorobenzene in DMF to yield the desired product, 
1,4-bis(4-fluorophenethyl)piperazine (JPC-140).  The final product was purified via silica 
gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 2.57-2.62 (m, 12H), 2.77-2.82 (m, 4H), 6.94-7.00 (m, 
4H), 7.17-7.26 (m, 4H) ppm. 
MS (EI) m/z 330 (M+). 
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 After the symmetrical 1,4-piperazine analogs were prepared, the design and 
synthesis of asymmetrical 1,4-piperazine analogs was conducted.  The synthetic was 
slightly more involved than the one step process that generated the symmetrical 
compounds in Figures 4.1 through 4.6, since it required a protection step (BOC protection 
of one amine functionality) on the 1,4-piperazine ring.  The synthetic methodology is 
shown in Scheme 4.2. 
 
 
Scheme 4.2 Synthesis of the asymmetrical 1,4-piperazine scaffold. 
 
 The starting material for this series of analogs was again 1,4-piperazine, which 
was subjected to BOC (butyloxycarbonyl) protection with di-tert-butyloxy dicarbonate in 
acetonitrile and a catalytic amount of DMAP (4-dimethylaminopyridine).  This yielded a 
mixture of products, with the major product being the desired tert-butyl piperazine-1-
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carboxylate; the other two side products were starting material and the di-protected di-
tert-butyl piperazine-1,4-dicarboxylate.  The desired product was separated via silica gel 
column chromatography, and was then subjected to a SN2 reaction with (2-
bromoethyl)benzene to yield the tert-butyl-4-phenethylpiperazine-1-carboxylate product, 
which was purified via silica gel column chromatography.  At this point, the BOC 
protecting group was removed by subjecting it to a 1:3 trifluoroacetic 
acid:dichloromethane reaction mixture.  Purification via silica gel column 
chromatography afforded the desired 1-phenethylpiperazine, which was utilized as the 
common intermediate for the synthesis of five asymmetrical compounds in this series.  
The 1-phenethylpiperazine was then subjected to a SN2 reaction with the appropriately 
substituted (2-bromoethyl)benzene to yield the desired final products, which were 
purified via silica gel column chromatography.  The structures and analytical data of the 
five compounds generated in this series are shown in Figures 4.7 through 4.11.  NMR 
spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on one of three 
Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are reported in ppm 
relative to either TMS as internal standard or as relative to the solvent peak present in 
13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC incorporating an 
Agilent 7683 autosampler and an Agilent 5973 MSD. 
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Figure 4.7 Structure of 1-(2-methoxyphenethyl)-4-phenethylpiperazine (JPC-141) 
Chemical Formula: C21H28N2O Molecular Weight: 324.46 
 
This compound incorporates a 2-methoxy substituent into one of the phenethyl 
moieties, while retaining the second phenethyl moiety that is present in lobelane.  
Synthesis began with 1,4-piperazine, which was subjected to BOC (butoxycarbonyl) 
protection via di-tert-butyloxy dicarbonate in acetonitrile and a catalytic amount of 
DMAP (4-dimethylaminopyridine).  The major product, tert-butyl piperazine-1-
carboxylate, was separated via silica column chromatography, and reacted with (2-
bromoethyl)benzene to yield the tert-butyl 4-phenethylpiperazine-1-carboxylate, which 
was purified via silica gel column chromatography.  Deprotection of the BOC protecting 
group was achieved utilizing a trifluoroacetic acid:dichloromethane 1:3 mixture.  
Purification of the deprotected product via silica gel column chromatography afforded the 
desired 1-phenethylpiperazine, which was then reacted with 1-(2-bromoethyl)-2-
methoxybenzene to yield the desired final product, 1-(2-methoxyphenethyl)-4-
phenethylpiperazine (JPC-141) after purification via silica column chromatography. 
 1H NMR (300 MHz, CDCl3): δ 2.60-2.66 (m, 12H), 2.78-2.86 (m, 4H), 3.82 (s, 3H), 
6.81-6.92 (m, 2H), 7.15-7.38 (m, 7H) ppm. 
MS (EI) m/z 324 (M+). 
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Figure 4.8 Structure of 1-(3-methoxyphenethyl)-4-phenethylpiperazine (JPC-142) 
Chemical Formula: C21H28N2O Molecular Weight: 324.46 
 
This compound incorporates a 3-methoxy substituent into one of the phenethyl 
moieties, while retaining the second phenethyl moiety that is present in lobelane.  1-
phenethylpiperazine was reacted with 1-(2-bromoethyl)-3-methoxybenzene to yield the 
desired final product 1-(3-methoxyphenethyl)-4-phenethylpiperazine (JPC-142), which 
was purified via silica gel column chromatography. 
 1H NMR (300 MHz, CDCl3): δ 2.55-2.66 (m, 12H), 2.73-2.83 (m, 4H), 3.81 (s, 3H), 
6.84-6.96 (m, 2H), 7.18-7.36 (m, 7H) ppm. 
MS (EI) m/z 324 (M+). 
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Figure 4.9 Structure of 1-(4-methoxyphenethyl)-4-phenethylpiperazine (JPC-143) 
Chemical Formula: C21H28N2O Molecular Weight: 324.46 
 
This compound incorporates a 4-methoxy substituent into one of the phenethyl 
moieties, while retaining the second phenethyl moiety that is present in lobelane.  1-
Phenethylpiperazine was reacted with 1-(2-bromoethyl)-4-methoxybenzene to yield the 
desired final product 1-(4-methoxyphenethyl)-4-phenethylpiperazine (JPC-143), which 
was purified via silica gel column chromatography. 
 1H NMR (300 MHz, CDCl3): δ 2.51-2.70 (m, 12H), 2.75-2.89 (m, 4H), 3.83 (s, 3H), 
6.87-6.99 (m, 2H), 7.14-7.38 (m, 7H) ppm. 
MS (EI) m/z 324 (M+). 
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Figure 4.10 Structure of 1-(2-chlorophenethyl)-4-phenethylpiperazine (JPC-144) 
Chemical Formula: C20H25ClN2 Molecular Weight: 328.88 
 
This compound incorporates  a 2-chloro substituent into one of the phenethyl 
moieties, while retaining the second phenethyl moiety that is present in lobelane.  1-
Phenethylpiperazine, was reacted with 1-(2-bromoethyl)-2-chlorobenzene to yield the 
desired final product 1-(2-chlorophenethyl)-4-phenethylpiperazine (JPC-144), which was 
purified via silica gel column chromatography. 
 1H NMR (300 MHz, CDCl3): δ 2.54-2.66 (m, 12H), 2.78-2.87 (m, 4H), 7.19-7.42 (m, 
9H) ppm. 
MS (EI) m/z 328 (M+). 
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Figure 4.11 Structure of 1-(4-fluorophenethyl)-4-phenethylpiperazine (JPC-145) 
Chemical Formula: C20H25FN2 Molecular Weight: 312.42 
 
This compound incorporated a 4-fluoro substituent into one of the phenethyl 
moieties, while retaining the second phenethyl moiety that is present in lobelane.  1-
Phenethylpiperazine was ereacted with 1-(2-bromoethyl)-4-fluorobenzene to yield the 
desired final product 1-(4-fluorophenethyl)-4-phenethylpiperazine (JPC-145), which was 
purified via silica gel column chromatography. 
 1H NMR (300 MHz, CDCl3): δ 2.53-2.64 (m, 12H), 2.73-2.84 (m, 4H), 6.96-7.31 (m, 
9H) ppm. 
MS (EI) m/z 312 (M+). 
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 After the series of asymmetrical 1,4-piperazine analogs were synthesized, further 
modification of the central ring of the 1,4-scaffold was explored.  Thus, the central six-
membered 1,4-piperazine ring was expanded to a seven-membered 1,4-diazepane ring. 
Six compounds were designed and synthesized in this series.  The chemistry utilized to 
generate the symmetrical 1,4-diazepane series was very similar to that which afforded the 
symmetrical 1,4-piperazine series.  The one-step process utilized is outlined in Scheme 
4.3. 
 
 
Scheme 4.3 Synthesis of the symmetrical 1,4-diazepane series of analogs 
 
 A simple one-step reaction process was used to generate six compounds in the 
symmetrical 1,4-substituted diazepane analog series.  The starting material for this 
reaction was 1.4-diazapene (readily available from Sigma Aldrich Chemical Company), 
which was then subjected to SN2 reaction conditions with appropriately substituted (2-
bromoethyl)benzene and excess potassium carbonate as base in dimethylformamide as 
solvent.  Once all materials were dissolved, 2.2 equivalents of the appropriately 
substituted (2-bromoethyl)benzene was added drop-wise into the reaction mixture.  The 
reaction was heated to 70-80° Celsius for 12-18 hours until the 1,4-diazepane starting 
material was no longer visible by TLC chromatography (visualized with Dragendorff’s 
reagent).  The reaction was cooled, excess solvent removed under reduced pressure, and 
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the product adsorbed onto silica gel and purified via silica gel chromatography to yield 
the desired product in the 1,4-substituted diazepane analog series. 
The structures and analytical data of the five compounds generated in this series are 
shown in Figures 4.12 through 4.17.  NMR spectra were recorded in either CDCl3 or 
DMSO-d6 (as designated) on one of three Varian instruments (300 MHz, 400 MHz, or 
500 MHz) as indicated are reported in ppm relative to either TMS as internal standard or 
as relative to the solvent peak present in 13C spectra. GC-mass spectra were recorded on 
an Agilent 6890 GC incorporating an Agilent 7683 autosampler and an Agilent 5973 
MSD. 
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Figure 4.12 Structure of 1,4-diphenethyl-1,4-diazepane (JPC-146) 
Chemical Formula: C21H28N2 Molecular Weight: 308.46 
 
 This compound incorporates a second nitrogen atom into the central ring of the 
1,4-piperidine scaffold while increasing the ring size from six-membered heterocycle to a 
seven-membered heterocycle and retaining the two phenethyl moieties that are present in 
lobelane.  1,4-Diazepane (readily available from Sigma Aldrich Chemical Company) was 
reacted via a SN2 reaction with potassium carbonate and 2.2 equivalents of (2-
bromoethyl)benzene in DMF to yield the desired product 1,4-diphenethyl-1,4-diazepane 
(JPC-146).  The final product was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.76-1.78 (m, 2H) 2.64-3.01 (m, 16H), 7.23-7.39 (m, 
10H) ppm. 
MS (EI) m/z 308 (M+). 
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Figure 4.13 Structure of 1,4-bis(2-methoxyphenethyl)-1,4-diazepane (JPC-147) 
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51 
 
 This compound incorporates a 2-methoxy substituent into each of the two 
phenethyl moieties that are present in lobelane.  1,4-Diazepane was reacted with 
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-methoxybenzene in DMF 
to yield the desired product, 1,4-bis(2-methoxyphenethyl)-1,4-diazepane (JPC-147).  The 
final product was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.74-1.77 (m, 2H) 2.63-2.99 (m, 16H), 3.81 (s, 6H), 6.83-
7.27 (m, 8H) ppm. 
MS (EI) m/z 368 (M+). 
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Figure 4.14 Structure of 1,4-bis(3-methoxyphenethyl)-1,4-diazepane (JPC-148) 
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51 
 
 This compound incorporated a 3-methoxy substituent into each of the two 
phenethyl moieties that are present in lobelane.  1,4-Diazepane was reacted with 
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-3-methoxybenzene in DMF 
to yield the desired product, 1,4-bis(3-methoxyphenethyl)-1,4-diazepane (JPC-148).  The 
final product was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.74-1.78 (m, 2H) 2.66-3.02 (m, 16H), 3.80 (s, 6H), 6.71-
6.83 (m, 6H), 7.15-7.24 (m, 2H) ppm. 
MS (EI) m/z 368 (M+). 
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Figure 4.15 Structure of 1,4-bis(4-methoxyphenethyl)-1,4-diazepane (JPC-149) 
Chemical Formula: C23H32N2O2 Molecular Weight: 368.51 
 
 This compound incorporated a 4-methoxy substituent into each of the two 
phenethyl moieties that are present in lobelane.  1,4-Diazepane was reacted with 
potassium carbonate and 2.2 equivalents of 1-(2-bromoethyl)-4-methoxybenzene in DMF 
to yield the desired product, 1,4-bis(4-methoxyphenethyl)-1,4-diazepane (JPC-149).  The 
final product was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.72-1.78 (m, 2H) 2.66-3.00 (m, 16H), ), 3.79 (s, 6H), 
6.82-6.85 (m, 2H), 7.11-7.26 (m, 4H)  ppm. 
MS (EI) m/z 368 (M+). 
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Figure 4.16 Structure of 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150) 
Chemical Formula: C21H26Cl2N2 Molecular Weight: 377.35 
 
 This compound incorporated a 2-chloro substituent into each of the two phenethyl 
moieties that are present in lobelane.  1,4-Diazepane was reacted with potassium 
carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the 
desired product, 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150).  The final product 
was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.71-1.77 (m, 2H) 2.64-2.97 (m, 16H), 7.14-7.31 (m, 8H) 
ppm. 
MS (EI) m/z 376 (M+). 
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Figure 4.17 Structure of 1,4-bis(4-fluorophenethyl)-1,4-diazepane (JPC-151) 
Chemical Formula: C21H26F2N2 Molecular Weight: 344.44 
 
 This compound incorporates a 2-chloro substituent into each of the two phenethyl 
moieties that are present in lobelane.  1,4-Diazepane was reacted with potassium 
carbonate and 2.2 equivalents of 1-(2-bromoethyl)-2-chlorobenzene in DMF to yield the 
desired product, 1,4-bis(2-chlorophenethyl)-1,4-diazepane (JPC-150).  The final product 
was purified via silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.73-1.78 (m, 2H) 2.64-2.98 (m, 16H), 6.93-7.00 (m, 4H), 
7.14-7.23 (m, 4H) ppm. 
MS (EI) m/z 344 (M+). 
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Another small series of compounds incorporating two 4-benzylpiperidine moieties 
linked together by an N,N’-ethylene bridge was also designed and synthesized, to explore 
the possibility that two benzyl piperidine moieties linked by an ethylene chain may be 
tolerated by the TBZ site on VMAT2.  The synthetic methodology for the generation of 
the two compounds in this series is shown in Scheme 4.4. 
 
 
Scheme 4.4 Synthesis of 1,2-bis(4-benzylpiperidin-1-yl)ethane and 1,2-bis(4-
phenethylpiperidin-1-yl)ethane 
 
 The chemistry for generating the above two molecules is simple and quick.  Two 
equivalents of the appropriate 4-substituted piperidine starting material was subjected to a 
SN2 reaction with one equivalent 1,2-dibromoethane using potassium carbonate as a base 
in DMF at 70-80° C.  After disappearance of the starting material (TLC monitoring of the 
reaction visualized with Dragendorff’s reagent), the reaction material was cooled and 
excess solvent removed under reduced pressure. The resulting residue was purified by 
silica gel column chromatography to yield the desired final products. The structures of 
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the two compounds in this series and the supporting analytical data are shown in Figures 
4.18 and 4.19. NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) 
on one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are 
reported in ppm relative to either TMS as internal standard or as relative to the solvent 
peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC 
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
224 
 
  
Figure 4.18 Structure of 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132) 
Chemical Formula: C26H36N2 Molecular Weight: 376.58 
 
 The synthesis began with 4-benzylpiperidine as the starting material.  Two 
equivalents of 4-benzylpiperidine were reacted with one equivalent 1,2-dibromoethane 
using potassium carbonate as a base in DMF at 70-80° C.  After disappearance of the 
starting material (TLC monitoring and visualization with Dragendorff’s reagent) the 
reaction material was cooled and excess solvent removed under reduced pressure. The 
residue was purified via silica gel column chromatography to yield the desired 
compound, 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132). 
1H NMR (300 MHz, CDCl3): δ 1.17-1.82 (m, 10H) 2.06-2.78 (m, 16H), 7.06-7.23 (m, 
10H) ppm. 
13C NMR (75 MHz, CDCl3): δ 32.6, 37.7, 43.5, 46.7, 56.2, 125.9, 128.3, 129.3, 140.9 
ppm. 
MS (EI) m/z 376 (M+). 
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Figure 4.19 Structure of 1,2-bis(4-phenethylpiperidin-1-yl)ethane (JPC-133) 
Chemical Formula: C28H40N2 Molecular Weight: 404.32 
 
 Two equivalents of 4-benzylpiperidine were reacted with one equivalent of 1,2-
dibromoethane using potassium carbonate as a base in DMF at 70-80° C.  After 
disappearance of the starting material (monitored by TLC and visualized with 
Dragendorff’s reagent) the reaction material was cooled, and excess solvent removed 
under reduced pressure. The residue was purified via silica gel column chromatography 
to yield the desired 1,2-bis(4-benzylpiperidin-1-yl)ethane (JPC-132). 
1H NMR (300 MHz, CDCl3): δ 1.23-1.76 (m, 14H) 2.26-2.73 (m, 16H), 7.10-7.28 (m, 
10H) ppm. 
MS (EI) m/z 404 (M+). 
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 One final set of two compounds were designed and synthesized to evaluate 
analogs that possessed a branched alkyl linker unit between one of the piperazine N-
atoms and the phenyl moiety, to afford a racemic 1-phenylpropan-2-yl moiety attached to 
N1 of the piperazine ring, while maintaining the phenethyl linker on N4 of the piperazine 
ring.  One of the compounds in this set also incorporated a 4-bromo substituent in the 
phenyl ring attached to the N1 position of the piperazine ring.  The synthetic pathway for 
these two compounds is shown in Scheme 4.5. 
 
 
Scheme 4.5 Synthesis of the 1-phenethyl-4-(1-phenylpropan-2-yl)piperazine set of 
compounds 
 
 Starting from 1-phenethylpiperazine, a reductive amination was carried out 
utilizing the appropriately substituted 1-phenylpropan-2-one to yield the two racemic 1-
phenethyl-4-(1-phenylpropan-2-yl)piperazines.  The structures of the two compounds in 
this series and the analytical data supporting their structures are shown in Figures 4.20 
and 4.21.  NMR spectra were recorded in either CDCl3 or DMSO-d6 (as designated) on 
one of three Varian instruments (300 MHz, 400 MHz, or 500 MHz) as indicated are 
reported in ppm relative to either TMS as internal standard or as relative to the solvent 
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peak present in 13C spectra. GC-mass spectra were recorded on an Agilent 6890 GC 
incorporating an Agilent 7683 autosampler and an Agilent 5973 MSD. 
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 Figure 4.20 Structure of racemic 1-phenethyl-4-(1-phenylpropan-2-yl)piperazine  
(JPC-176) Chemical Formula: C21H28N2 Molecular Weight: 308.46 
 
1-Phenethylpiperazine was reacted with 1-phenylpropan-2-one under reductive 
amination conditions with sodium cyanoborohydride in methanol to afford the final 
product, (±)-1-phenethyl-4-(1-phenylpropan-2-yl)piperazine (JPC-176), which was 
purified by silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 1.01-1.03 (d, 3H), 2.43-3.18 (m, 15H), 7.22-7.34 (m, 
10H) ppm. 
 13C NMR (75 MHz, CDCl3):  δ 14.64, 33.9, 39.5, 48.5, 53.8, 60.8, 61.5, 125.9, 126.1, 
128.3, 128.4, 128.7, 129.3, 140.60, 140.64 ppm. 
MS (EI) m/z 308 (M+). 
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Figure 4.21 Structure of racemic 1-(1-(4-bromophenyl)propan-2-yl)-4-
phenethylpiperazine (JPC-173)  
Chemical Formula: C21H27BrN2 Molecular Weight: 387.36 
 
1-Phenethylpiperazine  was reacted with 1-(4-bromophenyl)propan-2-one in 
methanol via reductive amination with sodium cyanoborohydride to afforded the final 
product, (±)- 1-(1-(4-bromophenyl)propan-2-yl)-4-phenethylpiperazine (JPC-173), which 
was purified by silica gel column chromatography. 
1H NMR (300 MHz, CDCl3): δ 0.96-0.98 (d, 3H), 2.35-3.05 (m, 15H), 7.06-7.43 (m, 9H) 
ppm. 
 13C NMR (75 MHz, CDCl3):  δ 14.64, 33.9, 39.0, 48.55, 53.7, 53.8, 60.9, 61.3, 119.7, 
126.9, 128.5, 128.8, 131.1, 131.4, 139.7, 140.4 ppm. 
MS (EI) m/z 387 (M+). 
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4.2 Summary of the 1,4-disubstituted piperazine analog series 
 
In summary, 21 compounds were designed and synthesized in the 1,4-
disubstituted piperidine scaffold series by utilizing four distinct chemical approaches. Of 
the total number of compounds prepared, 11 were 1,4-disubstituted piperazine analogs 
containing a variety of aromatic substituents in each of the two phenyl rings, including 
methoxy, fluoro, and chloro substituents.  Another series of six 1,4-disubstituted 
diazepane analogs were  designed and synthesized to determine if an increase in the size 
of the central heterocyclic (1,4-piperazine) ring from six membered ring to a seven 
membered would improve affinity for VMAT2.  Another small series of compounds were 
designed and synthesized to determine if two benzyl piperidine rings linked together by 
an ethylene chain would be tolerated by the TBZ binding site on VMAT2.  The 
remaining two compounds were analogs that possessed a branched N1 alkyl linker in the 
form of a racemic 1-phenylpropan-2-yl moiety attached to N1 of the piperazine ring, as 
well as a phenethyl moiety at N4 of the piperazine ring.  This set of compounds also 
included an analog containing a 4-bromophenyl moiety at the N1 position of the 
piperazine ring.  The pharmacological assay data for these 21 compounds are discussed in 
Chapter 5. 
 
 
 
 
Copyright © John P. Culver 2015 
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Chapter 5 
 Pharmacology Assays and Data 
 
5.1 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay 
Background 
 Pharmacology (from Greek pharmakon, "poison" in classic Greek; "drug" in 
modern Greek; and -λογία, -logia "study of", "knowledge of") is the extension and 
cohesion of medicine and biology concerned with the study of drug action (De Jong et 
al., 2005).  Just as organic and medicinal chemistry is vital to the invention and discovery 
of new drug molecules, pharmacology is a cornerstone of the drug discovery process.  
While it is the medicinal chemist that designs and synthesizes the candidate drug 
compound, the pharmacologist is the one who tests it for physiologic activity. A 
promising compound will be investigated by many other scientists to include 
toxicologists, microbiologists, and medical clinicians, but the initial discovery of the 
potential therapeutic effect by the pharmacologist must always come first.  Well prior to 
being studied in humans, candidate drug molecules must first be studied either “in vitro” 
or “in vivo” in animal models.  In vivo (Latin for "within the living") (Merriam-Webster, 
2013)  is experimentation using a whole, living organism as opposed to a partial or dead 
organism which is an in vitro (Latin for "within the glass", for example in a test tube or 
petri dish) (Merriam-Webster, 2013) within a more controlled environment. 
The assays used to analyze the effectiveness of the 107 compounds described in 
Chapters 2 through 4 are of the “in vitro”  variety and are described as the [3H] 
Dihydrotetrabenazine Binding Assay and [3H] Dopamine Vesicular Uptake Assay. 
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 The [3H] Dihydrotetrabenazine Binding Assay was used to determine the affinity 
of the analogs in the synthesized compound library for the TBZ binding site on VMAT2.  
Potency of a compound in binding to the TBZ site of VMAT2 does not directly correlate 
into inhibition of VMAT2 function.  It was therefore necessary to evaluate the ability of 
the compounds to inhibit [3H]DA uptake into synaptic vesicles as well (Nickell et al., 
2010).    
In the [3H] Dihydrotetrabenazine Binding Assay and the [3H] Dopamine Vesicular 
Uptake Assay, the following materials and methods were used (Nickell et al., 2010).  
Assays were conducted by J. Nickell and G. Deaciuc in the laboratories of Dr. Linda 
Dwoskin.  Methodology was developed and used in those laboratories and is shown here 
in original format. 
 
Animals. Male Sprague-Dawley rats (200–250 g upon arrival) were purchased from 
Harlan (Indianapolis, IN). Rats were housed in the Division of Laboratory Animal 
Resources at the College of Pharmacy at the University of Kentucky (Lexington, KY) 
and had ad libitum access to food and water. Experimental protocols involving the 
animals were in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of Kentucky. 
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Materials. [3H]DA (specific activity, 28.0 Ci/mmol) was purchased from PerkinElmer 
Life and Analytical Sciences (Boston, MA). [3H]DTBZ (specific activity, 79.0 Ci/mmol) 
was a gift from Dr. Michael R. Kilbourn (Department of Internal Medicine and 
Neurology, University of Michigan, Ann Arbor, MI). Bovine serum albumin, EDTA, 
EGTA, L-(-)-tartaric acid, sucrose, magnesium sulfate, polyethyleneimine, adenosine 5-
triphosphate magnesium salt, HEPES, S(-)-nicotine ditartrate (nicotine), 3-
hydroxytyramine (dopamine, DA), DOPAC, d-methamphetamine hydrochloride 
(methamphetamine), sodium chloride, magnesium sulfate and ascorbate oxidase were 
purchased from Sigma-Aldrich (St. Louis, MO).  (-)-D-Glucose, L-ascorbic acid, and 
monobasic potassium phosphate were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), AnalaR-BHD Ltd. (Poole, UK), and Mallinckrodt (St. Louis, MO), 
respectively. Perchloric acid (70%) was purchased from Mallinckrodt Baker 
(Phillipsburg, NJ). Ro4-1284 was obtained from Hoffman-La Roche Ltd. (Basel, 
Switzerland).  All other commercial chemicals were purchased from Fisher Scientific Co. 
(Pittsburgh, PA) (Nickell et al., 2010).  
 
[3H]DTBZ Binding Assay. Analog-induced inhibition of [3H]DTBZ binding was 
determined by use of modifications of a method described previously (Teng et al., 1998). 
Rat whole brain (excluding cerebellum) or striatum was homogenized in 20 ml of ice-
cold 0.32 M sucrose solution with seven up-and-down strokes of a Teflon pestle 
homogenizer (clearance ~ 0.003 inch). Homogenates were centrifuged at 1000g for 12 
min at 4°C, and the resulting supernatants were again centrifuged at 22,000g for 10 min 
at 4°C. Resulting pellets were incubated in 18 ml of ice-cold water for 5 min, and 2 ml of 
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HEPES (25 mM) and potassium tartrate (100 mM) solution were subsequently added. 
Samples were centrifuged (20,000g for 20 min at 4°C), and 20 µl of MgSO4 (1 mM) 
solution was then added to the supernatants. Solutions were centrifuged 
(100,000g for 45 min at 4°C) and pellets resuspended in ice-cold assay buffer (25 mM 
HEPES, 100 mM potassium tartrate, 5 mM MgSO4, 0.1 mM EDTA, and 0.05 mM 
EGTA, pH 7.5). Assays were performed in duplicate by use of 96-well plates. Aliquots of 
vesicular suspension (15 µg of protein in 100 µl) were added to wells containing 5 nM 
[3H]DTBZ, 50 µl of analog (1 nM to 1 mM), and 50 µl of buffer. Nonspecific binding 
was determined in the presence of Ro4-1284 (20 µM). Reactions were terminated by 
filtration (Packard Filtermate harvester; PerkinElmer Life and Analytical Sciences) onto 
Unifilter-96 GF/B filter plates (presoaked in 0.5% polyethyleneimine).  Filters were 
subsequently washed five times with 350 µl of ice-cold buffer (25 mM HEPES, 100 mM 
potassium tartrate, 5 mM MgSO4, and 10 mM NaCl, pH 7.5). Filter plates were dried and 
bottom-sealed, and each well was filled with 40 µl of scintillation cocktail (MicroScint 
20; PerkinElmer Life and Analytical Sciences). Radioactivity on the filters was 
determined by liquid β-scintillation spectrometry (TopCount NXT; PerkinElmer Life and 
Analytical Sciences).  Inhibition curves will be analyzed by non-linear regression and 
IC50 values used to yield Ki values (Teng, et al., 1997; Teng et al., 1998; Cheng-Prusoff, 
1973; Nickell et al., 2010). 
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Vesicular [3H]DA Uptake Assay. Inhibition of [3H]DA uptake was conducted by use of 
a preparation of isolated synaptic vesicles as described previously (Teng et al., 1997). In 
brief, rat striata were homogenized with 10 up-and-down strokes of a Teflon pestle 
homogenizer (clearance ~ 0.003 inch) in 14 ml of 0.32 M sucrose solution. Homogenates 
were centrifuged (2000g for 10 min at 4°C), and the resulting supernatants were 
centrifuged again (10,000g for 30 min at 4°C). Pellets were resuspended in 2 ml of 0.32 
M sucrose solution and subjected to osmotic shock by adding 7 ml of ice-cold water to 
the preparation, followed by the immediate restoration of osmolarity by adding 900 µl of 
0.25 M HEPES buffer and 900 µl of 1.0 M potassium tartrate solution. Samples were 
centrifuged (20,000g for 20 min at 4°C), and the resulting supernatants were centrifuged 
again (55,000g for 1 h at 4°C), followed by the addition of 100 µl of 10 mM MgSO4, 100 
µl of 0.25 M HEPES, and 100 µl of 1.0 M potassium tartrate solution before the final 
centrifugation (100,000g for 45 min at 4°C). Final pellets were resuspended in 2.4 ml of 
assay buffer (25 mM HEPES, 100 mM potassium tartrate, 50 µM EGTA, 100 µM EDTA, 
1.7 mM ascorbic acid, 2 mM ATP-Mg2+, pH 7.4). Aliquots of the vesicular suspension 
(100 µl) were added to tubes containing assay buffer, various concentrations of analog 
(0.1 nM to 10 mM) and 0.1 µM [3H]DA to produce a final volume of 500 µl. Nonspecific 
uptake was determined in the presence of Ro4-1284 (10 µM). Reactions were terminated 
by filtration, and radioactivity retained by the filters was determined as described 
previously (Nickell et al., 2010). 
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5.2 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay 
Results 
 The structures of 107 JPC compounds designed and synthesized as relayed in 
Chapters 2-4 are presented in Tables 5.1 (18 compounds), 5.2 (68 compounds), and 5.3 
(21 compounds) along with their corresponding Ki values in the [3H] 
Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay.  The structures 
and corresponding Ki values in the [3H] Dihydrotetrabenazine Binding Assay and [3H] 
Dopamine Uptake Assay for lobeline and lobelane are included in each table for 
comparison convenience.   
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Compound 
Code 
Structure VMAT2 
[3H]DTBZ 
Binding 
Assay; 
Ki ± SEM 
(µM) 
VMAT2 
[3H]DA 
Uptake; 
Ki ± SEM 
(µM) 
 
 
Lobeline 
 
 
 
2.04 ± 0.64 
 
 
0.47 ± 0.045 
 
 
lobelane 
 
 
 
0.97 ± 0.19 
 
 
0.045 ± 0.002 
 
 
JPC-001 
 
 
 
5.24 ± 1.81 
 
 
0.043 ± 0.0034 
 
 
JPC-011 
 
 
 
0.29 ± 0.03 
 
 
 
0.156 ± 0.0323  
 
JPC-002 
 
 
3.88 ± 0.43 
 
* 
 
JPC-008 
 
 
30.6 
 
* 
 
JPC-003 
 
 
5.09 ± 1.37 
 
0.084 ± 0.0071 
 
JPC-007 
 
 
3.09 ± 0.60 
 
0.19 ± 0.025 
 
JPC-130A 
 
 
2.24 ± 0.15 
 
0.056 ± 0.026 
Table 5.1 (continued) 
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JPC-130B 
 
 
0.43 ± 0.050 
 
0.030 ± 0.0017 
 
 
JPC-004 
 
 
 
2.57 ± 0.48 
 
 
0.30 ± 0.080 
 
 
JPC-010 
 
 
 
2.87 ± 0.83 
 
 
0.23 ± 0.023 
 
 
JPC-033 
 
 
 
29.0 ± 5.0 
 
 
0.58 ± 0.096 
 
 
JPC-034 
 
 
 
5.93 ± 1.40 
 
 
0.99 ± 0.079 
 
JPC-035 
 
 
2.08 ± 0.098 
 
0.23 ± 0.065 
 
JPC-036 
 
 
0.62 ± 0.020 
 
0.30 ± 0.077 
 
 
JPC-041 
 
 
 
2.70 ± 0.70 
 
 
0.14 ± 0.033 
 
 
JPC-042 
 
 
 
0.56 ± 0.082 
 
 
0.13 ± 0.0087 
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JPC-161B 
 
 
2.25 ± 0.28 
 
0.032 ± 0.0022 
 
JPC-161C 
 
 
0.35 ± 0.042 
 
0.036 ± 0.010 
 
Table 5.1 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake 
Assay Data for JPC compounds in the 2,6-substituted piperidine analog scaffold of 
lobelane 
 
Compound 
Code 
Structure VMAT2 
[3H]DTBZ 
Binding 
Assay; 
Ki ± SEM 
(µM) 
VMAT2 
[3H]DA 
Uptake; 
Ki ± SEM 
(µM) 
 
 
Lobeline 
 
 
 
2.04 ± 0.64 
 
 
0.47 ± 0.045 
 
 
lobelane 
 
 
 
0.97 ± 0.19 
 
 
0.045 ± 0.002 
 
 
JPC-057 
 
 
 
0.255 ± 0.026 
 
 
0.030 ± 0.0020 
 
 
JPC-058 
 
 
 
2.80 ± 0.11 
 
 
0.056 ± 0.009 
Table 5.2 (continued)  
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JPC-059 
 
 
 
0.265 ± 0.038 
 
 
0.022 ± 0.00087 
 
 
JPC-060 
 
 
 
1.62 ± 0.19 
 
 
0.046 ± 0.0037 
 
 
 
JPC-072 
 
 
 
0.38 ± 0.0058 
 
 
0.047 ± 0.0063 
 
 
JPC-073 
 
 
 
1.82 ± 0.0058 
 
 
0.032 ± 0.0038 
 
 
JPC-078 
 
 
 
0.69 ± 0.050 
 
 
0.022± 0.0028 
 
 
JPC-077 
 
 
 
0.19 ± 0.0088 
 
 
 
 
0.0093 ± 0.0006 
 
 
JPC-094 
 
 
 
0.15 ± 0.0058 
 
 
 
0.013 ± 0.0015 
 
 
JPC-095 
 
 
 
0.50 ± 0.10 
 
 
0.043 ± 0.0028 
 
 
JPC-096 
 
 
 
0.19 ± 0.020 
 
 
0.020 ± 0.0030 
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JPC-097 
 
 
 
0.40 ± 0.097 
 
 
0.013 ± 0.0021 
 
 
JPC-079 
 
 
 
0.32 ± 0.015 
 
 
0.056 ± 0.0086 
 
 
JPC-080 
 
 
 
0.32 ± 0.055 
 
 
0.040 ±0.0075 
 
 
JPC-081 
 
 
 
0.23 ± 0.019 
 
 
0.085 ± 0.010 
 
 
JPC-082  
 
 
0.45 ± 0.13 
 
 
0.13 ± 0.023 
 
 
JPC-083 
 
 
 
0.46 ± 0.098 
 
 
0.42 ± 0.049 
 
 
JPC-084  
 
 
0.96 ± 0.047 
 
 
0.069 ± 0.004 
 
 
JPC-085 
 
 
 
0.51 ± 0.087 
 
 
0.11 ± 0.007 
 
 
JPC-086 
 
 
 
0.42 ± 0.019 
 
 
0.083 ± 0.009 
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JPC-087 
 
 
 
0.23 ± 0.047 
 
 
0.075 ± 0.004 
 
 
JPC-088  
 
 
2.47 ± 0.27 
 
 
0.16 ± 0.012 
 
 
JPC-089 
 
 
 
0.23 ± 0.020 
 
 
0.040 ± 0.007 
 
 
JPC-090  
 
 
0.47 ± 0.067 
 
 
0.060 ± 0.005 
 
 
JPC-098 
 
 
 
0.53 ± 0.11 
 
 
0.053 ± 0.0055 
 
 
JPC-099 
 
 
 
0.35 ± 0.048 
 
 
0.041 ±0.012 
 
 
JPC-100 
 
 
 
0.27 ± 0.015 
 
 
0.029 ± 0.0055 
 
 
JPC-101  
 
 
1.30 ± 0.17 
 
 
0.070 ± 0.0051 
 
 
JPC-102 
 
 
 
0.24 ± 0.038 
 
 
0.11 ± 0.019 
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JPC-103 
 
 
 
1.45 ± 0.24 
 
 
0.043 ± 0.014 
 
 
JPC-104 
 
 
 
0.29 ± 0.064 
 
 
0.12 ± 0.0085 
 
 
JPC-105 
 
 
 
0.33 ± 0.018 
 
 
0.076 ± 0.010 
 
 
JPC-106 
 
 
 
0.19 ± 0.009 
 
 
0.083 ± 0.0038 
 
 
JPC-107  
 
 
1.61 ± 0.078 
 
 
0.044 ± 0.0033 
 
 
JPC-108 
 
 
 
0.23 ± 0.015 
 
 
0.067 ± 0.021 
 
 
JPC-109  
 
 
0.60 ± 0.075 
 
 
0.060 ± 0.0082 
 
 
JPC-110 
 
 
 
1.10 ± 0.087 
 
 
0.051 ± 0.0035 
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JPC-111 
 
 
 
0.41 ± 0.038 
 
 
0.034 ± 0.0039 
 
 
JPC-112 
 
 
 
0.25 ± 0.003 
 
 
0.028 ± 0.0027 
 
 
JPC-113 
 
 
 
2.03 ± 0.13 
 
 
0.12 ± 0.028 
 
 
JPC-114 
 
 
 
0.66 ± 0.058 
 
 
0.18 ± 0.068 
 
 
JPC-115 
 
 
 
1.43 ± 0.28 
 
 
0.068 ± 0.016 
 
 
JPC-068 
 
 
 
0.38 ± 0.049 
 
 
0.094 ± 0.0096 
 
 
 
JPC-061 
 
 
 
 
2.76 ± 0.31 
 
 
 
0.13 ± 0.015 
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JPC-062 
 
 
 
 
1.53 ± 0.10 
 
 
 
0.077 ± 0.0098 
 
 
 
JPC-063 
 
 
 
 
2.99 ± 0.17 
 
 
 
0.24 ± 0.034 
 
 
 
JPC-064 
 
 
 
 
1.94 ± 0.43 
 
 
 
0.18 ± 0.011 
 
 
JPC-152 
 
 
 
21.7 ± 2.08 
 
 
0.19 ± 0.63 
 
 
JPC-153 
 
 
 
9.36 ± 1.32 
 
 
0.070 ± 0.0075 
 
 
JPC-154 
 
 
 
12.7 ± 4.28 
 
 
0.19 ± 0.020 
 
 
JPC-155 
 
 
 
6.23 ± 0.56 
 
 
0.25 ± 0.027 
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JPC-156 
 
 
 
44.5 ± 17.8 
 
 
0.27 ± 0.042 
 
 
JPC-157 
 
 
 
10.1 ± 0.58 
 
 
0.21 ± 0.012 
 
 
 
JPC-174 
 
 
 
 
* 
 
 
 
0.020 ± 0.0082 
 
 
 
 
JPC-175 
 
 
 
 
 
2.32 ± 0.26 
 
 
 
 
0.073 ± 0.0008 
 
 
 
JPC-171 
 
 
 
 
2.56 ± 0.34 
 
 
 
0.21 ± 0.052 
 
 
 
 
JPC-172 
 
 
 
 
 
0.257 ± 0.37 
 
 
 
 
0.30 ± 0.032 
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JPC-116 
 
 
 
30.3 ± 5.97 
 
 
2.32 ± 0.50 
 
 
JPC-117 
 
 
 
>100 
 
 
6.28 ± 0.39 
 
 
JPC-118 
 
 
 
11.5 ± 0.80 
 
 
2.19 ± 0.37 
 
 
JPC-119 
 
 
 
>100 
 
 
3.74 ± 1.03 
 
 
JPC-120 
 
 
 
9.26 ± 1.27 
 
 
1.18 ± 0.12 
 
 
JPC-121 
 
 
 
>100 
 
 
2.90 ± 0.36 
 
 
JPC-122 
 
 
 
14.1 ± 2.36 
 
 
0.36 ± 0.050 
 
 
JPC-123 
 
 
 
22.0 ± 4.48 
 
 
1.12 ± 0.19 
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JPC-124 
 
 
 
19.7 ± 4.40 
 
 
0.60 ± 0.11 
 
 
JPC-125 
 
 
 
22.9 ± 1.9 
 
 
2.00 ± 0.32 
 
 
JPC-126 
 
 
 
6.27 ± 0.22 
 
 
0.42 ± 0.04 
 
Table 5.2 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake 
Assay Data for JPC compounds in the 1,4-substituted piperidine analog scaffold of 
lobelane 
 
Compound 
Code 
Structure VMAT2 
[3H]DTBZ 
Binding 
Assay; 
Ki ± SEM 
(µM) 
VMAT2 
[3H]DA 
Uptake; 
Ki ± SEM 
(µM) 
 
 
Lobeline 
 
 
 
2.04 ± 0.64 
 
 
0.47 ± 0.045 
 
 
lobelane 
 
 
 
0.97 ± 0.19 
 
 
0.045 ± 0.002 
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JPC-134 
 
 
 
3.05  ± 0.64 
 
 
0.11 ± 0.012 
 
 
JPC-135 
 
 
 
1.17 ± 0.13 
 
 
0.035 ± 
0.0012 
 
 
 
JPC-137 
 
 
 
 
1.05 ± 0.087 
 
 
 
 
0.060 ± 0.004 
 
 
JPC-138 
 
 
 
6.63 ± 0.84 
 
 
0.41 ± 0.005 
 
 
JPC-139 
 
 
 
0.37 ± 0.038 
 
 
0.048 ± 0.003 
 
 
JPC-140 
 
 
 
3.71 ± 0.48 
 
 
0.058 ± 0.012 
 
 
JPC-141 
 
 
 
1.07 ± 0.25 
 
 
0.037 ± 
0.0005 
 
 
JPC-142 
 
 
 
1.30 ± 0.33 
 
 
0.098 ± 0.016 
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JPC-143 
 
 
 
4.63 ± 1.31 
 
 
0.10 ± 0.011 
 
 
JPC-144 
 
 
 
1.59 ± 0.26 
 
 
0.063 ± 
0.0069 
 
 
JPC-145 
 
 
 
3.86 ± 1.01 
 
 
0.088 ± 
0.0069 
 
 
JPC-146 
 
 
 
 
3.17 ± 0.55 
 
 
0.17 ± 0.017 
 
 
JPC-147 
 
 
 
 
2.02 ± 0.11 
 
 
0.18 ± 0.011 
 
 
JPC-148 
 
 
 
2.24 ± 0.53 
 
 
0.10 ± 0.010 
 
 
JPC-149 
 
 
 
 
2.88 ± 0.25 
 
 
0.25 ± 0.015 
 
 
JPC-150 
 
 
 
 
0.93 ± 0.021 
 
 
0.17 ± 0.025 
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JPC-151 
 
 
 
 
5.05 ± 0.77 
 
 
0.085 ± 
0.0052 
 
 
JPC-132 
 
 
 
0.82 ± 0.19 
 
 
0.26 ± 0.019 
 
 
JPC-133 
 
 
 
3.42 ± 0.34 
 
 
0.11 ± 0.0087 
 
 
 
 
JPC-176 
 
 
 
 
 
13.3 ± 1.10 
 
 
 
 
0.15 ± 0.015 
 
 
 
 
JPC-173 
 
 
 
 
 
4.55 ± 0.94 
 
 
 
 
0.31 ± 0.005 
 
Table 5.3 [3H] Dihydrotetrabenazine Binding Assay Data and [3H] Dopamine Uptake 
Assay Data for JPC compounds in the 1,4-substituted piperazine and diazepane  analog 
scaffolds of lobelane and similar compounds 
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5.3 [3H] Dihydrotetrabenazine Binding Assay and [3H] Dopamine Uptake Assay 
Results Discussion 
The 107 JPC compounds designed, synthesized, and assayed for activity and function 
at VMAT2 can and have been assigned to one of three groups based on structure.  These 
groups are 1) the 2,6-substituted piperidine analog scaffold of lobelane, 2) the 1,4-
substituted piperidine analog scaffold of lobelane, and 3) the 1,4-substituted piperazine 
and diazepane  analog scaffolds of lobelane.  Groups 2 and 3 can be divided further into 
subgroups based on structure to allow later SAR discussions to better describe trends.  In 
order for a compound to be selected for further testing in the whole animal model, it must 
meet two requirements: 1) be among the most potent compounds if not the most potent 
compound among a designated series or scaffold of compounds and 2) have a potency in 
the functional [3H] Dopamine Uptake Assay of better than 100 nM.  Compounds that 
have been selected from the 107 JPC compounds that were designed and synthesized 
have been marked in bold face font within the tables present in Chapter 5. 
   The 2,6-substituted piperidine analog scaffold of lobelane contained 18 compounds 
that are similar in scaffold structure to remain in one group without further division.  The 
compounds differed in their [3H]DTBZ affinities by as much as two orders of magnitude, 
with the best compound (JPC-011) having an affinity for the TBZ binding site on 
VMAT2 of 0.29 µM and the least effective compound (JPC-008) having a binding 
affinity for the TBZ binding site on VMAT2 of 30.6 µM.  The compounds that did not 
possess a N-methyl substituent (nor-compounds) were generally 10-fold less potent than 
their N-methyl containing counterparts, a trend that is in line with previous data collected 
in our laboratories with other compounds in the 2,6-substituted piperidine analog 
scaffold. The two compounds that possessed completely saturated cyclohexyl moieties in 
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place of the phenyl rings found in lobelane (JPC-003 and JPC-007) had 3-5 fold less 
affinity for the TBZ site on VMAT2, so again the presence of two hydrophobic phenyl 
rings is shown to be necessary for the TBZ site of VMAT2 to recognize a ligand 
molecule.   
The analogs that possessed two substituents in each of the phenyl rings showed 
interesting binding characteristics.  Compounds JPC-011 and JPC-130B that contained 
two very electronegative (and therefore electron withdrawing) fluoro moieties (3,5-
difluoro and 2,4-difluoro respectively), had the best affinities for the TBZ binding site on 
VMAT2 with Ki values of 0.29 µM (JPC-011) and 0.43 µM (JPC-130B).  Analogs that 
possess less localized electron density present in the phenyl rings appears to bind slightly 
better to VMAT2.  The analogs that possess dimethoxy functionalities in the phenyl rings 
showed large differences in affinity depending on the attachment point of the methoxy 
groups.   The analog that has methoxy functionalities in the 3,5-positions of the phenyl 
rings (JPC-010) had approximately 2.5 fold less affinity for VMAT2 (Ki = 2.57 µM) than 
lobelane (0.97 µM), and when the methoxy moieties were moved to the 3,4-positions of 
the phenyl rings (JPC-034), the affinity decreased 6-fold (Ki = 5.93 µM) compared to 
lobelane.  Analogs that contain methoxy functionalities in the 2,3-positions of the phenyl 
rings (JPC-036) and in the 2,5-positions of the phenyl rings (JPC-042) had affinities  (Ki 
= 0.62 µM and Ki = 0.56 µM),  for the TBZ binding site on VMAT2 similar to lobelane, 
if not slightly stronger.  It is postulated that when the methoxy groups are in the 3,5 and 
3,4 positions of the phenyl rings, a steric effect must be occurring in the binding site that 
does not allow those analogs to bind as tightly, while when methoxy substituents are 
located in the 2,3 and 2,5 positions of the phenyl rings, the steric issues can be avoided.  
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The analog containing both a methoxy functionality and a fluoro functionality (JPC-
161C) supports this idea, as the methoxy group is in the meta (3) position of the phenyl 
rings and the fluoro is in the para (4) position of the phenyl rings (same 3,4-substitution 
pattern as JPC-034), and the binding affinity was almost 17-fold greater for JPC-161C  
(Ki = 0.35) than for JPC-034 (Ki = 5.93).  
In comparison to compounds previously generated that contained mono-
substituted phenyl rings, the compounds that contain two functionalities in each phenyl 
ring met with mixed results in reference to affinity at VMAT2. Compounds that 
possessed two methoxy moieties were comparable to their mono-methoxy substituted 
counterparts, as two methoxy substitution patterns (2,3 and 2,5) on the phenyl rings 
yielded analogs with comparable to equal affinities, while two substitution patterns on the 
phenyl rings (3,4 and 3,5) yielded analogs with moderately less affinity for the TBZ site 
on VMAT2.  Compounds that possessed two fluoro substituents or one fluoro and one 
methoxy substituents in the phenyl rings displayed affinities for VMAT2 that were equal 
to slightly (2-4 fold) better than their mono-substituted counterparts synthesized 
previously.   
The best compound in the 2,6-substituted piperidine analog scaffold with respect 
to the DTBZ binding assay was JPC-011.  None of the compounds within the 2,6-
substituted piperidine analog series showed tremendous potency with respect to the 
functional vesicular [3H]DA uptake assay and therefore none have yet been selected for 
further study in the whole animal model.  While half of the dimethoxy substituted 
analogs faired reasonably well in the [3H]DTBZ binding assay, all of the dimethoxy 
substituted compounds were equal in functional potency when compared to lobelane, as 
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most of them were an order of magnitude less potent in the functional vesicular [3H]DA 
uptake assay.  Compounds JPC-001, JPC-130A, JPC-130B, JPC-161B, and JPC-161C 
were similar in potency to lobelane. 
The second group of compounds to be discussed are those within 1,4-substituted 
piperidine analog scaffold of lobelane.  This series, which consists of 68 compounds, will 
be divided into subgroups for discussion: 1) the 1,4-substituted isomeric analogs of 
lobelane, 2) the 4-benzyl-1-phenethylpiperidine and 1-benzyl-4-phenethylpiperidine 
analogs, 3) the 4-phenethyl-1-(1-phenylpropan-2-yl)piperidine and 4-benzyl-1-(1-
phenylpropan-2-yl)piperidine analogs, and 4) the 4-phenethyl-1-(2-(piperidin-1-
yl)ethyl)piperidine and 4-(2-(4-phenethylpiperidin-1-yl)ethyl)morpholine analogs. 
The 43 designed and synthesized 1,4-substituted isomeric analogs of lobelane 
ranged from 5-fold greater affinity to 2.5-fold less affinity for the TBZ site on VMAT2 
when compared to lobelane.  The six compounds that began the series possessed a 
phenethyl linker attached to the C4 position of the piperidine ring and a substituted 
phenethyl linker attached to the N1 position of the piperidine ring.  Compounds JPC-057 
and JPC-059 contain methoxy functionalities in the ortho (2) and meta (3) positions of 
the phenethyl linker attached to the N1 position of the piperidine ring, respectively.  
These two compounds displayed affinities 4-fold stronger than lobelane, with JPC-057 
displaying a Ki = 0.255 µM and JPC-059 displaying a Ki = 0.265 µM.  Both JPC-057 and 
JPC-059 displayed potencies in the functional vesicular [3H]DA uptake assay slightly 
better than lobelane.  Again, as was seen in the 2,6-substituted piperazine series, 
compounds containing a methoxy moiety in the ortho or meta position of the phenyl ring 
appear to be recognized by the TBZ site on VMAT2 better than compounds without 
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substituents or with methoxy substituents in the para position.  Addition of a 2-chloro 
substitutent (JPC-072) did improve affinity in the [3H]DTBZ binding assay (Ki = 0.38 
µM) by 3-fold compared to lobelane, and had nearly identical potency in the functional 
vesicular [3H]DA uptake assay (Ki = 0.047 µM).  Three of the six compounds had 
slightly less affinity at the TBZ site on VMAT2 when compared to lobelane (JPC-058, 
JPC-060, and JPC-073) with affinities of Ki = 2.80 µM, Ki = 1.62 µM, Ki = 1.82 µM 
respectively.   These compounds did, however, have comparable affinities in the 
functional vesicular [3H]DA uptake assay with Ki = 0.056 µM, Ki = 0.046 µM, Ki = 0.032 
µM, correspondingly. 
The next subseries of compounds possessed a 2-methoxy moiety in the phenyl 
ring of the phenyethyl linker attached to the C4 position of the piperidine ring.  This 
entire group of six compounds had stronger affinity for the TBZ site on VMAT2, so 
placing a methoxy group in the ortho position of the phenyl ring attached to the linker at 
C4 is beneficial to the recognition of the molecule at the binding site.  These six analogs 
have Ki’s in the [3H]DTBZ binding assay ranging from 0.15 µM to 0.69 µM.  The most 
potent three compounds in this subseries are JPC-077, JPC-094, and JPC-096 with nearly 
identical affinity values in [3H]DTBZ binding assay (Ki’s = 0.19 µM, Ki = 0.15 µM, Ki = 
0.19 µM, respectively).  It should be noted that the three moieties in the phenethyl 
substitutents attached at the N1 position that continue to give the highest affinities in each 
subseries are 2-methoxy, 3-methoxy, and 2-chloro.  The same three compounds that were 
most potent in binding to the TBZ site on VMAT2 were among the best in their ability to 
inhibit DA uptake into the vesicle, with functional vesicular [3H]DA uptake assay values 
of Ki = 0.0093 µM, Ki = 0.013 µM, Ki = 0.020 µM, correspondingly.  JPC-077 was the 
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most potent compound in the entire 43 designed and synthesized 1,4-substituted isomeric 
analogs in inhibiting DA uptake into the vesicle, with potency nearly 5-fold stronger than 
lobelane. 
The next subseries of compounds possessed a 3-methoxy moiety in the phenyl 
ring of the phenyethyl linker attached to the C4 position of the piperidine ring. Again, 
this entire group of six compounds had stronger affinity for the TBZ site on VMAT2, so 
placing a methoxy group in the meta position of the phenyl ring attached to the linker at 
C4 is also beneficial to the recognition of the molecule at the binding site.  These six 
analogs have Ki’s in the [3H]DTBZ binding assay ranging from 0.15 µM to 0.69 µM.  
The most potent three compounds in this subseries are JPC-079, JPC-080, and JPC-081 
with nearly identical affinity values in [3H]DTBZ binding assay (Ki’s = 0.32 µM, Ki = 
0.32 µM, Ki = 0.23 µM, respectively).  Again, the best two compounds possessed a 2-
methoxy or 3-methoxy moiety in the phenyl ring of the phenethyl linker attached to the 
N1 position of the piperidine ring.  A significant trend is seen developing, as molecules 
containing 2-methoxy and 3-methoxy moieties in either one or both phenyl rings are 
continuing to be recognized better by the TBZ binding site on VMAT2.  This series of six 
compounds did not fare as well in the functional assay, with potencies comparable to 
lobelane if not slightly inferior. 
The next subseries of compounds possessed a 4-methoxy moiety in the phenyl 
ring of the phenyethyl linker attached to the C4 position of the piperidine ring, and 
displayed similar trends. Five analogs in this group of six compounds had stronger 
affinity than lobelane for the TBZ site on VMAT2, so placing a methoxy group in the 
para position of the phenyl ring attached to the linker at C4 is also beneficial to the 
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recognition of the molecule at the binding site, but it can be said that compounds 
containing 4-methoxy substitutents in both phenyl rings is not as well tolerated, as JPC-
088 has this feature, and has a Ki = 2.47 µM, which is 2.5-fold less potent than the parent 
compound with just two unsubstituted phenyl rings as well as 2.5-fold less potent than 
lobelane, and JPC-088 is 5-10 fold less potent than the other compounds in this subseries.  
It should be again be noted that the three moieties in the phenethyl substitutents attached 
at the N1 position that continue to give the highest affinities in each subseries are 2-
methoxy, 3-methoxy, and 2-chloro (Ki’s = 0.42 µM, Ki = 0.23 µM, Ki = 0.23 µM, 
respectively).  The same three compounds that were most potent in binding to the TBZ 
site on VMAT2 were also the best in their ability to inhibit DA uptake into the vesicle, 
with functional vesicular [3H]DA uptake assay values of Ki = 0.083 µM, Ki = 0.075 µM, 
Ki = 0.040 µM, correspondingly, which is comparable to lobelane. 
The next subseries of compounds possessed 2,4-fluoro substituents in the phenyl 
ring of the phenyethyl linker attached to the C4 position of the piperidine ring, and 
displayed similar trends. Four analogs in this group of six compounds had stronger 
affinity than lobelane for the TBZ site on VMAT2, with the other two comparable to 
lobelane, so placing 2,4-fluoro substituents the phenyl ring attached to the linker at C4 is 
also beneficial to the recognition of the molecule at the binding site.  Again, it should be 
noted that the three moieties in the phenethyl substitutents attached at the N1 position that 
continue to give the highest affinities in each subseries are 2-methoxy (JPC-099), 3-
methoxy (JPC-100), and 2-chloro (JPC-102), with affinities in the [3H]DTBZ binding 
assay ranging from 0.24 µM to 0.35 µM (Ki’s = 0.35 µM, Ki = 0.27 µM, Ki = 0.24 µM, 
respectively).  Analogs JPC-100 and JPC-101 were again the most potent in the 
259 
 
functional vesicular [3H]DA uptake assay values of Ki = 0.041 µM, Ki = 0.029 µM, 
correspondingly, which is comparable to lobelane (slightly more potent) and continues 
the trend. 
The next subseries of compounds possessed 2-fluoro, 4-methoxy substituents in 
the phenyl ring of the phenyethyl linker attached to the C4 position of the piperidine ring, 
and displayed similar trends. Five analogs in this group of six compounds had stronger 
affinity than lobelane for the TBZ site on VMAT2, with the other comparable to 
lobelane, so placing 2-fluoro, 4-methoxy substituents the phenyl ring attached to the 
linker at C4 is also beneficial to the recognition of the molecule at the binding site.  Once 
again, the three moieties in the phenethyl substitutents attached at the N1 position that 
continue to give the highest affinities in each subseries are 2-methoxy (JPC-105), 3-
methoxy (JPC-106), and 2-chloro (JPC-108), with affinities in the [3H]DTBZ binding 
assay ranging from 0.19 µM to 0.33 µM (Ki’s = 0.33 µM, Ki = 0.19 µM, Ki = 0.23 µM, 
respectively).  Compound JPC-108 is the first analog that possessed the combination of 
three different moieties in the two phenyl rings.  All compounds in this subseries 
displayed similar potencies in the functional vesicular [3H]DA uptake assay comparable 
to lobelane. 
The next subseries of compounds possessed 3,5-difluoro substituents in the 
phenyl ring of the phenyethyl linker attached to the C4 position of the piperidine ring, 
and displayed similar trends. Four analogs in this group of six compounds had stronger 
affinity than lobelane for the TBZ site on VMAT2, with the other comparable to 
lobelane, so placing 3,5-difluoro substituents the phenyl ring attached to the linker at C4 
is also beneficial to the recognition of the molecule at the binding site.  Once again, the 
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three moieties in the phenethyl substitutents attached at the N1 position that continue to 
give the highest affinities in each subseries are 2-methoxy (JPC-111), 3-methoxy (JPC-
112), and 2-chloro (JPC-114), with affinities in the [3H]DTBZ binding assay ranging 
from 0.25 µM to 0.66 µM (Ki’s = 0.41 µM, Ki = 0.25 µM, Ki = 0.66 µM, respectively).  
Analogs JPC-111 and JPC-112 were again the most potent in the functional vesicular 
[3H]DA uptake assay values of Ki = 0.034 µM, Ki = 0.028 µM, correspondingly, which is 
comparable to lobelane (slightly more potent) and continues the trend. 
The final compound in this group of 43 among the 1,4-substituted piperidine 
analog scaffold of lobelane is JPC-068.  This analog contains a 2,4,5-trimethoxy 
substituent in the phenyl ring of the phenyethyl linker attached to the C4 position of the 
piperidine ring, and an unsubstituted phenethyl linker attached to the N1 position.  
Previously, in the 2,6-substituted piperidine series, compounds with multiple methoxy 
groups present in the meta and para positions in both phenyl rings were 5-6 fold less 
potent in the [3H]DTBZ binding assay, and this was postulated to be due to steric issues.  
This compound had only one phenyl ring substituted with multiple methoxy substituents, 
and has an affinity for the TBZ site on VMAT2 3-fold more potent than lobelane.  It 
appears that if steric hindrance is the issue for earlier compounds not being able to bind 
as strongly, it is only on one portion of the binding site, as this compound was tolerated 
quite well.  Despite having a 3-fold better binding affinity at the TBZ binding site, JPC-
068 did not improve upon lobelane in the functional vesicular [3H]DA uptake assay, with 
values comparable but not enhanced. 
The next series of series of 1,4-substituted piperidine analogs was designed and 
synthesized with shorter linkers between the C4 position of the piperidine ring while 
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maintaining a substituted phenethyl linker on the N1 position were prepared to further 
analyze the ability of the TBZ binding site on VMAT2 to recognize compounds with 
shorter linkers and less degrees of freedom of rotation (one carbon shorter on the C4 
attached linker.  Four compounds were generated in this series and all had weaker affinity 
than lobelane for the TBZ site on VMAT2, with the other comparable to lobelane, so 
placing shorter linkers between the C4 position of the piperidine ring is not beneficial to 
the recognition of the molecule at the binding site.  The most appealing compound among 
the four in the series is JPC-062, which has a 3-methoxy substituent in the phenyl ring 
attached to the N1 position of the piperidine ring.  Affinity at the TBZ site of VMAT2 
was comparable (Ki = 1.53 µM) to lobelane, and effectiveness in the functional vesicular 
[3H]DA uptake assay was comparable (Ki = 0.077 µM), but was not enhanced. 
A series of 1,4-substituted piperidine analogs with shorter linkers between the N1 
position of the piperidine ring while maintaining a substituted phenethyl linker on the C4 
position were prepared to further analyze the ability of the TBZ binding site on VMAT2 
to recognize compounds with shorter linkers and less degrees of freedom of rotation (one 
carbon shorter) on the N1 attached linker.  The entire series of six compounds had less 
affinity for the TBZ site on VMAT2 with Ki values ranging from 6.23 µM to 44.5 µM.  
One analog, JPC-153, containing a 2-methoxy substituent in the phenyl ring attached by a 
one carbon linker to the N1 position of the piperidine ring did have effectiveness in the 
functional vesicular [3H]DA uptake assay was comparable (Ki = 0.070 µM), but all others 
were 4-6 fold less potent than lobelane.  It is clear that reducing the length of the linker 
between the N1 position of the piperidine ring and the phenyl ring is not beneficial, and 
262 
 
has a detrimental effect on how the TBZ binding site on VMAT2 recognizes the 
molecule. 
Similarly, another series of 1,4-substituted piperidine analogs combined these 
factors with shorter linkers between the N1 position of the piperidine ring while 
maintaining a substituted phenethyl linker on the C4 position  or with shorter linkers 
between the C4 position of the piperidine ring while maintaining a substituted phenethyl 
linker on the N1 position were prepared to further analyze the ability of the TBZ binding 
site on VMAT2 to recognize compounds with shorter linkers and less degrees of freedom 
of rotation (one carbon shorter) on the N1 attached linker.  This series of compounds was 
designed to possess a branch in the N1 alkyl linker in the form of a racemic 1-
phenylpropan-2-yl functionality attached to N1 of the piperidine ring.  Four compounds 
were generated in this series, and had similar affinities as lobelane for the TBZ site on 
VMAT2 with one exception.  JPC-172, containing a 4-bromo substituent on the phenyl 
ring of the 1-phenylpropan-2-yl linker attached to the N1 position of the piperidine ring 
displayed a Ki = 0.257 µM in the [3H]DTBZ binding assay, approximately 4-fold more 
potent than lobelane.  JPC-174 and JPC-175 exhibited effectiveness in the functional 
vesicular [3H]DA uptake assay was comparable (Ki = 0.073 µM and Ki = 0.073 µM, 
respectively) to lobelane. 
The final series of compounds of 1,4-substituted piperidine analogs was designed 
to increase the water solubility of the scaffold by replacing the phenyl ring on the N1 
phenethyl linker with saturated heterocyclic moieties, either piperidine or morpholine and 
to study what effect the introduction of a more polar moiety would have on binding 
affinity at the TBZ site of VMAT2.  Of the 11 compounds generated in this series, all had 
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much lower affinity in the [3H]DTBZ binding assay than compounds possessing two 
phenyl rings.  Values in the [3H]DTBZ binding assay ranged from Ki = 6.27 µM to >100 
µM.   Effectiveness in the functional vesicular [3H]DA uptake assay was also greatly 
diminished with Ki’s ranging from 0.36 to 6.28 µM.  Clearly, attempting to increase 
water solubility by replacing one of the phenyl rings with a piperidine or morpholine 
moiety is not effective.  The next series of compounds attempted to maintain the two 
phenyl rings while increasing the water solubility characteristics of the analogs by 
placing a second amino moiety inside the central saturated ring. 
The series of 1,4-piperazine and 1,4-diazepane analogs were designed and 
synthesized to add the second amino functionality into the central ring of the lobelane 
scaffold.  The addition of another polar functionality into the central ring will increase the 
water solubilizing characteristics of the scaffold, which is desirable in development of 
drugs with higher bioavailability than lobelane, and several series of compounds were 
designed and synthesized to explore these possibilities, resulting in the generation of 21 
compounds.   
The first series of six compounds consisted of symmetrical 1,4-piperazine 
analogs.  Of these six compounds, all had affinities for the TBZ site on VMAT2 similar 
to that possessed by lobelane, ranging from slightly better (Ki = 0.37 µM) to slightly 
worse (6.63 µM).  Considering that this series of compounds should be at least 2-3 times 
as soluble in water as their piperidine counterparts, these affinities are remarkably 
effective, especially when one considers the large loss of affinity found when replacing 
one of the phenyl rings of the piperidine scaffold with a water solubilizing piperidine or 
morpholine moiety.  It was not surprising, however, that the three most potent analogs in 
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both the [3H]DTBZ binding assay and the functional vesicular [3H]DA uptake assay 
maintained the same trend as seen before.  Analogs that possessed a 2-methoxy (JPC-
135), a 3-methoxy (JPC-137), or a 2-chloro (JPC-139) functionality in both of the two 
phenyl rings had the strongest affinity for the TBZ site on VMAT2 with Ki’s of 1.17 µM, 
1.05 µM, and 0.37 µM, respectively.  In the functional vesicular [3H]DA uptake assay the 
same three analogs displayed Ki’s of 0.035 µM, 0.060 µM, and 0.048 µM, respectively, 
which were all quite similar to lobelane. 
The second series of five compounds were asymmetrical 1,4-piperazine analogs 
containing an unsubstituted phenethyl linker attached to N4 position of the piperazine 
ring, and a substituted phenethyl linker attached to the N1 position of the piperazine ring. 
Of these five compounds, all had affinities for the TBZ site on VMAT2 similar to that 
possessed by lobelane, ranging from the same (Ki = 1.07 µM) to slightly worse (4.63 
µM).  As is nearly standard by this point, the three compounds that have the best affinity 
for the TBZ site on VMAT2 were those that that possessed a 2-methoxy (JPC-141), a 3-
methoxy (JPC-142), or a 2-chloro (JPC-144) functionality in the phenyl ring attached to 
the N1 position of the piperazine ring, Ki’s of 1.07 µM, 1.30 µM, and 1.59 µM, 
respectively.  In the functional vesicular [3H]DA uptake assay the same three analogs 
displayed Ki’s of 0.037 µM, 0.098 µM, and 0.063 µM, respectively, which were all quite 
similar to lobelane. 
After the series of asymmetrical 1,4-piperazine analogs were synthesized, further 
modification of the central ring of the 1,4-scaffold was desired.  Enlarging the central six-
membered piperazine ring to a seven-membered 1,4-diazepane ring was explored, with 
six compounds designed and synthesized to explore this series.  All analogs in this series 
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displayed affinities for the TBZ site on VMAT2 similar to that possessed by lobelane, 
ranging from the same (Ki = 0.93 µM) to slightly worse (5.05 µM).  These compounds 
did not fare as well as the 1,4-piperazine analogs in the functional vesicular [3H]DA 
uptake assay, ranging from 2-5 fold less potent than lobelane. 
The next small series of compounds, JPC-132 and JPC-133, contain two amine 
moieties central to the molecule and were designed and synthesized to explore the idea 
that two piperidine rings linked by ethylene chain may be tolerated by the TBZ site on 
VMAT2.  While JPC-132 displayed an affinity in the [3H]DTBZ binding assay slightly 
better (Ki = 0.82 µM)  than lobelane, it had less potency in the functional vesicular 
[3H]DA uptake assay (Ki = 0.26 µM), or 5-fold less potent than lobelane. 
The final series of compounds in the library consisted of two compounds were 
designed and synthesized to evaluate analogs that possess a branch in the N1 alkyl linker 
in the form of a racemic 1-phenylpropan-2-yl functionality attached to N1 of the 
piperazine ring, while maintaining the phenethyl linker on N4 of the piperazine ring.  
This series also explored the addition of a 4-bromo moiety in the phenyl ring attached to 
the N1 position of the piperazine ring.  This mirrored a similar series generated in the 
piperidine scaffold, and the results in the assays were of a similar nature.  JPC-176 had 
10-fold less affinity for the TBZ site on VMAT2 than lobelane, and JPC-173, which 
contained the 4-bromo substituent, was 5-fold less potent than lobelane. 
Of the 107 compounds generated in the library, many showed improved affinity 
in the [3H]DTBZ binding and the functional vesicular [3H]DA uptake assay when 
compared to the first and second generation analogs that were prepared previously.  The 
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compounds selected for further evaluation are: JPC-077, JPC-078, JPC-089, JPC-141, 
JPC-142, and JPC-143, and these improved compounds were chosen to undergo further 
in vivo evaluation in rat models of behavior.  These experiments are still ongoing, but 
preliminary results look quite promising.  JPC-077 has displayed the ability to inhibit 
METH self-administration in the rat model as well as the ability to prevent METH 
induced locomotor response in rats.  JPC-078 also shows potential, as it has shown the 
ability to prevent METH induced locomotor response in rats.  JPC-141, a 1,4-piperazine 
analog, has also displayed the capability to prevent METH induced locomotor response 
in the rat model.  The other three compounds are still in the process of evaluation.   
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Chapter 6 
Ligand based pharmacophore modeling of the VMAT2 binding site 
 
6.1 Background of computational modeling 
 Modern SAR efforts require the use of computational resources and programs that 
use mathematical models of the drug molecule and target.  This part of the drug discovery 
pathway has become more and more complex as it evolves.  Entire research groups are 
dedicated to the “virtual synthesis” and “virtual screening” of molecules and drug targets.  
These virtual efforts go hand in hand with traditional drug discovery procedures, and are 
mainly used to support the continuing synthetic efforts to make more and more efficient 
drug candidates.  By taking advantage of the information gleaned from prior synthetic 
efforts and biological experimentation, computational SAR can uncover the required 
molecular features of the lead compounds from past generations of synthesis and provide 
direction and novel ideas for structural chemical modification.  
 The computational methods for SAR differ depending on the circumstances and 
information at hand.  The different methods are described as: 1.) development of ligand-
receptor models (also known as docking models), and these are used specifically for 
situations where the receptor or biomolecular target structure has been previously 
identified through methods such as x-ray crystallography, or 2.) development of a 
pharmacophore-based model, also known as a ligand based model, which consists of 
SAR modeling based on certain molecular features of the ligand molecules from the 
constructed compound library; these methods used in situations where little information 
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is  known about the drug target, or when the critical molecular structural features of the 
target are not well defined, as in this case with VMAT2.   
6.2  Model Methods of automatic pharmacophore modeling of VMAT2 inhibitors. 
Computational pharmacophore modeling has emerged as one of the major 
computational techniques in pharmaceutical drug design, especially in the absence of a 
protein 3D structure. For instance, when active compounds are available, chemists use 
the geometric and electronic structures of the chemical compounds to naturally define a 
chemical model of how a particular ligand or a series of structurally related ligands 
interact with the receptor, and/or to deduce structure-activity relationships.  
In the current study, pharmacophore modeling has been performed using the small 
molecule ligands that have been discovered to bind to the TBZ site on VMAT2 by 
conventional screening procedures. The discovered compounds demonstrated what can 
be considered strong inhibitory activity in the [3H]DTBZ binding assay and the functional 
vesicular [3H]DA uptake assay.  In order to understand the specific chemical features that 
are responsible for the activity of the compounds, the elucidation of the pharmacophore 
has been performed.  
MOE software was utilized extensively for the pharmacophore modeling. Two 
kinds of pharmacophore modeling can be performed, 1.) manual pharmacophore 
generation, and 2.) automatic pharmacophore generation. Briefly, manual pharmacophore 
modeling can be performed by using each of the most active compounds from the current 
series of compounds. Automatic pharmacophore generation can be performed when one 
or more active compounds with a similar binding mode at the targeted binding site are 
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available in the library of compounds. Since the compounds reported in this study are all 
analogs of similar structural scaffolds, and since the binding modes of the compounds 
cannot be generated due to the absence of a defined binding site structure, for now, we 
must assume that all the inhibitors bind in a similar binding mode. 
The three major steps involved in automatic pharmacophore modeling are:  
1. Conformation generation 
 2. Alignment 
3. Pharmacophore query elucidation. 
 
Prior to running the pharmacophore application in MOE, all the compounds have 
to be imported into the MOE database along with the [3H]DTBZ binding and the 
functional vesicular [3H]DA uptake assay data.  Briefly, the input database must contain 
in one field molecules either in 2D or 3D format. The pharmacophore elucidator in MOE 
only works with 3D conformations, and if the 2D structures are provided, MOE can 
automatically convert the 2D structures to 3D conformations, or the conformations of the 
compounds can be generated with any other method or software and imported into the 
MOE database. For the current work, the internal MOE conformation generator was used 
on the library of compounds (which were all protonated and charged at biological pH) 
utilizing a Stochastic search. In general, it is best to use the same method for generating 
conformations as is used for preparing the 3D search databases. The generated 
conformations per compound were stored in the molecule field of the database. In the 
second field, the activity data (biological assay data) is provided. If no limit of activity is 
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specified, the MOE elucidator will assume all the compounds to be active, therefore, in 
the current study, all the compounds with affinities in the [3H]DTBZ binding assay that 
were less than 1.0 µM were treated as active and all compounds with affinities > 1.0 µM 
were treated as inactive compounds. After the input database is prepared, the next step is 
to specify a scheme. In MOE the modeling of H-donor and H-acceptor features depends 
on the selected pharmacophore scheme. There are six schemes supplied with MOE: PCH, 
PCHD, PCH_All, PPCH, PPCH_All, and CHD. The default CHD scheme was selected 
for use in the current work. Finally, before generation of the pharmacophore queries, 
molecular geometric alignments from the collection of input conformations was done by 
considering all possible discrete geometries and all possible combinations of feature 
query expressions. The default CHD contains a feature limit of 5, which means the 
pharmacophore with a maximum of 5 features are generated, and this is due to the 
preliminary nature of this study. Pharmacophore queries with higher numbers of features 
to be matched predictably tend to match fewer molecules outside the input database, 
which would be less useful in this early process. 
 
6.3  Results of automatic pharmacophore modeling of VMAT2 inhibitors. 
A total of 177 different pharmacophore models (queries) were generated by using 
the CHD scheme and the above mentioned method. The best pharmacophore is displayed 
and discussed further. The pharmacophore query resulting from the MOE pharmacophore 
elucidator is shown in Figure 6.1 and Figure 6.2. The statistics of the pharmacophore 
model are shown in Table 6.1, with descriptions below to describe the different 
categorical results.  The model was developed based on the input that all compounds with 
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affinities for the TBZ site on VMAT2  >1 µM are treated as inactive and all others as 
active compounds.  
 
Query Cover Overlap Accuracy acc1 No. of features 
HHH+ 10 7.3009 1.0 1.0 4 
 
Table 6.1 Statistics of best pharmacophore model query obtained by using the MOE 
pharmacophore elucidator (automatic pharmacophore modeling). 
Cover: The number of active molecules that match the query.  
Overlap: The score of the alignment. This number varies between [0,n] where n is the 
number of active molecules, therefore the larger this number, the better the alignments.  
Accuracy: The accuracy of the query in separating actives and inactives. A value of 1.0 
(the value actually obtained) signifies that the query matched all active compounds, and 
did not match any inactive compounds. The accuracy is measured on clustered 
conformations.  
acc1: The accuracy of the query in matching the active compounds. The value of 1.0 (the 
value actually obtained) signifies that all actives were matched, while a value 0.0 would 
mean that none were matched. The accuracy is measured on clustered conformations.  
 
The best pharmacophore generated by this method is shown in Figure 6.1.  The 
quality of the pharmacophore query or model depends on the hit rate, which in other 
words can be defined as number of active compounds (true positives) that were captured 
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leaving behind the inactive compounds. The pharmacophore model shown in Figure 6.1 
retrieves the known active compounds with an accuracy of 100.0% (see Table 6.1).  
 
Figure 6.1 The most reliable pharmacophore model generated by automatic 
pharmacophore model generation in the MOE pharmacophore elucidator.  The spheres in 
green represent the hydrophobic features and the blue sphere represents the central cation 
feature. 
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Figure 6.2 The most reliable pharmacophore model generated by automatic 
pharmacophore model generation in the MOE pharmacophore elucidator with all active 
compounds aligned in their best fit to the pharmacophore model. 
The pharmacophore query produced by the MOE pharmacophore elucidator 
contains three hydrophobic features and a cation feature. The query has an overlap of 7.3 
and accuracy of 100% which means the query could match all the 10 active compounds 
which were used as input. When we run the query against the 66 compound input 
database with active compounds, this query was able to retrieve 61 out of 66 compounds 
of input database, which suggests that the query describes the chemical features with 
huge significance. 
In addition to running the pharmacophore model against the known active 
compounds, the query was used to run on an external database of 1000 random 
compounds from NCI, which resulted in 74 hits being retrieved from the NCI database.  
In summary, the pharmacophore query resulting from the MOE pharmacophore 
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elucidator suggests that hydrophobic features in the middle of the compounds and two 
hydrophobic features one each on either side of the central hydrophobic feature and one 
cation feature to the bottom of the central hydrophobic feature are necessary for the 
biological activity of the compounds. These observations can be used in further designing 
and synthesizing the similar analogs to the current series of compounds.  
 
6.4  Model Methods of manual pharmacophore modeling of VMAT2 inhibitors. 
In the manual pharmacophore modeling, two compounds with best inhibitory 
activity were selected. The conformations of all the compounds were generated in the 
same way as conformations generated by automatic pharmacophore modeling (stochastic 
method). The conformations with lowest energy were finally utilized as input for the 
pharmacophore modeling. Manual pharmacophore modeling was performed with each 
compound separately, therefore, two pharmacophore queries were generated.  
In the first step, JPC-077 has been manually imported into the MOE environment 
and used to create the pharmacophore. MOE’s pharmacophore query editor detected the 
pharmacophore features automatically and quickly generated four features which best 
describe the compound for biological activity. One hydrophobic and one cation and 
donor feature were created in the center of the compound (JPC-077) and two 
hydrophobic but slightly anionic features, one at either end of the compound (due to the 
aromatic methoxy functionalities). The compound JPC-077 with its manually created 
pharmacophoric query is shown in Figure 6.3. Likewise, the pharmacophore query of an 
active compound from the library, namely lobelane was created and shown in Figures 
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6.4. Finally, a manual pharmacophore model of lobeline was completed and is shown in 
Figure 6.5.  Briefly, the pharmacophore models for lobeline and cis- contain three 
hydrophobic features and a cation and donor feature at different locations in the structure 
of the compounds and with different speherical volume.  
 
 
 
Figure 6.3 Pharmacophoric features derived manually using compound JPC-077. The 
four pharmacophore features are displayed in red (anionic/acceptor), green 
(hydrophobic), and purple (cationic/donor) colored spheres. 
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Figure 6.4 Pharmacophoric features derived manually using lobelane. The four 
pharmacophore features are displayed in green (hydrophobic) and purple (cationic/donor) 
colored spheres. 
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Figure 6.5 Pharmacophoric features derived manually using the compound lobeline. The 
four pharmacophore features are displayed in yellow (hydrophobic), green (hydrophobic) 
and purple (cationic/donor) colored spheres. 
6.5 Results of manual pharmacophore modeling of VMAT2 inhibitors. 
All the three above mentioned queries differs from each other in several 
significant ways. Only the hydrophobic feature at the center of molecule and the cationic 
and donor features are features that are considered common among all the queries, and 
even then, each one differs by the spherical volume. Also, the anionic features of JPC-
077 were not included in the other two queries; instead, hydrophobic features on either 
side of the central hydrophobic feature are used. All four of the pharmacophore queries 
were able to retrieve approximately 50 compounds (varying by only one or two hits) of 
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the 66 active compounds of the current library. The pharmacophore queries suggest that 
the presence of a hydrophobic feature in the center of the molecule, a cationic and donor 
feature, and another two hydrophobic features on either side of the central hydrophobic 
feature, and possibly an anionic feature at the terminal aromatic methoxy group 
containing phenyl rings, are responsible for the biological activity of the compounds.  
In perspective, following the initial pharmacophore modeling, much more could 
be done in the future.  Possible next steps in molecular modeling to include building a 
homology model of VMAT2, which is as close to an actual crystal structure as possible 
with this trans-membrane transporter (Vardy et al., 2004).  This step would be followed 
by docking and molecular dynamics simulation to provide insights into the interaction 
between the inhibitors and the protein structure, and finally, this would be followed by 
virtual screening, using the pharmacophore query and docking for discovering possible 
new inhibitors.  
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Chapter 7 
Review and Discussion 
 
Psychostimulant abuse has become a severe worldwide problem that has shown 
no sign of lessening the hold that it has on much of mainstream society.  There exists an 
ongoing need for new therapies and medications that can provide efficacy in the 
treatment of psychostimulant abuse.  METH especially is identified as an addictive and 
increasingly popular psychostimulant drug, and there are no effective, Food and Drug 
Administration (FDA) approved pharmacological treatments available for the addicts 
who wish to quit.  This project has been designed to address the needs of those people 
who currently abuse psychostimulants such as METH, and who need an effective therapy 
that will help them break away from their addiction. The design and synthesis of a library 
of analogs similar to lobelane has been completed, with structural alterations designed 
into the molecules to make them more potent at the target protein: VMAT2. The 
overriding goal of this study was to provide one or multiple potential drug candidates that 
could ultimately become a treatment for psychostimulant abuse for that part of the 
population that currently abuses psychostimulants but wishes to quit. 
Three distinct scaffolds were designed and synthesized.  The first scaffold was 
based directly on lobelane.  Further optimization and study was needed to ascertain if 
addition of different aromatic substituents into the phenyl rings would enhance binding 
affinity at VMAT2.  Addition of two aromatic substituents into each of the two phenyl 
rings was also explored in order to determine if multiple substituents could also improve 
affinity.  Eighteen compounds in this series were designed and synthesized.  JPC-011 was 
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found to be the most potent compound within this series in the [3H]DTBZ binding assay 
(was 4-fold more potent than lobelane), but was disappointing in potency in the 
functional vesicular [3H]DA uptake assay, which better predicts how it will effect METH 
self-administration in the rat model and correspondingly the human model.   In the 
second scaffold, further optimization and study was needed to ascertain if the addition of 
different aromatic substituents into the phenyl rings of the 1,4-substituted lobelane 
scaffold would enhance binding affinity at VMAT2.  Addition of multiple aromatic 
substituents into the phenyl rings was also explored.  43 compounds in this series were 
designed and synthesized, and of those 43 analogs, 32 had improved affinity for the TBZ 
site on VMAT2 when compared to lobelane, with some compounds exhibiting as much 
as 5-fold improvement compared to lobelane and 13 compounds exhibited significant 
improvement in the functional vesicular [3H]DA uptake assay compared to lobelane, with 
JPC-077 displaying a 5-fold enhancement over lobelane. 
The third scaffold was designed to increase the water-solubility of the analogs 
while maintaining, if not improving the compound’s affinity and function at VMAT2. 
The addition of another N-atom into the central heterocyclic piperidine ring was 
predicted to improve the water solubilizing characteristics of the scaffold, which is 
desirable property in the development of drugs that have a higher bioavailability than 
lobelane, and several series of compounds were designed and synthesized to explore 
these possibilities, resulting in the generation of 21 novel compounds.  Of these 21 
analogs, seven displayed affinities for the TBZ site on VMAT2 that either maintained the 
affinity exhibited by lobelane, or improved it by as much as 3-fold (JPC-139).  Six 
compounds had comparable potency in the functional vesicular [3H]DA uptake assay 
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when compared to lobelane. Considering that these analogs have at least 2-3 fold 
improved water solubility compared to lobelane and other related analogs in the 
piperidine series of compounds, these results are encouraging, and may lead to clinical 
candidates with greater oral bioavailability.  
 In summary, of the 107 compounds generated in the current library, many showed 
improved affinity in both the [3H]DTBZ binding assay, and the functional vesicular 
[3H]DA uptake assay, when compared to the first and second generation analogs that 
were prepared earlier.  The compounds selected for further evaluation are: JPC-077, JPC-
078, JPC-089, JPC-141, JPC-142, and JPC-143, and these improved compounds were 
chosen to undergo further in vivo evaluation in rat models of behavior.  These 
experiments are still ongoing, but preliminary results look quite promising.  JPC-077 has 
displayed the ability to inhibit METH self-administration in a rat model of METH 
addiction, as well as the ability to prevent METH- induced locomotor responses in rats.  
JPC-078 also shows potential as a clinical candidate, since it has been shown to prevent 
METH-induced locomotor responses in rats.  JPC-141, a 1,4-piperazine analog, is also 
able to prevent METH-induced locomotor responses in the rat model.  The other three 
JPC compounds are still in the process of evaluation.   
A preliminary ligand-based pharmacophore model has been generated utilizing 
the SAR data accumulated from the library of compounds and their evaluation in the 
binding and functional assays.  It proved to be very accurate in retrieval of the active 
compounds from the library. 
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This study involved three central hypotheses.  One hypothesis of this work was that 
structural analogs of lobelane that maintain the 2,6-disubstitued piperidine scaffold, but 
incorporated preferred aromatic substituents into the two phenyl rings present in the 
lobelane structure, can improve binding affinity at the Vesicular Monoamine Transporter-
2 (VMAT2), and can also improve functional inhibition of VMAT2. A second hypothesis 
of this work was that structural analogs of lobelane in which the phenethyl moieties 
present in the C2 and C6 positions of the piperidine ring can be structurally modified to 
afford analogs in which these moieties are located on the N1 and C4 positions of the 
piperidine ring, and these 1,4-disubstuted analogs have increased affinity for VMAT2 
and increased potency as functional inhibitors of VMAT2.  A third hypothesis of this 
work was that introduction of an additional N-atom into the piperidine ring of the 
lobelane scaffold will increase water-solubility while maintaining similar binding affinity 
and functional inhibition potency for VMAT2 when compared to lobelane. 
As a summary of the results pertaining to the three initial hypotheses, the first 
hypothesis was valid in part: examples are present where structural analogs of lobelane 
that maintain the 2,6-disubstitued piperidine scaffold, but incorporated preferred aromatic 
substituents into the two phenyl rings present in the lobelane structure improved binding 
affinity at the Vesicular Monoamine Transporter-2 (VMAT2), but were not shown to also 
improve functional inhibition of VMAT2. The second and third hypotheses were shown 
to be valid, in that several examples from each series of compounds in the study 
displayed both greater affinity for the TBZ site on VMAT2 and greater potency as 
functional inhibitors at VMAT2 when compared to lobelane.  
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The data presented in this work have further demonstrated that VMAT2 is a valid 
target for the treatment of methamphetamine abuse, and should continue to strengthen 
that argument as the data from the whole animal model studies are revealed.  With in-vivo 
studies currently underway and initial results for several compounds generated within this 
library looking promising, the primary three hypotheses of the study were addressed 
through well designed and executed experiments and initiative.  The experiments detailed 
here have successfully expanded our knowledge and understanding of the properties of 
these novel compounds, as they relate to their binding and functional inhibition of 
VMAT2, and several JPC compounds are currently being evaluated as potential 
candidates for the treatment of METH abuse.  It is highly possible that several of the 
compounds were presented in this manuscript and were designed and synthesized by this 
author will go into human clinical trials for the treatment of methamphetamine abuse, and 
if one proves effective in the human, this work will have not only verified that VMAT2 is 
an excellent target for the treatment of methamphetamine abuse, but will also have made 
available a pharmacological treatment for the addicts who wish to quit. 
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